Inflammatory Bowel Diseases Final Programme
© Den Blå Planet, National Aquarium Denmark 14th Congress of ECCO Bella Center Copenhagen March 6-9, 2019
www.ecco-ibd.eu Become a 3-year membership: member! Regular & Y-ECCO Members save up to 20%
Be a bee in our hive to experience the ECCO Spirit
To reach our objectives, our members can access the following ECCO Initiatives: • Reduced Congress fee • Quarterly ECCO News – the society’s • JCC – Journal of Crohn’s and Colitis • magazine • (12 online issues/year)* • Educational and networking activities • e-CCO Learning Platform incl. • Guidelines, ECCO Fellowships, Grants and • e-Courses & e-Library • Travel Awards • Monthly eNewsletter • Priority access to UR-CARE - United • Access to online Members’ Area • Registries for Clinical Assessment and Research • Voting rights in General Assembly
Scan and contact the ECCO Office www.ecco-ibd.eu *For Regular Members (incl. Y-ECCO) only; online access only
2019_POSTER Membership bees.indd 1 21.12.2018 16:26:09 14th Congress of ECCO • March 6-9, 2019 • Copenhagen, Denmark
Word of welcome Dear Colleagues,
Welcome to the 14th Congress of ECCO in the wonderful city of Copenhagen, Denmark! Copenhagen blends tradition and state-of-the-art design in a city full of contrast and balance. The qualities of this city are reflective of what is valued in this year’s congress programme. In this country of continuous and significant medical research, the ECCO Congress is in an environment that embraces new methods and research while holding on to well-established knowledge and Silvio Danese traditions.
After a very successful ECCO Congress in Denmark in 2014, it is a great privilege to return to Bella Center for the ECCO Congress in 2019. The immense growth in the recent years has firmly established the ECCO Congress as THE major IBD meeting in the world. Attracting over 6,500 participants, ECCO offers opportunities for nurses, dietitians, surgeons, gastroenterologists and physicians in the field of IBD to exchange knowledge and participate in a growing spectrum of Educational Courses and Masterclasses. Additionally, ECCO reaches out to young clinicians and scientists offering this international platform to pursue improvement in every pillar of IBD patient care.
As we witness major breakthroughs of innovation in new drugs hitting clinics and also new personalised approaches for individual patient treatments, the ECCO Congress theme for this year is suitably titled “Research drives clinical care”.
The Congress sessions are focused on the present best practices for adult IBD patients, including paediatric and surgical lectures, and also highlighting the newest trends for patient management. As new challenges in IBD approach, now, more than ever, research must strive for best clinical care. For this reason, active participation and interaction is vital and fuels success in reaching our goal of improving IBD patient care.
On behalf of the whole ECCO Team and the Organising Committee, I extend a warm welcome to you all!
Yours sincerely,
Silvio Danese ECCO President 2018-2020 & Chair of Organising Committee
March 6-9, 2019 • Copenhagen, Denmark 3 Table of contents
Table of contents
Word of welcome...... 3 ECCO Structure...... 5 Scientific Information: A-Z...... 11 Opening hours...... 18 Scientific programme day by day...... 19 Abstract presentation format...... 37 Digital oral presentations...... 41 Hard copy poster presentations/poster exhibition...... 65 Educational programme...... 69 17th IBD Intensive Advanced Course...... 69 3rd School for Clinical Trialists...... 72 10h N-ECCO School...... 73 6th ECCO-ESGAR Ultrasound Workshop – Advanced...... 75 4th Advanced ECCO: EduCational COurse for Industry...... 76 5th Y-ECCO Basic Science Workshop...... 77 11th Y-ECCO Career Workshop...... 78 1st ECCO-ESGAR Basic Imaging Workshop...... 79 7th SciCom Workshop...... 83 1st Guideline Methodology and GRADE Workshop...... 84 6th P-ECCO Educational Course...... 85 13th N-ECCO Network Meeting...... 86 8th S-ECCO IBD Masterclass in collaboration with ESCP...... 88 4th ECCO-AOCC Forum: East meets West...... 91 4th H-ECCO IBD Masterclass...... 93 4th D-ECCO Workshop...... 96 Congress information...... 98 Industry sponsored satellite symposia...... 106 ECCO Interaction: Hearts and Minds...... 115 Corporate Members...... 116 Floor plans...... 119 Index of authors...... 122
4 14th Congress of ECCO - European Crohn‘s and Colitis Organisation ECCO Structure
ECCO Structure
General Assembly
Governing Board
Scientific Education Secretary President President- Past Treasurer Officer Officer Elect President
ECCO ECCO Office JCC News Corporate Members
Operational Board Strategic Council Scientific Education President- Past Officer Officer Secretary President Elect President
SciCom EduCom S-ECCO Honorary Members
Global Relations ClinCom GuiCom P-ECCO National Representatives Committee
EpiCom N-ECCO Y-ECCO ECCO Partners
H-ECCO D-ECCO
Governing Board President Silvio Danese (Italy) President-Elect Laurent Peyrin-Biroulet (France) Past-President and Liaison Officer Julián Panés (Spain) Secretary Willem Bemelman (The Netherlands) Treasurer Ailsa Hart (United Kingdom) Education Officer James Lindsay (United Kingdom) Scientific Officer Gerhard Rogler (Switzerland)
March 6-9, 2019 • Copenhagen, Denmark 5 ECCO Structure
ClinCom Clinical Research Committee Chair Marc Ferrante (Belgium) Members Krisztina Gecse (The Netherlands) Javier Gisbert (Spain) Uri Kopylov (Israel) John Mansfield (United Kingdom)
D-ECCO Dietitians of ECCO Chair Rotem Sigall-Boneh (Israel) Members Marjo Campmans-Kuijpers (The Netherlands) Konstantinos Gerasimidis (United Kingdom) Arie Levine (Israel) Catherine Wall (United Kingdom)
EduCom Education Committee Chair Antonio López-Sanromán (Spain) Members Marietta Iacucci (United Kingdom) Pascal Juillerat (Switzerland) Paulo Kotze (Brazil) Giovanni Maconi (Italy) Henit Yanai (Israel)
EpiCom Epidemiological Committee Chair Marieke Pierik (The Netherlands) Members Naila Arebi (United Kingdom) Laurent Beaugerie (France) Nynne Nyboe Andersen (Denmark) Valerie Pittet (Switzerland)
GuiCom Guidelines Committee Chair Christian Maaser (Germany) Members Glen Doherty (Ireland) Tim Raine (United Kingdom) Joana Torres (Portugal) Stephan Vavricka (Switzerland)
H-ECCO Histopathologists of ECCO Chair Roger Feakins (United Kingdom) Members Paula Borralho Nunes (Portugal) Gert De Hertogh (Belgium) Magali Svrcek (France) Monika Tripathi (United Kingdom)
6 14th Congress of ECCO - European Crohn‘s and Colitis Organisation ECCO Structure
N-ECCO Nurses of ECCO Chair Kay Greveson (United Kingdom) Members Wladyslawa Czuber-Dochan (United Kingdom) Petra Hartmann (Germany) Susanna Jäghult (Sweden)
P-ECCO Paediatricians of ECCO Chair Patrick van Rheenen (The Netherlands) Members Marina Aloi (Italy) Lissy de Ridder (The Netherlands) Jaroslaw Kierkus (Poland) David Wilson (United Kingdom)
SciCom Scientific Committee Chair Janneke van der Woude (The Netherlands) Members Shomron Ben-Horin (Israel) Florian Rieder (United States) Michael Scharl (Switzerland) Sebastian Zeissig (Germany)
S-ECCO Surgeons of ECCO Chair Yves Panis (France) Members Michel Adamina (Switzerland) Christianne Buskens (The Netherlands) Antonino Spinelli (Italy) Hagit Tulchinsky (Israel)
Y-ECCO Young ECCO Chair Nuha Yassin (United Kingdom) Members Dominik Bettenworth (Germany) Johan Burisch (Denmark) Nik Sheng Ding (Australia) Charlotte Hedin (Sweden) Organising Committee – 14th Congress of ECCO Chair Silvio Danese (Italy) Members Laurent Peyrin-Biroulet (France) Willem Bemelman (The Netherlands) Janneke van der Woude (The Netherlands) Antonio López-Sanromán (Spain)
March 6-9, 2019 • Copenhagen, Denmark 7 ECCO Structure
National Representatives (as of February 1, 2019) Christoph Högenauer Tamás Molnár Alexander Moschen Károly Palatka
Cathérine Reenaers Jane McCarthy Pieter Dewint Garret Cullen
Ante Bogut Matti Waterman Emil Babić Henit Yanai
Zoya Spassova Emma Calabrese Iskren Kotzev Sandro Ardizzone
Željko Krznarić Aleksejs Derovs Ante Tonkic Jelena Derova
Ioannis Kaimakliotis Limas Kupčinskas Theodora Demetriou Gediminas Kiudelis
Tomáš Douda Pavel Drastich Pierre Ellul
Jørn Brynskov Vlada Dumbravă Signe Wildt Svetlana Turcan
Karin Kull Kristin Kaasen Jørgensen Triin Remmel Marte Lie Høivik
Clas-Göran af Björkesten Maria Kłopocka Tuire Ilus Małgorzata Sładek
Arnaud Bourreille Ana Isabel Vieira Xavier Roblin Rosa Isadora
Britta Siegmund Mihai Mircea Diculescu Raja Atreya Adrian Goldis
Ioannis Koutroubakis Alexander Potapov Giorgos Bamias Pavel Makarchuck
8 14th Congress of ECCO - European Crohn‘s and Colitis Organisation ECCO Structure
Mirjana Cvetkovic Pierre Michetti Srdjan Djuranovic Frank Seibold
Martin Huorka Andrea van der Meulen-de Jong Mária Zakuciová Dirk de Jong
# ## David Drobne Yusuf Ziya Erzin Gregor Novak Filiz Akyüz
Pilar Nos Mateu Tetyana Zvyagintseva Manuel Barreiro de Acosta Andrey Dorofeyev
Michael Eberhardson Tariq Ahmad Ann-Sofie Backman Ian Arnott
Honorary Members (as of February 1, 2019) Filip Baert (Belgium) Gerassimos Mantzaris (Greece) Renzo Caprilli (Italy) Pierre Michetti (Switzerland) Yehuda Chowers (Israel) Pia Munkholm (Denmark) Jean-Frédéric Colombel (United States) Walter Reinisch (Austria) Geert D‘Haens (The Netherlands) Herbert Tilg (Austria) Axel Dignass (Germany) Simon Travis (United Kingdom) Miquel Gassull (Spain) Séverine Vermeire (Belgium) Daniel Hommes (The Netherlands) Boris Vucelić (Croatia)
Corporate Members (as of February 1, 2019) AbbVie Cosmo Pharmaceuticals Pfizer Amgen Dr. Falk Pharma Roche Biogen Eli Lilly and Company Sandoz Bristol-Myers Squibb Ferring Takeda Bühlmann Laboratories Gilead Tillotts Pharma Celgene Janssen Vifor Pharma Celltrion MSD
March 6-9, 2019 • Copenhagen, Denmark 9 Announcement 2020 Inflammatory Bowel Diseases
th 15 Congress of ECCO Vienna, February 12-15, 2020
• Reed Messe Wien • EACCME applied • Register at www.ecco-ibd.eu/ecco20
Scan and contact the ECCO Office www.ecco-ibd.eu
2020_Poster_Vienna_2020.indd 1 21.12.2018 16:06:17 Scientific Information: A-Z
Scientific Information: A-Z Abstracts ECCO is proud to announce that a total of 1228 abstracts have been submitted to the 14th Congress of ECCO. A panel of expert reviewers have evaluated and selected the strongest, most scientifically relevant abstracts for presentation at this year’s Congress. Authors of the best abstracts have been invited to present their studies as oral presentations, digital oral presentations and hard copy poster presentations. For details regarding abstract presentation, see pg. 37. Business meetings Attendance at business meetings is upon invitation only. The General Assembly will be held in C1-M1 at Bella Center, on Thursday, March 7, 20:00-21:00. Stop by the ECCO Booth for more information on business meetings. Compliance Based on the EFPIA HCP Code and the guidelines and codes of practice applicable to Denmark, ENLI (Danish Ethical Board for Pharmaceutical Industries) and the Danish Medicines Agency, ECCO has adopted measures that allow compliance with applicable regulations regarding publicity and promotion of medicines at the ECCO Congress 2019. ••Exhibitors have been asked to respect the Code of Practice in the context of the ECCO’19 Exhibitor & Sponsor Prospectus. ••Exhibitors have been alerted to the regulations about the promotion of prescription-only medicine, explaining that non-HCPs congress delegates can be identified with the non-HCP sign on the congress badge. Furthermore non-HCPs have no access to areas where advertising for HCPs is allowed. ••In the course of the online and onsite registration, the congress delegates are also informed about the regulations regarding publicity and promotion of medicine and are asked to indicate their HCP/non-HCP status accordingly. Disclosure policy ECCO has diligently maintained a disclosure policy of potential Conflicts of Interest (CoI) with the aim of fostering transparency and ensuring scientific rigour and objectivity in all scientific and educational activities. Therefore, all presenters, including invited faculty members and abstract presenters, are required to disclose relevant financial support and relationships that may generate potential conflict. Please note that the presenting author holds responsibility for the content of his or her presentation.
All presenters are required to complete a Conflict of Interest form disclosing any financial support and advisory/consultancy roles in the biomedical industry. These forms are made public on the ECCO Website at www.ecco-ibd.eu/about-ecco/ecco-disclosures providing a comprehensive overview of potential Conflicts of Interest of presenters. Once published, the ECCO Office will notify IBD Community in an eNewsletter of the online access to the up-to-date CoI forms.
All conflicts are to be disclosed on the nd2 slide of each PowerPoint presentation. To facilitate and reinforce the 2nd slide policy, faculty speakers are reminded to disclose their potential Conflicts of Interest in their presentation in line with European Union of Medical Specialists (UEMS) regulations.
March 6-9, 2019 • Copenhagen, Denmark 11 Scientific information: A-Z
A draft CoI slide will be prepared for each speaker based on the submitted CoI form, and will be made available in the Speakers’ Centre to be included in the presentation. Please be reminded that if the respective presentation does not yet include a disclosure form, the slide draft should be checked and amended before it is inserted into the presentation.
Conflicts of Interest may include, but is not limited to, financial relationships, whether the individual had the opportunity to influence the content of a presentation, grants, honoraria, shares, and paid positions on advisory boards. ECCO expects many presenters to have some Conflicts of Interest, which do not prevent them from presenting their work given that the conflict is disclosed. EACCME – Continuing Medical Education The 14th Congress of ECCO in Copenhagen is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activities for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.eu.
Event CME Credits 14th Congress of ECCO Scientific Programme 15 1st ECCO-ESGAR Basic Imaging Workshop 7 1st Guideline Methodology and GRADE Workshop 3 3rd School for Clinical Trialists 3 4th D-ECCO Workshop 3 4th ECCO-AOCC Forum N/A 4th Advanced ECCO: EduCational COurse for Industry N/A 4th H-ECCO IBD Masterclass 6 5th Y-ECCO Basic Science Workshop 3 6th ECCO-ESGAR Ultrasound Workshop - Advanced 3 6th P-ECCO Educational Course 2 7th SciCom Workshop 2 8th S-ECCO IBD Masterclass 6 10th N-ECCO School N/A 11th Y-ECCO Career Workshop 2 13th N-ECCO Network Meeting N/A 17th IBD Intensive Advanced Course 10
The submission of the ECCO’19 Congress evaluation serves as a prerequisite to receiving CME credits. At the conclusion of the Congress, delegates will receive an e-mail with a link to the online evaluation platform.
On the evaluation platform, you are invited to evaluate the Scientific Programme and all educational activities you attended. Upon submission of these evaluations, your CME Certificates will be available for download or print.
12 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Scientific information: A-Z
ECCO Fellowships & Grants 2019 On Friday, March 8, 2019 15:45-15:55, ECCO officially announces the following prizes: ■■ ECCO Pioneer Award 2019 ■■ ECCO Travel Awards 2019 ■■ ECCO Fellowships 2019 ■■ ECCO-Pfizer Research Grant on Predictors of ■■ ECCO Grants 2019 response to JAK inhibitors 2019 ■■ ECCO-AOCC Visiting Travel Grant 2019 ■■ ECCO-Pfizer Research Awards 2019
The awarded candidates will formally receive their prizes and announce the titles of their fellowship or grant research projects in this session of the Scientific Programme.
For further information and guidelines for these awards please refer to www.ecco-ibd.eu.
Plenary session The plenary session is held from Thursday to Saturday, March 7-9, 2019, starting with an official welcome and the opening of the core scientific programme. This programme includes talks and presentations from a collection of official and invited speakers, as well as oral presentations of the best submitted scientific abstracts. Scientific congress theme The theme of the 14th Congress of ECCO is “Research drives clinical care”. Top tips for chairs All chairs are kindly invited to watch the “Top tips for chairs” on the ECCO Website: www.ecco-ibd.eu/toptips. In this video, Laurence Egan shares instructions on how to chair scientific sessions in a highly humorous manner – do not miss out on it!
March 6-9, 2019 • Copenhagen, Denmark 13 Copenhagen Denmark How to receive your CME Certificates
Submit your evaluation forms online!
CME Certificates for the ECCO’19 Scientific Programme and accredited Educational Courses will be available online at the end of the Congress. To download your certificates, follow these steps: Check your account details • Visit the ECCO Website to make sure your e-mail address and login details are up-to-date. Check your e-mail • At the end of the Congress, you will receive an e-mail with a link to the online evaluation platform. Fill out your evaluation forms • You will be able to evaluate the Scientific Programme and any Educational Activities you attended. Download your certificates • Once you have submitted your surveys, your CME Certificates will be available for download or print.
Scan and contact the ECCO Office www.ecco-ibd.eu
2019_POSTER_CME Certificates.indd 1 21.12.2018 16:16:00 Programme overview – Educational programme
Educational programme
Room 08:00-08:30 08:30-09:30 09:30-11:30 11:30-12:30 12:30-13:30 13:30-14:00 14:00-14:30 14:30-16:15 16:15-16:30 16:30-16:45 16:45-17:00 17:00-18:00 18:00-19:00 HB4 M1-2 17th IBD Intensive Advanced Course pg. 69 B3 M1-2 6th ECCO-ESGAR Ultrasound 1st ECCO-ESGAR Basic Imaging Workshop Workshop Advanced pg. 75 pg. 75 B3 M5-6 10th N-ECCO School pg. 73 B3 M7-8 5th Y-ECCO Basic Science Workshop 11th Y-ECCO Career Workshop
WED March 6, 2019 pg. 77 pg. 78 3rd School for Clinical Trialists 4th Advanced ECCO: EduCational COurse for Industry Auditorium 15 pg. 72 pg. 76
Room 07:30-08:00 08:00-08:45 08:45-08:50 08:50-10:00 10:00-10:30 10:30-11:40 11:40-12:00 12:00-13:30 13:30-16:45 16:45-17:15 HB4 M1-2 17th IBD Intensive Advanced Course pg. 69 B3-M1-2 1st ECCO-ESGAR Basic Imaging Workshop pg. 81 B3 M7-8 1st Guideline Methodology and GRADE Workshop pg. 84 B3 M9-10 7th SciCom Workshop 4th H-ECCO IBD Masterclass pg. 83 pg. 93 6th P-ECCO Educational Course 13th N-ECCO Network Meeting C1 M 0 pg. 85 pg. 86 THU March 7, 2019 THU March 7, C1 M2 8th S-ECCO IBD Masterclass pg. 88 C1 M3 4th ECCO-AOCC Forum pg. 91
Room 08:00-08:15 08:15-12:00 12:00-12:25 HB4 M1-2 4th D-ECCO Workshop pg. 96 2019 B3 M9-10 4th H-ECCO IBD Masterclass
FRI MarchFRI 8, pg. 93 = Scientific session SS =Scientific overview Programme Scientific programme Scientific SAT March 9, 2019 FRI March 8, 2019 THU March 7, 2019 C1 M2,M3 C1 M0,M1 Plenary Hall Plenary Auditorium Exhibition Auditorium 15 Exhibition Hall C1 M4-5 C1 M2,M3 C1 M0,M1 C1 M4-5 (Hall C) (Hall A) C1 M1 Room Plenary Hall Plenary Exhibition Hall Hall B Hall Plenary Hall Plenary C1 M4-5 C1 M4-5 15 (Hall C) (Hall A) Room Hall B (Hall C) (Hall A) Room Hall B pg. 109 ISSS 3b ISSS 3c pg.109 07:15- 08:15 10:30-11:00 08:00-08:15 08:15- 08:30 = Industry sponsored satellite symposium ISSS =Industry 08:30- 09:30 Best practice inUC Best practice 11:00-12:00 Overflow Scientific room - programme Overflow ISSS 1b ISSS 1a ISSS 1c pg. 106 pg. 107 pg. 107 08:15-08:30 SS4: Exhibition Industry Industry Congress theme: “Research drives clinical care” clinical drives “Research Congress theme: 09:30- 10:30 SS10: ofIBDlifeThe cycle inclinicalpractice pg. 117 pg. 22 12:00-12:15 Industry Exhibition Industry 10:30- Coffee 11:00 Break 08:30-09:30 Overflow Scientific room - programme Overflow and Opening 12:15-12:30 11:00- 11:30 IBD around the Welcome Exhibition Industry world pg. 19 SS5: pg. 117 11:30- Industry Exhibition Industry 12:30 pg. 24 09:30-10:20 12:30-13:00 SS1: SilencingIBD Poster Session Lunch break 12:30-12:40 and Guided pg. 117 pg. 32 ELSS =Educational lunchtimesatellite symposium 13:00-14:00 pg. 117 pg. 19 Coffee Break 10:20-10:50 12:40-13:20 ELSS LS3 ELSS LS1 ELSS LS2 ELSS LS3 pg. 110 pg. 110 pg. 110 pg. 110 14:00-14:30 Coffee Break Industry Exhibition Industry 13:20- 13:30 SS11: Towards thefuture ofIBD treatments: The good treatments: The SS2: Complementary SS2: Complementary and imaging inIBD Poster Exhibition doing endoscopy SS6: New waysSS6: New of Poster Exhibition Overflow Scientific room - programme Overflow and thebad 13:30-14:40 10:50-12:20 14:30-16:00 pg. 117 pg. 25 pg. 20 Overflow Scientific room - programme Overflow pg. 34 Coffee 14:40- 15:10 Break SS3: Precision medicine: Lessons and to learn paths to thefuture DOP =Digital oralpresentation Poster Exhibition 16:00-17:20 ECCO Fellowships cells andmicrobes: Ahappy SS12: ECCO Lecture SS9: Basic Science: Immune Immune SS9: BasicScience: 15:10-15:55 and Grants 12:20-12:50 SS7: marriage? marriage? Programme programme –Scientific overview pg. 20 pg. 26 Industry Exhibition Industry Industry Exhibition Industry pg. 35 17:20-17:30 15:55- 16:50 pg. 29 IBD Horizons Awards andclosingremarks SS8: Industry Exhibition Industry 16:50- pg. 27 Sessions 1-5 Sessions 17:30-18:30 16:55 12:50-12:55 DOP pg. 41 16:55- 17:20 18:30-18:45 Sessions 6-10 Sessions 17:20-18:20 pg. 35 DOP pg. 41 18:45-19:00 The ECCO Film 2019 18:20- 18:35 pg. 65 12:55-13:00 ISSS 2b ISSS 2a ISSS 2c pg. 65 18:35- 19:00 19:00-19:45 ISSS 4d ISSS 4a ISSS 4c pg. 112 pg. 112 pg. 117 pg. 112 pg. 117 pg. 117 pg. 108 pg. 108 pg. 107 pg. 65 pg. 35 19:00- 19:35 Copenhagen Denmark
e-CCO Learning Open access preview @ the ECCO Booth
Congress special: Open access preview
Are you looking for educational material? Check out... 27 e-Courses 31 Talking Heads 4 Skills Videos Case-based e-Courses to learn Two or three Key Opinion Skills Videos provide ECCO and test your knowledge about Leaders in IBD debating a Members with practical tips and common clinical scenarios in IBD controversial topic tricks on performing IBD related procedures New ECCO e-Library 10 Educational Audio ECCO IBD Curriculum Refined search functions: Podcasts A framework for ECCO’s Congress abstracts, Congress Opinions of recognised experts educational activities, outlining presentations, webcasts, on specialised topics in IBD what gastroenterologists need to scientific articles and tools know
Scan and visit www.e-learning.ecco-ibd.eu Research Grants and Fellowships 2020
Fund your innovative scientific research with ECCO’s Fellowships and Grants ECCO Pioneer Award • EUR 250,000 for innovative and collaborative research projects between at least 2 IBD Centres First Application deadline: June 3, 2019 ECCO Fellowships • EUR 60,000 for young and enthusiastic scientists to research in a host institute abroad ECCO Grants • EUR 50,000 for innovative, and original research projects N-ECCO Research Grant • EUR 20,000 for international IBD Nursing research ECCO Travel Awards • EUR 1,500 for young doctors, nurses and dietitians to enable visits of European IBD Centres Application deadline: June 3, 2019
Scan and visit www. ecco-ibd.eu
2019_POSTER_Fellowships and grants.indd 1 04.01.2019 18:18:45 ECCO Pioneer Award
Fund your innovative scientific research with the ECCO Pioneer Award The ECCO Pioneer Award aims to enhance visionary, collaborative, and interdisciplinary scientific research in IBD Centres. 2020: Open to all topics in IBD • EUR 250,000 prize • 1 exceptional award per year • Fund up to 24 months of basic/clinical research in IBD • For innovative and collaborative research projects between at least 2 equal participating institutions Application deadline (1st phase): June 3, 2019
Scan and contact the ECCO Office www.ecco-ibd.eu
2019_POSTER_Pioneer Award.indd 1 04.01.2019 18:20:48 Opening hours
Opening hours
Cloakroom Wednesday, March 6, 2019 07:00 - 19:30 Thursday, March 7, 2019 07:00 - 21:15 Friday, March 8, 2019 06:45 - 20:00 Saturday, March 9, 2019 08:00 - 13:30
ECCO Congress Office and Registration Desk Wednesday, March 6, 2019 07:00 - 19:00 Thursday, March 7, 2019 07:00 - 19:00 Friday, March 8, 2019 07:00 - 19:00 Saturday, March 9, 2019 08:00 - 13:00
Industry and Poster Exhibition Thursday, March 7, 2019 10:30 - 19:45 Friday, March 8, 2019 07:15 - 19:45 Saturday, March 9, 2019 08:00 - 13:00
Members’ Lounge (exclusive for ECCO Members) Thursday, March 7, 2019 10:30 - 19:45 Friday, March 8, 2019 07:15 - 19:45 Saturday, March 9, 2019 08:00 - 13:00
Poster exhibition Thursday, March 7, 2019 13:00 - 19:00 Friday, March 8, 2019 08:30 - 19:00 Saturday, March 9, 2019 08:00 - 13:00
Speakers’ Centre Wednesday, March 6, 2019 07:30 - 18:00 Thursday, March 7, 2019 07:00 - 19:30 Friday, March 8, 2019 06:30 - 19:45 Saturday, March 9, 2019 08:00 - 13:00
18 14th Congress of ECCO - European Crohn‘s and Colitis Organisation “Research drives clinical care”
“Research drives clinical care” Thursday, March 7, 2019 Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center Industry sponsored satellite symposia 1a & 1b & 1c 11:00 - 12:00 See pg. 106 1: Welcome 12:15 - 12:20 President of Dansk Selskab for Gastroenterologi og Hepatologi Henning Glerup, Silkeborg, Denmark 2: Opening 12:20 - 12:30 Silvio Danese, Milan, Italy Scientific Session 1: Silencing IBD 12:30 - 14:00 Peter Irving, London, United Kingdom Britta Siegmund, Berlin, Germany 3: Can we prevent IBD? 12:30 - 12:50 Jean-Frédéric Colombel, New York, United States 4: OP01: In-depth characterisation of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel Disease S. Hu1, A. Vich Vila1, R. Gacesa1, V. Collij1, R. Xavier2, C. Stevens3, M. Daly3, C. Wijmenga4, H. van Dullemen1, G. Dijkstra1, M. Visschedijk1, E. Festen1, J. Fu5, A. Kurilshikov4, A. Zhernakova4, R. Weersma1 12:50 - 13:00 1Universitair Medisch Centrum Groningen, Gastroenterology & Hepatology, Groningen, Netherlands, 2Massachusetts General Hospital, Molecular Biology, Boston, United States, 3Broad Institute, Boston, United States, 4Universitair Medisch Centrum Groningen, Genetics, Groningen, Netherlands, 5Universitair Medisch Centrum Groningen, Pediatrics, Groningen, Netherlands 5: Can we cure IBD? 13:00 - 13:20 Arthur Kaser, Cambridge, United Kingdom 6: OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s Disease 13:20 - 13:30 C. Li, J. Kuemmerle Virginia Commonwealth University, Internal Medicine, Richmond, United States 7: OP03: Inhibition of autophagy exacerbates intestinal fibrosis and EMT J. Cosin-Roger1,2, D. Ortiz-Masia3, F. Canet1, A. Trescoli-Garcia1, S. 13:30 - 13:40 Calatayud1, M. D. Barrachina1 1University of Valencia, Pharmacology, Valencia, Spain, 2Hospital Dr Peset, Valencia, Spain, 3University of Valencia, Medicine, Valencia, Spain 8: Are fibrotic complications reversible? 13:40 - 14:00 Geert D’Haens, Amsterdam, The Netherlands Massimo Pinzani, London, United Kingdom 14:00 - 14:30 Coffee break
OP = Oral presentation – Best abstracts March 6-9, 2019 • Copenhagen, Denmark 19 Scientific programme day by day
Thursday, March 7, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center
Scientific Session 2: Complementary treatments: The good and the bad 14:30 - 16:00 Shomron Ben-Horin, Tel Aviv, Israel Pascal Juillerat, Bern, Switzerland 9: The crazy stuff – what your patients are taking and why? 14:30 - 14:50 Fernando Gomollón Garcia, Zaragoza, Spain 10: OP04: Turning sweet in Inflammatory Bowel Disease: Glycans as novel immunomodulators of T cell-mediated immune response A. Dias1, M. Pereira1, A. Correia1, I. Alves1, V. Pinto1, L. Azevedo2, L. Maia3, R. Marcos-Pinto3, M. Vilanova1, P. Lago3, S. Pinho1 14:50 - 15:00 1Institute for Research and Innovation in Health (i3S), Immunology, Cancer & GlycoMedicine, Porto, Portugal, 2Medical Faculty, Department of Community Medicine, Information and Health Decision Sciences, Porto, Portugal, 3Porto Centre Hospital, Gastroenterology, Porto, Portugal 11: ECCO Topical Review on complementary medicine 15:00 - 15:20 Joana Torres, Lisbon, Portugal Stephan Vavricka, Zurich, Switzerland 12: OP05: Crohn’s Disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in Mild to Moderate Active Paediatric Crohn’s Disease: A prospective randomised controlled trial J. Van Limbergen1, 2, E. Wine3, A. Assa4, R. Sigall Boneh5, R. Shaoul6, M. Kori7, S. Cohen8, S. Peleg9, H. Shamaly10, A. On11, P. Milman12, L. Abramas5, T. Ziv Baran13, S. Grant14, A. Levine5, 13 15:20 - 15:30 1Dalhousie University, Halifax, Canada, 2IWK Center, Halifax, Canada, 3University Alberta, Edmonton, Canada, 4Schneider Medical Center, Petach Tikva, Israel, 5Wolfson Medical Center, Holon, Israel, 6Meyer Hospital, Haifa, Israel, 7Kaplan Hospital, Rehovot, Israel, 8Dana childrens Hospital, Tel Aviv, Israel, 9HaEmek Hospital, Afula, Israel, 10French Hospital, Nazareth, Israel, 11Poriah Hospital, Tiberias, Israel, 12Hadassah Hospital, Jerusalem, Israel, 13Tel Aviv University, Tel Aviv, Israel, 14Mount Saint Vincent University, Halifax, Canada 13: OP06: Gut-brain-axis revisited: Shedding light on the mucosa associated microbial composition in IBD patients with psychological distress, anxiety and depression F. Humbel1, P. Juillerat2, M. Scharl1, B. Misselwitz2, P. Schreiner1, A. Macpherson2, G. Rogler1, R. von Känel3, B. Yilmaz4, 5, L. Biedermann1, 5 15:30 - 15:40 1University Hospital Zurich, Department of Gastroenterology & Hepatology, Zurich, Switzerland, 2Bern University Hospital, Department of Visceral Surgery and Medicine, Bern, Switzerland, 3University Hospital Zurich, Consultation-Liaison Psychiatry and Psychosomatic Medicine, Zurich, Switzerland, 4University of Bern, Maurice Müller Laboratories, Bern, Switzerland, 5*Equal, Contribution, Switzerland 14: Psychological support in IBD 15:40 - 16:00 Yoram Inspector, London, United Kingdom
OP = Oral presentation – Best abstracts 20 14th Congress of ECCO - European Crohn‘s and Colitis Organisation “Research drives clinical care”
Thursday, March 7, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center
Scientific Session 3: Precision medicine: Lessons to learn and paths to the future 16:00 - 17:20 Axel Dignass, Frankfurt am Main, Germany Jesús Rivera-Nieves, San Diego, United States 15: What is system biology? 16:00 - 16:20 Dermot McGovern, Los Angeles, United States 16: Multi-omics profiling of IBD 16:20 - 16:40 Jonas Halfvarson, Örebrö, Sweden 17: OP07: Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn’s Disease due to autophagy impairment L. Gul1, E. Jones1, 2, Z. Matthews3, P. Sudhakar1, 2, 4, A. Treveil1, 2, D. Divekar2, 3, J. Buck3, M. Jefferson3, S. Armstrong5, A. Watson2, 3, S. Carding2, 3, U. Mayer6, P. Powell3, I. Hautefort1, T. Wileman2, 3, T. Korcsmaros1, 2 1Earlham Institute, Norwich, United Kingdom, 2Quadram Institute, 16:40 - 16:50 Norwich, United Kingdom, 3Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 4KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 5University of Liverpool, National Institute of Health Research, Liverpool, United Kingdom, 6School of Biological Sciences, University of East Anglia, Norwich, United Kingdom 18: OP08: Long-term efficacy and pharmacodynamics of the anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s Disease: The OPERA II study G. D‘Haens1, W. Reinisch2, S. D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D. I. Park9, X. Hébuterne10, K. J. Gorelick11, S. W. Martin12, A. Banerjee12, P. Nagy13, Y. Wang14, F. Cataldi14, W. J. Sandborn15 1Academic Medical Centre, Amsterdam, Netherlands, 2Medical University of Vienna, Vienna, Austria, 3University of Washington, Seattle, WA, United States, 4Clinic of Gastroenterology and Hepatology, Military 16:50 - 17:00 Medical Academy, Belgrade, Serbia, 5University Hospital of Liège, Liège, Belgium, 6Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 7University Hospital Ulm, Ulm, Germany, 8University Hospital Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany, 9Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, 10University of Nice Sophia Antipolis, Hospital l‘Archet, Nice, France, 11Zymo Consulting Group, Newtown Square, PA, United States, 12Pfizer, Cambridge, MA, United States,13 Shire, Zug, Switzerland, 14Shire, Lexington, MA, United States, 15University of California San Diego, La Jolla, CA, United States 19: Stratifying by disease biology to choose the right drug for the 17:00 - 17:20 right patient Charlie Lees, Edinburgh, United Kingdom Digital Oral Presentations (Sessions 1-5) 17:30 - 18:30 See pg. 41 Industry sponsored satellite symposia 2a & 2b & 2c 18:45 - 19:45 See pg. 108
OP = Oral presentation – Best abstracts March 6-9, 2019 • Copenhagen, Denmark 21 Scientific programme day by day
Friday, March 8, 2019 Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center Industry sponsored satellite symposia 3b & 3c 07:15 - 08:15 See pg. 109 Scientific Session 4: Best practice in UC 08:30 - 10:30 Andre D’Hoore, Leuven, Belgium Henit Yanai, Petah Tikva, Israel 08:30 - 08:50 20: When do you start a biologic? Simon Travis, Oxford, United Kingdom 21: OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with Moderately to Severely Active Ulcerative Colitis L. Peyrin-Biroulet1, J. Panés2, M. Chiorean3, J. Zhang4, S. Vermeire5, V. Jairath6, A. Yarur7, C. Cabell4, S. Naik4, W. J. Sandborn8 1 2 08:50 - 09:00 University Hospital of Nancy, Vandœuvre-lès-Nancy, France, Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 3Virginia Mason Medical Center, Seattle, United States, 4Arena Pharmaceuticals, Inc., San Diego, United States, 5University Hospitals Leuven, Leuven, Flanders, Belgium, 6Western University, London, Ontario, Canada, 7Medical College of Wisconsin, Milwaukee, United States, 8University of California San Diego, La Jolla, United States 22: OP10: Systems genomics of Ulcerative Colitis: Combining GWAS and signalling networks for patient stratification and individualised drug targeting in Ulcerative Colitis J. Brooks1, 2, D. Modos3, P. Sudhakar4, 5, D. Fazekas4, 6, A. Zoufir3, A. Watson1,7, M. Tremelling1, B. Verstockt8, S. Vermeire8, A. Bender3, S. Carding2, 7, T. Korcsmaros2, 4 1Norfolk and Norwich University Hospital, Gastroenterology, Norwich, United Kingdom, 2The Quadram Institute Bioscience, Gut Microbes 09:00 - 09:10 and Health Programs, Norwich, United Kingdom, 3Centre for Molecular Science Informatics, Department of Chemistry University of Cambridge, Cambridge, United Kingdom, 4Earlham Institute, Norwich Research Park, Norwich, United Kingdom, 5KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 6Eötvös Loránd, Department of Genetics, Budapest, Hungary, 7University of East Anglia, Norwich Medical School, Norwich, United Kingdom, 8University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 23: OP11: Organoids derived from inflamed intestinal biopsies of patients with Ulcerative Colitis lose their inflammatory phenotype during ex vivo culture K. Arnauts1, 2, B. Verstockt1, 3, M. Vancamelbeke1, S. Vermeire1, 3, C. 09:10 - 09:20 Verfaillie2, M. Ferrante1, 3 1KU Leuven, Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), Leuven, Belgium, 2KU Leuven, Department of Development and Regeneration, Leuven, Belgium, 3KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 09:20 - 09:40 24: Where is the exit? Marc Ferrante, Leuven, Belgium
OP = Oral presentation – Best abstracts 22 14th Congress of ECCO - European Crohn‘s and Colitis Organisation “Research drives clinical care”
Friday, March 8, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center 25: OP12: Targeting inflammation in Ulcerative Colitis by inhibiting glucose uptake R. Gropp1, H. Jodeleit1, J. Caesar1, C. Villarroel Aguilera1, F. Beigel2, 3, S. Breiteneicher3, J. Stallhofer3, M. Siebeck1 09:40 - 09:50 1Hospital of the Ludwig Maximilian University, General-, Visceral-, Vascular- and Transplantation Surgery, Munich, Germany, 2Hospital of the Ludwig Maximilian University, Laboratory Medicine, Munich, Germany, 3Hospital of the Ludwig Maximilian University, Medicine II, Munich, Germany 26: OP13: Molecular response to ustekinumab in Moderate to Severe Ulcerative Colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study 09:50 - 10:00 K. Li, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J. R. Friedman Janssen Research & Development, LLC, Spring House, United States 27: OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with Moderately to Severely Active Ulcerative Colitis: Data from the U-ACHIEVE study W. J. Sandborn1, S. Schreiber2, S. D. Lee3, J. O. Lindsay4, X. Hebuterne5, W. Zhou6, F. Cataldi6, A. P. Lacerda6, B. Huang6, W. Xie6, E. V. Loftus Jr7 1University of California San Diego, La Jolla, United States, 2University 10:00 - 10:10 Hospital Schleswig-Holstein, Kiel, Germany, 3University of Washington, Seattle, United States, 4Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 5Service de Gastroentérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France, 6AbbVie Inc., North Chicago, United States, 7Mayo Clinic, Rochester, United States 28: Precision surgery in UC 10:10 - 10:30 Yves Panis, Clichy, France 10:30 - 11:00 Coffee break
OP = Oral presentation – Best abstracts
March 6-9, 2019 • Copenhagen, Denmark 23 Scientific programme day by day
Friday, March 8, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center Scientific Session 5: IBD around the world 11:00 - 12:30 Toshifumi Hibi, Tokyo, Japan Giovanni Maconi, Milan, Italy 29: Vaccination and travelling with IBD: An update 11:00 - 11:20 Jean-François Rahier, Yvoir, Belgium 30: OP15: Cost-analysis in a prospective European population- based inception cohort. Is there a cost-saving effect of biological therapy? J. Burisch1, H. Vardi2, D. Schwartz3, Z. Krznaric4, P. L. Lakatos5, M. Fumery6, L. Kupcinskas7, F. Magro8, E. Belousova9, P. Oksanen10, N. Arebi11, E. Langholz12, S. Turcan13, R. D‘Inca14, V. Hernandez15, D. Valpiani16, Z. Vegh5, M. Giannotta17, K. H. Katsanos18, D. Duricova19, K. R. Nielsen20, H. A. L. Kievit21, P. Ellul22, R. Salupere23, A. Goldis24, I. Kaimakliotis25, N. Pedersen26, V. Andersen27, J. Halfvarson28, S. Sebastian29, J. F. Dahlerup30, P. Munkholm1, S. Odes3, Epi-IBD 1North Zealand University Hospital, Frederikssund, Denmark, 2Ben Gurion University of the Negev, Beer Sheva, Israel, 3Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel, 4University Hospital Center Zagreb, Zagreb, Croatia, 5Semmelweis University, Budapest, Hungary, 6Amiens University and Hospital, Amiens, France, 7Lithuanian University of Health Sciences, Kaunas, Lithuania, 8Hospital de São João, Porto, Portugal, 9Moscow Regional 11:20 - 11:30 Research Clinical Institute, Moscow, Russian Federation, 10Tampere University Hospital, Tampere, Finland, 11Imperial College London, London, United Kingdom, 12Herlev University Hospital, Herlev, Denmark, 13State University of Medicine and Pharmacy of the Republic Y-ECCO of Moldova, Chisinau, Moldova, Republic of, 14Azienda Ospedaliera di Abstract Award Padova, Padova, Italy, 15Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 16Morgagni Hospital, Forli, Italy, 17Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy, 18University Hospital, Ioannina, Greece, 19Charles University, Prague, Czech Republic, 20National Hospital of the Faroe Islands, Torshavn, Faroe Islands, 21Herning Hospital, Herning, Denmark, 22Mater Dei Hospital, Msida, Malta, 23Tartu University Hospital, Tartu, Estonia, 24University of Medicine ‘Victor Babes’, Timisoara, Romania, 25American Gastroenterology Center, Nicosia, Cyprus, 26Slagelse Hospital, Department of medicine, Denmark, 27Regional Hospital of Viborg, Viborg, Denmark, 28Örebro University, Örebro, Sweden, 29Hull and East Yorkshire NHS Trust, Hull, United Kingdom, 30Aarhus University Hospital, Aarhus, Denmark 31: Management of IBD outside of Europe: The example of India 11:30 - 11:50 Rupa Banerjee, Hyderabad, India 32: OP16: A randomised, multicentre, double-blind, placebo- controlled study of a targeted release oral cyclosporine formulation in the treatment of Mild to Moderate Ulcerative Colitis: Efficacy results S. Bloom1, T. Iqbal2, C. Nwokolo3, M. Smith4, D. O‘Donoghue5, J. Hall6, B. Dzyngel6 11:50 - 12:00 1University College London Hospitals, London, United Kingdom, 2Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, 3University Hospital Coventry & Warwickshire, Coventry, United Kingdom, 4Shrewsbury and Telford Hospital, Shrewsbury, United Kingdom, 5St Vincent’s University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 6Sublimity Therapeutics, Solana Beach, United States
24 14th Congress of ECCO - European Crohn‘s and Colitis Organisation “Research drives clinical care”
Friday, March 8, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center 33: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies R. Huang1, H. Irizar2, R. Kosoy3, W.-M. Song3, A. Dinarzo3, K. Hao3, J. Rogers4, A. Atreja4, M. Mahajan3, A. Stojmirovic5, J. Perrigoue5, C. Brodmerkel5, S. Plevy5, J. Friedman5, J.-F. Colombel4, M. Dubinsky4, B. Sands4, E. Schadt3, A. Kasarskis3, B. Losic3, C. Argmann3, M. Suarez-Farinas1, 3 1Icahn School at Mount Sinai, Department of Population, Health Science 12:00 - 12:10 and Policy, New York, United States, 2University College of London, London, United Kingdom, 3Icahn School at Mount Sinai, Department of Genetics and Genomic Science, New York, United States, 4Icahn School at Mount Sinai, Department of Medicine, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York City, United States, 5Janssen Research & Development, Janssen Biotech, Johnson & Johnson, Spring House, United States 34: East meets West: Epidemiology of IBD 12:10 - 12:30 Johan Burisch, Copenhagen, Denmark Siew Ng, Hong Kong, China Break / Guided Poster Session (Hall B) 12:30 - 13:30 See pg. 65 Educational Lunchtime Satellite Symposia LS1 & LS2 & LS3 & LS4 12:40 - 13:20 See pg. 110 Scientific Session 6: New ways of doing endoscopy and imaging in IBD 13:30 - 14:40 Hankje Escher, Rotterdam, The Netherlands Christian Maaser, Lüneburg, Germany 35: Assessing bowel damage in CD from adult to childhood 13:30 - 13:50 Anne Griffiths, Toronto, Canada 36: OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s Disease: The paediatric Crohn‘s Disease adalimumab level- based optimisation treatment (PAILOT) trial A. Assa1, M. Matar2, D. Turner3, E. Broide4, B. Weiss5, O. Ledder6, A. Guz Mark2, F. Rinawi2, S. Cohen7, C. Topf Olivestone8, R. Shaoul9, B. Yerushalmi10, R. Shamir2 1Schneider Children‘s Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 2Schneider Children‘s medical Center, 13:50 - 14:00 Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 3Shaare Zedek Medical Center, Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 4Assaf Harofeh, Pediatric Gastroenterology, IIS Zerifin, Israel,5 Sheba Medical Center, Pediatric Gastroenterology, Ramat Abstract Award Gan, Israel, 6Shaare Zedek Medical Center, Pediatric Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 7Tel Aviv Medical Center, Pediatric Gastroenterology, Tel-Aviv, Israel, 8Kaplan Medical Center, Pediatric Gastroenterology, Rehovot, Israel, 9Rambam Medical Center, Pediatric Gastroenterology, Haifa, Israel, 10Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel 37: Best practice in screening for dysplasia 14:00 - 14:20 Marietta Iacucci, Birmingham, United Kingdom
OP = Oral presentation – Best abstracts
March 6-9, 2019 • Copenhagen, Denmark 25 Scientific programme day by day
Friday, March 8, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center (Session 7 & 8) 38: OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve Ulcerative Colitis Y. Haberman1, 2, R. Karns2, P. Dexheimer2, M. Schirmer3, T. Braun1, M. Collins2, A. Mo4, M. Rosen2, N. Gotman5, PROTECT Study group, S. Kugathasan6, T. D. Walters7, G. Gibson4, S. Davis Thomas5, C. Huttenhower8, R. J. Xavier9, J. S. Hyams10, L. A. Denson2 1Sheba Medical Center, Tel Hashomer, Israel, 2Cincinnati Children 14:20 - 14:30 Hospital Medical Center, Cincinnati, United States, 3Broad Institute of MIT and Harvard University, Cambridge, United States, 4Georgia Institute of Technology, Atlanta, United States, 5University of North Carolina, Chapel Hill, United States, 6Emory University, Atlanta, United States, 7Hospital For Sick Children, Toronto, Canada, 8Harvard School of Public Health, Boston, United States, 9Broad Institute of MIT and Harvard University, Boston, United States, 10Connecticut Children’s Medical Center, Hartford, United States 39: OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s Disease A. Lewis1, R. Jeffrey1, T. Kumagai1, C. J. Hawkey2, M. M. Clark2, M. Allez3, J. Satsangi4, G. Rogler5, A. Silver1, J. O. Lindsay6 1Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Genomics and Child Health, London, United Kingdom, 2Centre for Digestive Diseases, Queens Medical Centre, Nottingham, United 14:30 - 14:40 Kingdom, 33Department of Gastroenterology, Hôpital Saint Louis, APHP, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité Unversity, Paris, France, 4Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 5Department of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland, 6Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Immunobiology, London, United Kingdom 14:40 - 15:10 Coffee break EITHER: Scientific Session 7: ECCO Fellowships and Grants (Plenary Hall, Hall A, Bella Center) 15:10 - 15:55 Edouard Louis, Liège, Belgium Janneke van der Woude, Rotterdam, The Netherlands 40: Outcomes from the ECCO Pioneer Award 2017: Faecal transplantation using a novel conditioning method for donor 15:10 - 15:17 and recipient in mild to moderate treatment refractory colitis in Inflammatory Bowel Disease Arie Levine, Tel Aviv, Israel 41: Outcomes from the ECCO Fellowship 2018: Role of TNF-inducible 15:17 - 15:24 gene-6 (TSG-6) in fistulising Crohn’s Disease Sudharshan Elangovan, Thuwal, Saudi Arabia 42: Outcomes from the ECCO Fellowship 2018: Monocyte-derived macrophages as crucial players in the resolution of inflammation 15:24 - 15:31 and tissue repair in Inflammatory Bowel Disease Sales Ibiza, Lisbon, Portugal 43: Outcomes from the ECCO-IOIBD Fellowship 2017: Precision 15:31 - 15:38 medicine for IBD using advanced machine learning Aria Zand, Los Angeles, United States 44: Outcomes from the ECCO-IOIBD Fellowship 2018: Deciphering 15:38 - 15:45 the gut-specific B cell response in Inflammatory Bowel Disease Mathieu Uzzan, Clichy, France 15:45 - 15:55 45: Announcement of ECCO Fellowships & Grants 2019 OP = Oral presentation – Best abstracts
26 14th Congress of ECCO - European Crohn‘s and Colitis Organisation “Research drives clinical care”
Friday, March 8, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center (Session 7 & 8) Scientific Session 8: IBD Horizons (Plenary Hall, Hall A, Bella Center) 15:55 - 16:55 Dominik Bettenworth, Münster, Germany Janneke N. Samsom, Rotterdam, The Netherlands 46: OP21: ABX464 is safe and efficacious in a proof of concept study in Ulcerative Colitis patients S. Vermeire1, X. Hébuterne2, P. Napora3, M. Wisniewska-Jarosinska4, G. Kiss5, A. Bourreille6, Z. Przemysław7, J. Nitcheu8, P. Gineste8, J.-M. Steens8, H. Ehrlich8 15:55 - 16:05 1University Hospitals Leuven, Leuven, Belgium, 2CHU Nice Hopital Archet 2, Nice, France, 3Piotr Napora Centrum Badań Klinicznych Lekarze Sp.p., Wroclaw, Poland, 4SANTA FAMILIA, Centrum Badań, Profilaktyki i Leczenia, Lodz, Poland, 5Vasútegészségügyi Nonprofit Közhasznú Kft, Debrecen, Hungary, 6CHU Nantes Hotel Dieu, Nantes, France, 7KO-Med, Lublin, Poland, 8Abivax, Paris, France 47: OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental Colitis M. Barnhoorn1, L. Plug1, E. Muller - de Jonge1, E. Bos2, A. van der Meulen- 16:05 - 16:15 de Jong1, H. Verspaget1, L. Hawinkels1 1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Leiden University Medical Center, Cell and Chemical Biology, Leiden, Netherlands 48: OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates Colitis in various animal models J. Shin1, N. Ha1, D. Bae1, D.-h. Suh1, J.-Y. Baek1, J. H. Jun1, Y. J. Lee1, Y. I. Choi1, K. H. Ryu1, G. S. Youn2, J. Park2, S.-M. Lee3, S.-K. Seo3, J. W. Lee4, J. S. Kim4, 5 1Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, South Korea, 2Hallym University, Department of Biomedical 16:15 - 16:25 Science, Chuncheon, South Korea, 3Inje University College of Medicine, Department of Microbiology and Immunology, Gimhae, South Korea, 4Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 5Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine and Healthcare Research Institute, Seoul, South Korea 49: OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn‘s Disease M. Fumery1, L. Peyrin-Biroulet2, S. Nancey3, R. Altwegg4, P. Veyrard5, G. Bouguen6, S. Viennot7, F. Poullenot8, J. Filippi9, A. Buisson10, A. Bozon11, C. Gilletta12, F. Brazier13, L. Pouillon2, B. Flourié14, L. Boivineau4, L. Siproudhis6, D. Laharie8, X. Roblin15, X. Treton11 1Amiens University Hospital, Gastroenterology, Amiens, France, 2Nancy University Hospital, Gastroenterology, Nancy, France, 3Lyon University Hospital, Lyon, France, 4Montpellier University Hospital, Gastroenterology, Montpellier, France, 5Saint Etienne University 16:25 - 16:35 Hospital, Gastroenterology, Saint Etienne, France, 6Rennes University Hospital, Gastroenterology, Rennes, France, 7Caen University Hospital, Gastroenterology, Caen, France, 8Bordeaux University Hospital, Gastroenterology, Bordeaux, France, 9Nice University Hospital, Gastroenterology, Nice, France, 10Clermont-Ferrand, Gastroenterology, Clermont Ferrand, France, 11Hopital Beaujon, Gastroenterology, Clichy, France, 12Toulouse University Hospital, Gastroenterology, Toulouse, France, 13Amiens University Hospital, Gastroenterology, Amiens, France, 14Lyon University Hospital, Gastroenterology, Lyon, France, 15Saint Etienne University Hospital, Gastroenterology, Saint-Etienne, France
OP = Oral presentation – Best abstracts
March 6-9, 2019 • Copenhagen, Denmark 27 Scientific programme day by day
Friday, March 8, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center (Session 7 & 8) 50: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s Disease E. Dreesen1, F. Baert2, D. Laharie3, P. Bossuyt4, Y. Bouhnik5, A. Buisson6, G. Lambrecht7, E. Louis8, B. Oldenburg9, B. Pariente10, M. Pierik11, C. J. van der Woude12, G. D‘Haens13, S. Vermeire14, 15, A. Gils1 1University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2AZ Delta, Department of Gastroenterology, Roeselare, Belgium, 3Hôpital Haut-Lévêque, Service d‘Hépato-gastroentérologie et Oncologie Digestive, Bordeaux, France, 4Imelda General Hospital, IBD Clinic, Bonheiden, Belgium, 5Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy, France, 6Estaing University Hospital, 16:35 - 16:45 Department of Gastroenterology, Clermont-Ferrand, France, 7AZ Damiaan, Department of Gastroenterology, Oostende, Belgium, 8Liège University Hospital, Department of Gastroenterology, Liège, Belgium, 9University Medical Centre, Department of IIS Gastroenterology and Hepatology, Utrecht, Netherlands, 10Huriez Abstract Award Hospital, Lille 2 University, Department of Gastroenterology and Hepatology, Lille, France, 11University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, 12Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, 13Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, 14University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 15University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium 51: OP26: Long-term safety of vedolizumab in Ulcerative Colitis and Crohn’s Disease: Final results from the GEMINI LTS study S. Vermeire1, J.-F. Colombel2, B. G. Feagan3, W. J. Sandborn4, B. E. Sands2, S. Danese5, G. D’Haens6, R. Panaccione7, D. T. Rubin8, I. Shafran9, A. Parfionovas10, R. Rogers10, R. A. Lirio10, E. V. Loftus, Jr11 1University Hospitals Leuven, Leuven, Belgium, 2Icahn School of Medicine at Mount Sinai, New York, United States, 3Western University, 16:45 - 16:55 London, Canada, 4University of California San Diego, La Jolla, United States, 5Humanitas University, Milan, Italy, 6Academic Medical Centre, Amsterdam, Netherlands, 7University of Calgary, Calgary, Canada, 8University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States, 9Shafran Gastroenterology Research Center, Winter Park, United States, 10Takeda Pharmaceuticals, Cambridge, United States, 11Mayo Clinic College of Medicine, Rochester, United States
OP = Oral presentation – Best abstracts
28 14th Congress of ECCO - European Crohn‘s and Colitis Organisation “Research drives clinical care”
Friday, March 8, 2019, cont. Scientific programme day by day (as of February 1, 2019) C1-M4-5, Hall C, Bella Center (Session 9) OR: Scientific Session 9: Basic Science: Immune cells and microbes: A happy marriage? (C1-M4-5, Hall C, Bella Center) 15:10 - 16:50 Tim Raine, Cambridge, United Kingdom Raja Atreya, Erlangen, Germany 52: Metabolic profiling – the new player in microbiome research 15:10 - 15:30 Stefan Schreiber, Kiel, Germany 53: OP27: High-dimensional mass cytometry reveals the immune cell landscape in Inflammatory Bowel Disease V. van Unen1, N. Li1, T. Abdelaal2, 3, Y. Kooy-Winkelaar1, L. Ouboter1, 4, G. Beyrend1, T. Höllt5, 6, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10, 1, A. van der Meulen - de Jong4, F. Koning1 1Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, Netherlands, 2Delft University of Technology, Delft Bioinformatics Lab, Delft, Netherlands, 3Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, 4Leiden University Medical Center, Department 15:30 - 15:40 of Gastroenterology, Leiden, Netherlands, 5Leiden University Medical Center, Leiden Computational Biology Centerc, Leiden, Netherlands, 6Delft University of Technology, Computer Graphics and Visualization, Delft, Netherlands, 7Leiden University Medical Center, Department of Paediatrics, Leiden, Netherlands, 8Alrijne Hospital, Department of Gastroenterology, Leiderdorp, Netherlands, 9Erasmus University Medical Center, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 10Delft University of Technology, Pattern Recognition and Bioinformatics Group, Delft, Netherlands, 11Leiden University Medical Center, Department of LKEB Radiology, Leiden, Netherlands 54: OP28: Host-microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis M. Neyazi1, N. Ilott2, Oxford IBD Cohort study investigators1, S. Travis1, C. 15:40 - 15:50 Arancibia1, F. Powrie2, A. Geremia1 1University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, 2University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom 55: Using mucosal immune pathways to predict disease outcome 15:50 - 16:10 Ahmed Hegazy, Berlin, Germany 56: OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer L. R. Lopetuso1, C. De Salvo2, L. Di Martino2, W. Goodman2, F. Scaldaferri3, A. Armuzzi3, A. Gasbarrini1, T. T. Pizarro2 1Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, 16:10 - 16:20 Gastroenterological and Endocrino-Metabolical Sciences Department, Y-ECCO Roma, Italy, 2Case Western Reserve University, Cleveland, United States, Abstract Award 3Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrino-Metabolical Sciences Department, Roma, Italy
OP = Oral presentation – Best abstracts
March 6-9, 2019 • Copenhagen, Denmark 29 Scientific programme day by day
Friday, March 8, 2019, cont. Scientific programme day by day (as of February 1, 2019) C1-M4-5, Hall C, Bella Center (Session 9) 57: OP30: Serum proteomic profiling predicts and diagnoses pouchitis in Ulcerative Colitis patients undergoing ileal pouch-anal anastomosis K. Machiels1, M. Ferrante1, 2, N. Davani1, A. Wolthuis3, A. D‘Hoore3, S. 16:20 - 16:30 Vermeire1, 2 1KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 2University Hospitals Leuven, Department of gastroenterology and hepatology, Leuven, Belgium, 3University Hospitals Leuven, Abdominal surgery, Leuven, Belgium 58: Resolution pathways: Next frontier to control intestinal 16:30 - 16:50 inflammation Silvia D’Alessio, Milan, Italy Digital Oral Presentations (Sessions 6 - 10) 17:05 - 18:05 See pg. 41 Industry sponsored satellite symposia 4a & 4c & 4d 18:35-19:35 See pg. 112
OP = Oral presentation – Best abstracts
30 14th Congress of ECCO - European Crohn‘s and Colitis Organisation UR-CARE Online now!
United Registries for Clinical Assess ment and RE search
The IBD Database for your patient records and your research studies
What to expect Highlights • Comprehensive registry capturing • Quality of care assessment demographics, environmental factors, clinical • High mobility & continuity of care for patients characteristics, examinations and therapeutic • Different options of printable patient reports interventions in IBD • Sophisticated, user friendly data export • Ground-breaking cross-project cooperation • Real-life test version • Retro- & prospective data collection and • Core paediatric & surgical variables available evaluation • Validation study: Published in JCC • Autonomous data management offered to study groups • Precise data ownership rules
Scan and visit www.ecco-ibd.eu/ur-care
MASTER_2018_POSTER_URCARE_print 1 04.01.2019 18:25:11 Scientific programme day by day
Saturday, March 9, 2019 Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center Scientific Session 10: The cycle of IBD life in clinical practice 08:30 - 10:20 Glen Doherty, Dublin, Ireland Richard Russell, Glasgow, United Kingdom 59: Challenges in managing the elderly 08:30 - 08:50 Guillaume Savoye, Rouen, France 60: OP31: TP53 mutation in human colonic organoids acquires resistance to in vitro long-term inflammation K. Tsuchiya, S. Watanabe, T. Shirasaki, R. Nishimura, N. Katsukura, S. 08:50 - 09:00 Hibiya, R. Okamoto, T. Nakamura, M. Watanabe Tokyo Medical and Dental Universityl and Dental Universityl and, Tokyo, Japan 61: OP32: A novel mechanism of colonic epithelial-T cell cross-talk is dysregulated in IBD R. J. Dart1, 2, 3, P. Vantourout1, 2, P. M. Irving3, A. Hayday1, 2 09:00 - 09:10 1King‘s College London, Peter Gorer Dept of Immunobiology, London, United Kingdom, 2Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom, 3Guy‘s and St Thomas Hospital, Department of Gastroenterology, London, United Kingdom Y-ECCO 62: The reproductive phase: Practical recommendations Abstract Award 09:10 - 09:30 Ailsa Hart, London, United Kingdom 09:30 - 09:40 63: OP33: Late-breaking Abstract 09:40 - 09:50 64: OP34: Late-breaking abstract
OP = Oral presentation – Best abstracts
32 14th Congress of ECCO - European Crohn‘s and Colitis Organisation “Research drives clinical care”
Saturday, March 9, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center 65: OP35: Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s Disease: Long-term data from CALM C. Yzet1, R. Ungaro2, P. Bossuyt3, F. Baert4, T. Vanasek5, G. D‘Haens6, V. Joustra6, R. Panaccione7, G. Novacek8, A. Armuzzi9, O. Golovchenko10, O. Prymak10, A. Goldis11, S. Travis12, X. Hébuterne13, M. Ferrante14, G. Rogler15, M. Fumery1, S. Danese16, G. Rydzewska17, B. Pariente18, E. Hertervig19, C. Stanciu20, J.-C. Grimaud21, M.-M. Diculescu22, L. Peyrin-Biroulet23, D. Laharie24, J. P. Wright25, F. Gomollón26, I. Gubonina27, S. Schreiber28, S. Motoya29, P. Hellström30, J. Halfvarson31, J.-F. Colombel2 1Amiens University Hospital, Amiens, France, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 3IBD Clinic, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, 4AZ Delta Roeselare, Roeselare, Belgium, 52-nd Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic, 6Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, 7Cumming School of Medicine, University of Calgary, Calgary, Canada, 8Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, 9Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, 10Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine, 11Universitatea de Medicina 09:50 - 10:00 si Farmacie, Timisoara, Romania, 12Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom, 13Gastro-Entérologie & Nutrition Clinique, Hopital de l‘Archet 2, Nice, France, 14University Hospitals Leuven, Leuven, Belgium, 15Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, 16Humanitas University, Istituto Clinico Humanitas, Milan, Italy, 17Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland, 18Claude Huriez Hospital, Lille University, Lille, France, 19Skane University Hospital, Lund, Sweden, 20Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, 21Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France, 22University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 23Hépato Gastro-Entérologie, Hôpital de Brabois, Nancy, France, 24Hépato-gastroentérologie et d‘oncologie digestive, Hôpital Haut-Lévêque, Pessac, France, 25Kingsbury Hospital, Cape Town, South Africa, 26Hospital Clínico de Zaragoza, IIS Aragón, Zaragoza, Spain, 27Military Medical Academy named after S.M.Kirov, Saint-Petersburg, Russian Federation, 28Department of Internal Medicine I, Kiel University, Kiel, Germany, 29IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan, 30Uppsala University Hospital, Uppsala, Sweden, 31Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden 66: Cancer risk in children with IBD, an under-recognised issue 10:00 - 10:20 Arie Levine, Tel Aviv, Israel 10:20 - 10:50 Coffee break
OP = Oral presentation – Best abstracts
March 6-9, 2019 • Copenhagen, Denmark 33 Scientific programme day by day
Saturday, March 9, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center Scientific Session 11: Towards the future of IBD 10:50 - 12:20 Nik Sheng Ding, Melbourne, Australia Marc Ferrante, Leuven, Belgium 67: Artificial intelligence augmenting medical management 10:50 - 11:10 Vishal Nangalia, London, United Kingdom 68: OP36: A colonic gene expression signature predicts non- response to anti-inflammatory therapies in Inflammatory Bowel Disease 11:10 - 11:20 T. Sato1, K. Li1, K. Hayden1, L. Tomsho1, F. Baribaud1, C. Brodmerkel1, L. E. Greenbaum1, J. R. Friedman1, M. Curran1, Y. Imai2, S. Plevy1, S. E. Telesco1 1Janssen Research & Development, LLC, Spring House, United States, 2Janssen Pharmaceutical K.K., Tokyo, Japan 69: Robot and surgeon: How will a partnership work? 11:20 - 11:40 Antonino Spinelli, Milan, Italy 70: OP37: Efficacy and safety of ustekinumab as maintenance therapy in Ulcerative Colitis: Week 44 results from UNIFI W. J. Sandborn1, B. E. Sands2, R. Panaccione3, C. D. O‘Brien4, H. Zhang4, J. Johanns4, L. Peyrin-Biroulet5, G. Van Assche6, S. Danese7, S. R. Targan8, M. T. Abreu9, T. Hisamatsu10, P. Szapary4, C. Marano4 1University of California San Diego, La Jolla, United States, 2Icahn School 11:40 - 11:50 of Medicine at Mount Sinai, New York, United States, 3University of Calgary, Calgary, Canada, 4Janssen Research & Development, LLC, Spring House, United States, 5Nancy University Hospital, Université de Lorraine, Nancy, France, 6University of Leuven, Leuven, Belgium, 7Humanitas Research Hospital, Milan, Italy, 8Cedars-Sinai Medical Center, Los Angeles, United States, 9University of Miami Miller School of Medicine, Miami, United States, 10Kyorin University, Tokyo, Japan 71: OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with Moderately to Severely Active Ulcerative Colitis G. R. D‘Haens1, W. J. Sandborn2, M. Ferrante3, B. R. Bhandari4, E. Berliba5, T. Hibi6, J. Tuttle7, J. B. Canavan8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2University California San Diego, La Jolla, California, United States, 3UZ 11:50 - 12:00 Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 4Delta Research Partners, LLC, Bastrop, LA, United States, 5Nicolae Testemițanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, 6Kitasato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, 7Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, 8Eli Lilly and Company, Indianapolis, Indiana, United States, 9Western University, Robarts Clinical Trials Inc, London, Ontario, Canada 72: Big data: Potential for transforming IBD research and care 12:00 - 12:20 Ignacio Hernandez-Medrano, Madrid, Spain
OP = Oral presentation – Best abstracts
34 14th Congress of ECCO - European Crohn‘s and Colitis Organisation “Research drives clinical care”
Saturday, March 9, 2019, cont. Scientific programme day by day (as of February 1, 2019) Plenary Hall, Hall A, Bella Center Scientific Session 12: ECCO Lecture 12:20 - 12:50 Silvio Danese, Milan, Italy Laurent Peyrin-Biroulet, Vandeouvre-Les-Nancy, France 73: ECCO Lecture: Inflammatory cytokines from discoveries to 12:20 - 12:50 therapies Charles Dinarello, Denver, United States 74: Awards and closing remarks 12:50 - 12:55 Silvio Danese, Milan, Italy 12:55 - 13:00 75: The ECCO Film
OP = Oral presentation – Best abstracts
March 6-9, 2019 • Copenhagen, Denmark 35 BarcelonaCopenhagen SpainDenmark
Abstracts 2019
Contains all ECCO’19 Abstracts
ECCO Key USB Drive Helmet shaped USB Drive • Pick up at ECCO Booth • Pick up at Booth #17 • Limited number only
Please be aware that upon receiving your special shaped USB key in the Exhibition hall, the sponsor will collect your name, city, country, affiliation and email address.
Scan and contact the ECCO Office www.ecco-ibd.eu
2019_POSTER_Abstracts 2019 USB Drive.indd 1 04.01.2019 18:16:05 Abstract presentation format
Abstract presentation format Oral presentations (OP) Out of 1228 submitted abstracts the 38 best submitted abstracts have carefully been chosen by a panel of referees and selected for oral presentation during the scientific programme. For the presentation schedule, please refer to the scientific programme on pg. 19. Note: Oral poster presentations will not be displayed as hard copy posters. Digital oral presentations (DOP) After the 38 selected for oral presentations in the scientific programme, the following 90 best abstracts are selected as digital oral presentations. Each author of an abstract accepted under this category is invited to hold a 5-minute oral presentation in one of ten Digital Oral Presentation sessions. DOP sessions 1-5 run parallel on Thursday, March 7, 2019 from 17:30 to 18:30. DOP Sessions 6-10 run parallel on Friday, March 8, 2019 from 17:05-18:05. You can find a detailed schedule of all DOP sessions on pg. 41. Note: Digital oral presentations will not be displayed as hard copy posters.
DOP award ceremony: On Saturday, March 9, 2019 from 12:50 to 12:55 the DOP prizes will be awarded to the “Top Ten Best DOPs”. One abstract of each digital oral presentation room will be nominated for this award by the chairs of the respective sessions.
Please note that this is the 9th year that the ECCO Congress hosts a separate nurse poster section in the poster exhibition area located in Hall B. Please find the link to nurse posters on pg. 68.
DOP award ceremony is chaired by: Silvio Danese (Italy) Laurent Peyrin-Biroulet (France) Willem Bemelman (The Netherlands) Janneke van der Woude (The Netherlands) Antonio López-Sanromán (Spain) Hard copy poster presentations Authors of accepted abstracts which are not OPs or DOPs are invited to present their studies as hard copy poster presentations. For details regarding the poster exhibition, visit the ECCO Website at www.ecco-ibd.eu/ecco19. An overview of the abstract topics with a link to the respective hard copy posters can be found on pg. 67. Hard copy posters will be installed on poster walls in the poster exhibition area in Hall B and will be available for viewing throughout the Congress.
March 6-9, 2019 • Copenhagen, Denmark 37 Abstract presentation format
Reviewers ECCO gratefully thanks the following reviewers for their valuable time and efforts in reviewing abstracts submitted to ECCO’19:
(i) Basic Science Giorgio Bamias (Greece), Mathilde Body (France), Paula Borralho Nunes (Portugal), Gerhard Rogler (Switzerland), Azucena Salas (Spain), Franco Scaldaferri (Italy), Michael Scharl (Switzerland), Anja Schirbel (Germany), Dror Shouval (Israel), Heitor Siffert de Souza (Brazil), Monika Tripathi (United Kingdom), Holm Uhlig (United Kingdom), Dominique Velin (Switzerland), David Bernardo (Spain), Jesús Cosín (Spain), George Kolios (Greece), Elias Kouroumalis (Greece), Daniel Marks (United Kingdom), Saurabh Mehandru (United States), Luis Menchen (Spain), Marie-Alice Meuwis (Belgium), Salomé Pinho (Portugal)
(ii) Clinical: Diagnosis and Outcome Matthieu Allez (France), Marina Aloi (Italy), Vito Annese (Italy), Raja Atreya (Germany), Oliver Bachmann (Germany), Filip Baert (Belgium), Manuel Barreiro de Acosta (Spain), Shomron Ben- Horin (Israel), Dominik Bettenworth (Germany), Bernd Bokemeyer (Germany), Yoram Bouhnik (France), Daniel Burger (Australia), Emma Calabrese (Italy), Andrea Cassinotti (Italy), Fabiana Castiglione (Italy), Cristina Cijevschi (Romania), Francesco Colombo (Italy), Marilia Cravo (Portugal), Silvio Danese (Italy), Gert De Hertogh (Belgium), Lissy de Ridder (The Netherlands), Vincenza Di Leo (Italy), Mircea Diculescu (Romania), Glen Doherty (Ireland), Eugeni Domènech (Spain), Tomas Douda (Czech Republic), David Drobne (Belgium), Martin Goetz (Germany), Gwo-Tzer Ho (United Kingdom), Marietta Iacucci (United Kingdom), Njegica Jojic (Serbia), Philippe Marteau (France), Florian Rieder (United States), Jordi Rimola (Spain), Richard Russell (United Kingdom), Hagit Tulchinsky (Israel), Patrick Van Rheenen (The Netherlands), Francesca Maccioni (Italy), Giovanni Maconi (Italy), Pasquale Paolantonio (Italy), Dina Tiniakos (Greece), Christos Zavos (Greece), Francesca Rosini (United Kingdom)
(iii) Clinical: Therapy and Clinical Observation Antonio Di Sabatino (Italy), Nick Kennedy (United Kingdom), Ioannis Papaconstantinou (Greece), Juris Pokrotnieks (Latvia), Frank Werner Seibold (Switzerland), Albert Wolthuis (Belgium), Alessandro Armuzzi (Italy), Willem Bemelman (The Netherlands), Franck Carbonnel (France), Mario Cottone (Italy), Joline de Groof (The Netherlands), Laurence Egan (Ireland), Hankje Escher (The Netherlands), Marc Ferrante (Belgium), Gionata Fiorino (Italy), Mayur Garg (Australia), Kristina Gecse (Hungary), Ann Gils (Belgium), Daniel Ginard Vicens (Spain), Paolo Gionchetti (Italy), Javier Perez Gisbert (Spain), Adrian Goldis (Romania), Dieter Hahnloser (Switzerland), Jonas Halfvarson (Sweden), Ailsa Hart (United Kingdom), Joaquin Hinojosa (Spain), Christoph Högenauer (Austria), Samuel Huber (Germany), Peter Irving (United Kingdom), Guru Iyngkaran (Australia), Laimas Jonaitis (Lithuania), Pascal Juillerat (Switzerland), Konstantinos Karmiris (Greece), Konstantinos Katsanos (Greece), Robert Koch (Austria), Pavel Kohout (Czech Republic), Uri Kopylov (Canada), Paulo Kotze (Brazil), Iskren Kotzev (Bulgaria), Ioannis Koutroubakis (Greece), Zeljko Krznaric (Croatia), David Laharie (France), Peter Lakatos (Hungary), Ebbe Langholz (Denmark), Charlie W. Lees (United Kingdom), Jimmy Limdi (United Kingdom), James Lindsay (United Kingdom), Loris Riccardo Lopetuso (Italy), Edouard Louis (Belgium), Fernando Magro (Portugal), Nitsan Maharshak (Israel), John Mansfield (United Kingdom), Gerassimos Mantzaris (Greece), Pierre Michetti (Switzerland), Paula Ministro (Portugal), Tamas Molnar (Hungary), Bjorn Moum (Norway), Pär Myrelid (Sweden), Gottfried Novacek (Austria), Tom Oresland (Norway), Julian Panes (Spain), Yves Panis (France),
38 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Abstract presentation format
Konstantinos Papadakis (Greece), Konstantinos Papamichail (Greece), Gareth Parkes (United Kingdom), Harald Peeters (Belgium), Guillaume Pineton de Chambrun (France), Valérie Pittet (Switzerland), Tim Raine (United Kingdom), Zhihua Ran (China), Catherine Reenaers (Belgium), Jonathan Rhodes (United Kingdom), Elena Ricart (Spain), Xavier Roblin (France), Simone Saibeni (Italy), Bruce Sands (United States), Shaji Sebastian (United Kingdom), Nik Sheng Ding (Australia), Britta Siegmund (Germany), Andreas Stallmach (Germany), Andreas Sturm (Germany), Dino Tarabar (Serbia), Herbert Tilg (Austria), Simon Travis (United Kingdom), John Triantafillidis (Greece), Dan Turner (Israel), Janneke van der Woude (The Netherlands), Stephan Vavricka (Switzerland), Bram Verstockt (Belgium)
(iv) Epidemiology Nynne Nyboe Andersen (Denmark), Marte Lie Hoivik (Norway), Jonas Ludvigsson (Sweden), Ola Olén (Sweden), Marko Banic (Croatia), Johan Burisch (Denmark), Silvija Cukovic Cavka (Croatia), Hannah Gordon (United Kingdom), Tine Jess (Denmark), Richard Pollok (United Kingdom), Guillaume Savoye (France), Marco Scarpa (Italy), Morten Vatn (Norway), Gabor Veres (Hungary), Ida Vind (Denmark), David Wilson (United Kingdom)
(v) Genetics Isabelle Cleynen (Belgium), Maria Gazouli (Greece), Debby Laukens (Belgium), Maikel Peppelenbosch (The Netherlands)
(vi) Microbiology Christine Edwards (United Kingdom), Gwenny Fuhler (The Netherlands), Charlotte Hedin (Sweden), Kathleen Machiels (Belgium), Philippe Seksik (France), Harry Sokol (France), Markus Tschurtschenthaler (Austria)
(vii) Nurses abstracts Wladzia Czuber-Dochan (United Kingdom), Kay Greveson (United Kingdom), Petra Hartmann (Germany), Karen Kemp (United Kingdom), Jochen Maul (Germany), Marian O’Connor (New Zealand)
March 6-9, 2019 • Copenhagen, Denmark 39 Why submit your research to JCC?
Prompt and professional peer review
JCC publishes research that has undergone rigorous peer review, including an initial screening by one of the Editors and recommendations by independent reviewers. The average time from submission to first decision is two weeks. Fast publication speeds • Fast Advance Access publication of the author manuscript version within one week of acceptance making your work discoverable faster. High Impact Factor • With its 2017 Impact Factor, which now stands at 6.637, JCC ranks highly among gastroenterology and hepatology journals. Wide dissemination • Publishing in JCC will ensure that your article will be seen, read and cited by your research community.
Scan and log in at www.ecco-ibd.eu
2019_POSTER_Why submit your research to JCC.indd 1 21.12.2018 16:19:00 Digital oral presentations
Digital oral presentations (DOP)
Thursday March 7, 2019 Digital Oral Presentation 17:30-18:30 Sessions 1-5 C1 Rooms, Hall C Friday, March 8, 2019 Digital Oral Presentation 17:05-18:05 Sessions 6-10 C1 Rooms, Hall C
Please find an overview of all DOP sessions below. A detailed schedule including selected abstracts for each digital oral presentation room can be found on the pages listed in the table.
Advances in IBD pathophysiology Digital Oral Presentation Session 1 Room: C1 M1 (please refer to page 42) Javier Gisbert, Madrid, Spain Maximilian Waldner, Erlangen, Germany Mechanisms of intestinal inflammation Digital Oral Presentation Session 2 Room: C1 M0 (please refer to page 43) Loris Riccardo Lopetuso, Rome, Italy Britta Siegmund, Berlin, Germany Translational science in IBD Digital Oral Presentation Session 3 Room: C1 M2 (please refer to page 45) Peter Bossuyt, Bonheiden, Belgium Axel Dignass, Frankfurt, Germany Practicalities of IBD patient care Digital Oral Presentation Session 4 Room: C1 M3 (please refer to page 47) Uri Kopylov, Tel Aviv, Israel Fernando Magro, Porto, Portugal Old and new treatment Digital Oral Presentation Session 5 Room: C1 M4-5 (please refer to page 50) Paolo Gionchetti, Bologna, Italy Anne Strik, Amsterdam, The Netherlands Novel treatments Digital Oral Presentation Session 6 Room C1 M4-5 (please refer to page 53) Marc Ferrante, Leuven, Belgium Gionata Fiorino, Rome, Italy Recent advances of biologic therapies Digital Oral Presentation Session 7 Room: C1 M3 (please refer to page 55) Filip Baert, Roeselare, Belgium Shomron Ben-Horin, Ramat Gan, Israel Intestinal healing Digital Oral Presentation Session 8 Room: C1 M2 (please refer to page 57) Raja Atreya, Erlangen, Germany Marietta Iacucci, Birmingham, United Kingdom Surgery and IBD Digital Oral Presentation Session 9 Room: C1 M1 (please refer to page 59) Paulo Kotze, Curitiba, Brazil Andre D‘Hoore, Leuven, Belgium Clinical epidemiology Digital Oral Presentation Session 10 Room: C1 M0 (please refer to page 62) Stefanos Bonovas, Milan, Italy Johan Burisch, Copenhagen, Denmark
March 6-9, 2019 • Copenhagen, Denmark 41 Digital oral presentations
Please find the detailed schedule for each session on the following pages: Thursday, March 7, 2019 Digital Oral Presentation Session 1 – Advances in IBD pathophysiology Room: C1 M1 17:30 - 18:30 Javier Gisbert, Madrid, Spain Maximilian Waldner, Erlangen, Germany DOP01: Extracellular nicotinamide phosphoribosyltransferase (eNAMPT): possible new target and biomarker in Inflammatory Bowel Diseases G. Colombo1, C. Travelli1, C. Porta1, G. Stocco2, F. Malavasi3, A. A. Genazzani1 17:30 - 17:36 1Università del Piemonte Orientale, Department of Pharmaceutical Sciences UNIUPO, Novara, Italy, 2Università degli studi di Trieste, Departement of Chemical and Pharmaceutical Sciences, Trieste, Italy, 3Università degli Studi di Torino, Department of Medical Science, Torino, Italy DOP02: Supplementation with butyrate producing bacteria reduces tumor load in a mouse model of Colitis associated cancer A. Montalban Arques1, I. Olivares Rivas1, K. Atrott1, C. Gottier1, S. Lang1, G. Leventhal2, T. DeWouters3, M. Scharl1, M. Spalinger1 17:36 - 17:42 1University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 2Massachusetts Institute of Technology, Department of Civil and Environmental Engineering, Cambridge, United States, 3Pharmabiome, Zurich, Switzerland DOP03: The correlation of regulatory miRNAs with cytokine serum levels and cytokine genes’ polymorphisms A. Surowiecka-Pastewka1, 2, M. Zagozda2, E. Zakościelna2, M. Durlik1, 2 17:42 - 17:48 1CSK Mswia, Department of Gastroenterological Surgery and Transplantation, Warsaw, Poland, 2Mossakowski Medical Research Centre of the Polish Academy of Sciences, Department of Surgical Research and Transplantology, Warsaw, Poland DOP04: The ability of epithelial regeneration is reduced in the Crohn’s Disease patient-derived organoids, especially in TNF-α enriched condition 17:48 - 17:54 J. H. Song, S. N. Hong, G. Seong, T. J. Kim, E. R. Kim, D. K. Chang, Y.-H. Kim, C. Lee, C. Lee Samsung Medical Center, Seoul, South Korea DOP05: Adipose-derived stem cells from Crohn’s Disease patients show antigen presenting cell-like properties C. Serena1, M. Terrón-Puig1, M. Ejarque1, F. Algaba-Chueca1, E. Maymó- Masip1, M. Millan2, M. Menacho3, E. Espin4, M. Martí4, S. Fernández- Veledo1, J. Vendrell1 17:54 - 18:00 1Health Institute Pere Virgili, Hospital Joan XXIII, Tarragona, Spain, 2Hospital Joan XXIII, Colorectal Surgery Unit, Tarragona, Spain, 3Hospital Joan XXIII, Digestive Unit, Tarragona, Spain, 4Hospital Vall Hebrón, Colorectal Surgery Unit, General Surgery Service, Barcelona, Spain DOP06: Dynamic shifts in the balance of gut homing Treg and Th17 cells play a critical role in Ulcerative Colitis and may predict response to vedolizumab therapy S. Hermangild Kottoor1, Z. Kassam1, P. Pavlidis1, 2, E. Alberts1, H. 18:00 - 18:06 Ibraheim1, 2, L. Constable1, J. Digby-Bell1, D. Warren2, S. Odukwe2, M. Samaan2, P. Irving2, J. Sanderson2, N. Powell1, 2 1King‘s College London, School of Immunology and Microbial sciences, London, United Kingdom, 2Guy‘s and St Thomas‘ NHS Foundation Trust, London, United Kingdom DOP07: IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases 18:06 - 18:12 M. Angin, C. Brignone, F. Triebel Immutep, Orsay, France
42 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Thursday, March 7, 2019, cont. DOP08: The regulatory landscape of intestinal cells – investigating the transcriptional effect of autophagy impairment observed in Crohn’s Disease using organoid and network biology approaches A. Treveil1, 2, P. Sudhakar1, 3, Z. Matthews4, T. Wrzesinkski1, E. Jones1, 2, P. Powell4, T. Wileman2, 4, I. Hautefort1, L. Hall2, F. Di Palma1, W. Haerty1, T. 18:12 - 18:18 Korcsmaros1, 2 1Earlham Institute, Norwich, United Kingdom, 2Quadram Institute, Norwich, United Kingdom, 3Catholic University of Leuven, Translational Research in Gastrointestinal Disorders, Leuven, Belgium, 4University of East Anglia, Norwich Medical School, Norwich, United Kingdom DOP09: Interleukin-20 subfamily cytokines in controlling intestinal inflammation and epithelial barrier integrity M. Moniruzzaman1, 2, R. Wang2, K. Wong2, H. Tong2, M. McGuckin3, S. Hasnain1, 2 18:18 - 18:24 1Faculty of Medicine, The University of Queensland, Brisbane, Australia, 2Immunopathology Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Brisbane, Australia, 3Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia
Digital Oral Presentation Session 2 – Mechanisms of intestinal inflammation Room: C1 M0 17:30 - 18:30 Loris Riccardo Lopetuso, Rome, Italy Britta Siegmund, Berlin, Germany DOP10: Serum N-glycomic biomarkers predict treatment escalation in Inflammatory Bowel Disease A. Shubhakar1, B. Jansen1, A. Adams2, K. Reiding3, N. Ventham4, D. Bergemalm5, P. Urbanowicz1, R. Gardner1, IBD-BIOM Consortium, J. Halfvarson6, J. Satsangi2, D. Fernandes1, M. Wuhrer7, D. Spencer1 1Ludger Ltd, Abingdon, United Kingdom, 2University of Oxford, 17:30 - 17:36 Translational Gastroenterology Unit, Oxford, United Kingdom, 3Utrecht University, Division of Biomolecular Mass Spectrometry, Utrecht, Netherlands, 4University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, 5Örebro University, Department of Gastroenterology, Örebro, Sweden, 6Örebro University, Örebro, Sweden, 7Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, Netherlands DOP11: Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in Ulcerative Colitis S. Slevin1, M. Tan1, C. Lahiff1, L. M. Wang2, B. Greenaway1, K. Lynch1, A. Geremia1, S. Hughes3, K. Leavens3, K. Nevin3, D. J. B. Marks3, R. Tarzi3, N. 17:36 - 17:42 Srinivasan3, S. Travis1, C. Arancibia1, S. Keshav1 1University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, 2Changi General Hospital, SingHealth, Department of Laboratory Medicine, Singapore, Singapore, 3GlaxoSmithKline, Experimental Medicine Unit, Stevenage, United Kingdom DOP12: Mutations in the X-linked inhibitor of apoptosis protein promote susceptibility to microbiota-induced intestinal inflammation S. Gopalakrishnan1, 2, Y. Zeissig2, A. Strigli1, M. Basic3, J. Hartwig2, J. Wang4, M. Muders5, G. Barreton5, J. F. Baines4, A. Bleich3, J. Hampe1, 5, 17:42 - 17:48 S. Zeissig1, 2, 5 1Center for Regenerative Therapies Dresden, TU Dresden, Dresden, Germany, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3Hannover Medical School, Hannover, Germany, 4Max-Planck Institute for Evolutinary Biology, Kiel, Germany, 5University Hospital Carl-Gustav Carus, Dresden, Germany
March 6-9, 2019 • Copenhagen, Denmark 43 Digital oral presentations
Thursday, March 7, 2019, cont. DOP13: Immune profiling of adipose tissue in murine models of Inflammatory Bowel Disease (IBD) M. Letizia1, Y. Rodriguez Sillke1, F. Schmidt1, C. Günther2, D. Kunkel3, R. Glauben1, B. Siegmund1, C. Weidinger1 17:48 - 17:54 1Charité - Universitätsmedizin Berlin, Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany, 2Universitätsklinikum Erlangen, Gastroenterologie, Erlangen, Germany, 3Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany DOP14: TiO2 nanoparticles abrogate the protective effect of the autoimmunity-associated PTPN22R619W variant during acute DSS Colitis 17:54 - 18:00 M. Schwarzfischer, L. Hering, E. Katkeviciute, A. Niechcial, K. Atrott, K. Bäbler, P. Busenhart, G. Rogler, M. Scharl, M. Spalinger University of Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland DOP15: Metabolomics coupled with pathway analysis characterise metabolic changes in treatment-naive Ulcerative Colitis patients J. Diab1, T. Hansen1, R. Goll2, E. Jensen1, T. Moritz3, J. Florholmen4, G. Forsdahl1 1Natural Products and Medicinal Chemistry Research Group, Department of pharmacy, University of Tromsø The Arctic University 18:00 - 18:06 of Norway, Tromsø, Norway, 2Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, University of Tromsø The Arctic University of Norway, Tromsø, Norway, 3Swedish Metabolomics Center, Swedish University of Agricultural Sciences, Umeå, Sweden, 4Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, Tromsø, Norway DOP16: Endoplasmic reticulum stress in subepithelial myofibroblasts increases the TGF-β1 activity that regulates fibrosis in Crohn’s Disease 18:06 - 18:12 C. Li, J. Kuemmerle Virginia Commonwealth University, Internal Medicine, Richmond, United States DOP17: AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of Inflammatory Bowel Disease (IBD) M. Wang1, T. John2, L. Zhang1, L. Zhu1, Y. Xu1, K. Chen1, S. Han1, J. Li1, F. Wang1, C. Deceneux3, 4, A. Behren3, 4, Z. Yang1 18:12 - 18:18 1Dizal (Jiangsu) Pharmaceutical Co., Ltd, Shanghai, China, 2Austin Health, Heidelberg, Australia, 3Olivia Newton-John Cancer Research Institute, Heidelberg, Australia, 4La Trobe University, School of Cancer Medicine, Heidelberg, Australia DOP18: OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production A. Vossenkamper1, K. Foster2, K. Nevin2, G. Tannahill2, S. Flint2, T. T. McDonald1 18:18 - 18:24 1Blizard Institute, Barts and the London School of Medicine and Dentistry, Immunobiology, London, United Kingdom, 2GlaxoSmithKline, Immunoinflammation Unit, Stevenage, United Kingdom
44 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Thursday, March 7, 2019, cont. Digital Oral Presentation Session 3 – Translational science in IBD Room: C1 M2 17:30 - 18:30 Peter Bossuyt, Bonheiden, Belgium Axel Dignass, Frankfurt, Germany DOP19: Spermidine treatment ameliorates experimental Colitis in vivo A. Niechcial1, E. Katkeviciute1, L. Hering1, M. Wawrzyniak1, M. 17:30 - 17:36 Schwarzfischer1, K. Bäbler1, K. Attrot1, M. Scharl1, 2, M. R. Spalinger1 1University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Zurich, Zurich Center for Integrative Human Physiology, Zurich, Switzerland DOP20: Drugs that modulate histone acetylation disrupt TGF-β- signalling and reduce collagen I expression in models of stricturing Crohn’s Disease A. Lewis1, A. Nijhuis1, G. Berti1, C. Felice2, R. Jeffrey1, S. Iqbal1, A. B. Pomeranc1, S. Aldelemi1, S. Mehta1, E. Giannoulatou3, R. Feakins4, A. Armuzzi2, J. O. Lindsay5, A. Silver1 1Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Genomics and Child Health, London, United 17:36 - 17:42 Kingdom, 2IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, 3Victor Chang Cardiac Research Institute and 4St Vincent’s Clinical School, University of New South Wales, Sydney, Australia, 4Department of Histopathology, The Royal London Hospital, London, United Kingdom, 5Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Immunobiology, London, United Kingdom 17:42 - 17:48 DOP21: This abstract has been withdrawn. DOP22: UC-related and segment-specific properties of patient- derived colonic organoids K. Suzuki, H. Shimizu, M. Kawai, J. Takahashi, S. Anzai, A. Kawamoto, 17:48 - 17:54 S. Nagata, Y. Hiraguri, S. Yui, K. Tsuchiya, T. Nakamura, K. Ohtsuka, K. Ohtsuka, R. Okamoto, M. Watanabe Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan DOP23: Myenteric plexitis and post-operative recurrence in Crohn’s Disease: The role of enteric glial cells and ICAM-1 C. Le Berre1, J. Pabois1, T. Durand1, E. Durieu1, M. Rolli-Derkinderen1, C. Bossard2, J. Podevin3, M. Neunlist1, I. Neveu1, P. Naveilhan1, A. Bourreille1, 4 1Nantes University Hospital, UMR Inserm 1235 - TENS, 17:54 - 18:00 Gastroenterology department, Institut des Maladies de l’Appareil Digestif, Nantes, France, 2Nantes University Hospital, Pathology department, Nantes, France, 3Nantes University Hospital, Digestive surgery department, Institut des Maladies de l’Appareil Digestif, Nantes, France, 4Nantes University Hospital, CIC, INSERM 1413, Nantes, France DOP24: Intestinal acidification sensed by pH-sensing receptor GPR4 contributes to fibrogenesis B. Weder1, W. T. Van Haaften2, K. Baebler1, G. Rogler3, G. Dijkstra4, P. H. Imenez Silva5, Y. Wang5, C. De Vallière3, C. Wagner5, I. Frey-Wagner3, K. Seuwen6, P. Ruiz3, M. Hausmann3 1University of Zurich, Zurich, Switzerland, 2University Medical Center 18:00 - 18:06 Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 3University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, 4University of Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 5University of Zurich, Institute of Physiology, Zurich, Switzerland, 6Novartis Institutes for Biomedical Research, Basel, Switzerland
March 6-9, 2019 • Copenhagen, Denmark 45 Digital oral presentations
Thursday, March 7, 2019, cont. DOP25: Unravelling vedolizumab mechanism of action in Ulcerative Colitis M. Veny1, A. Garrido1, H. Bassolas-Molina1, M. C. Masamunt1, M. Esteller1, M. Arroyes1, A. M. Corraliza1, E. Tristán2, A. Fernández-Clotet1, I. 18:06 - 18:12 Ordás1, E. Ricart1, M. Esteve2, J. Panés1, A. Salas1 1IDIBAPS, Hospital Clínic, CIBERehd, Department of Gastroenterology, Barcelona, Spain, 2Hospital Universitari Mutua Terrassa, Department of Gastroenterology, Terrassa, Spain DOP26: Biological therapy increases NCR+ ILC3 levels in IBD patients B. Creyns1, 2, B. Verstockt2, 3, J. Cremer1, 2, V. Ballet3, M. Ferrante2, 3, S. Vermeire2, 3, J. Ceuppens1, G. Van Assche2, 3, C. Breynaert1 18:12 - 18:18 1KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 18:18 - 18:24 DOP27: Late-breaking Abstract
46 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Thursday, March 7, 2019, cont. Digital Oral Presentation Session 4 – Practicalities of IBD patient care Room: C1 M3 17:30 - 18:30 Uri Kopylov, Tel Aviv, Israel Fernando Magro, Porto, Portugal DOP28: Maternal obstetric outcomes in women with IBD compared to the general population G. Lever1, T. Glanville1, C. Selinger2 17:30 - 17:36 1Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2Leeds Teaching Hospitals NHS Trust, Gastroenterology, Leeds, United Kingdom DOP29: Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF or conventional therapy A. Moens1, 2, C. van der Woude3, M. Julsgaard4, S. Sebastian5, 6, N. Arebi7, M. Alzinaty7, E. Humblet8, K. B. Kok9, J. Sheridan10, C. Gilletta De Saint-Joseph11, S. Nancey12, J.-F. Rahier13, P. Bossuyt14, A. Cremer15, S. Dewit16, C. Eriksson17, F. Hoentjen18, T. Krause19, E. Louis20, E. Macken21, Z. Milenkovic22, J. Nijs23, A. Posen24, A. Van Hootegem25, W. Van Moerkercke26, S. Vermeire1, 2, A. Bar-Gil Shitrit27, M. Ferrante1, 2 1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2Catholic University Leuven, Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, 4Aarhus University Hospital, Department of Gastroenterology and Hepatology, Aarhus, Denmark, 5Hull & East Yorkshire NHS Trust, IBD Unit, Hull, United Kingdom, 6University of Hull & York, Hull York Medical School, Hull, United Kingdom, 7St. Marks Hospital, Department of Gastroenterology, London, United Kingdom, 8Ziekenhuis Oost-Limburg - Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, 9Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom, 10St. Vincent’s University Hospital, Department of Gastroenterology, Dublin, 17:36 - 17:42 Ireland, 11Hôpital Rangueil, Department of Gastroenterology, Toulouse, France, 12CHU Lyon, Department of Gastroenterology and Hepatology, Lyon, France, 13CHU UCL Namur, Université catholique de Louvain, Deparment of Gastroenterology, Yvoir, Belgium, 14Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, 15Hôpital Erasme, Université Libre de Bruxelles, Department of Gastroenterology, Brussels, Belgium, 16Mariaziekenhuis Noord-Limburg, Department of Gastroenterology, Overpelt, Belgium, 17Faculty of Medicine and Health Orebro University, Department of Gastroenterology, Orebro, Sweden, 18Radboud UMC, Department of Gastroenterology, Nijmegen, Netherlands, 19Opernstrasse, Department of Gastroenterology, Kassel, Germany, 20CHU Liège, Department of Gastroenterology, Liège, Belgium, 21Universiteit ziekenhuis Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 22Military Medical Academy Belgrade, Department of Gastroenterology, Belgrade, Serbia, 23Sint- Trudo Ziekenhuis, Department of Gastroenterology, St-Truiden, Belgium, 24AZ Vesalius, Department of Gastroenterology, Tongeren, Belgium, 25AZ Klina, Department of Gastroenterology, Brasschaat, Belgium, 26AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, 27Shaare Zedek Medical Center, Hebrew University Jerusalem, Digestive diseases institute, Jerusalem, Israel DOP30: Factors associated with life satisfaction in people with Crohn’s Disease and Ulcerative Colitis: Results from the national 2018 Crohn’s and Colitis UK Inflammatory Bowel Disease Quality of Life Survey 17:42 - 17:48 G. Rowse1, S. Hollobone2, S. Afhim2, P. Oliver3 1University of Sheffield, Clinical Psychology Unit, Sheffield, United Kingdom, 2Crohn‘s and Colitis UK, St Albans, United Kingdom, 3University of Sheffield, Academic Unit of Primary Medical Care, Sheffield, United Kingdom
March 6-9, 2019 • Copenhagen, Denmark 47 Digital oral presentations
Thursday, March 7, 2019, cont. DOP31: Development and validation of the IBD-REFER criteria: When should a general practitioner or paediatrician refer a patient for suspected IBD? O. Atia1, G. Focht1, A. Assa2, B. Yerushalmi3, R. Shaoul4, D. S. Shouval5, A. Bar-Gil Shitrit6, B. Koslowsky6, I. Dotan7, R. Kariv8, E. Lavon8, D. Turner1 1Institute of Pediatric Gastroenterology, The Hebrew University of Jerusalem, Jerusalem, Israel, 2Schneider Children‘s Hospital, Petach Tikva, Israel, 3Soroka University Medical Center and Faculty of Pediatric 17:48 - 17:54 Gastroenetrology Unit, Health Sciences, Beer-Sheva, Israel, 4Pediatric Gastroenterology Institute, Ruth Children‘s Hospital, Rambam Medical Center, Haifa, Israel, 5Pediatric Gastroenterology Unit, Edmond and Lily Safra Children‘s Hospital, Sheba Medical Center, Ramat gan, Israel, 6Digestive diseases institute , Shaare Zedek Medical Center, Jerusalem, Israel, 7Division of Gastroenterology, Rabin Medical Center, Sackler Faculty of Medicine, Petach Tikva, Israel, 8Health Division, Maccabi Healthcare Services, Jerusalem, Israel DOP32: Withdrawal of thiopurines in Crohn’s Disease treated with scheduled adalimumab maintenance: A prospective randomised clinical trial (DIAMOND2) T. Hisamatsu1, S. Kato2, R. Kunisaki3, M. Matsuura4, M. Nagahori5, S. Motoya6, M. Esaki7, N. Fukata8, S. Inoue9, T. Sugaya10, H. Sakuraba11, F. Hirai12, K. Watanabe13, 14, T. Kanai15, M. Naganuma15, H. Nakase16, Y. Suzuki17, M. Watanabe5, T. Hibi18, M. Nojima19, T. Matsumoto20, DIAMOND2 Study Group 1Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, 2Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Saitama, Japan, 3Yokohama City University Medical Center, Inflammatory Bowel Disease Centre, Kanagawa, Japan,4 Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, 5Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 6Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan, 7Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, 17:54 - 18:00 Japan, 8Kansai Medical University, Third Department of Internal Medicine, Osaka, Japan, 9Kobe City Medical Center General Hospital, Departments of Gastroenterology, Hyogo, Japan, 10Japan Red Cross Ashikaga Hospital, Department of Internal Medicine, Tochigi, Japan, Japan, 11Hirosaki University Graduate School of Medicine, Department of Gastroenterology and Hematology, Hirosaki, Japan, 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 13Osaka City General Hospital, Division of Gastroenterology,, Osaka, Japan, 14Hyogo College of Medicine, Department of Intestinal Inflammation Research, Nishinomiya, Japan, 15Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, 16Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan, 17Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, 18Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 19Institute of Medical Science Hospital, University of Tokyo, Center for Translational Research, Tokyo, Japan, 20Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan
48 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Thursday, March 7, 2019, cont. DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn’s Disease: A multi-centre Belgian cohort study C. Liefferinckx1, B. Verstockt2, A. Gils3, M. Noman2, C. Van Kemseke4, E. Macken5, M. De Vos6, W. Van Moerkercke7, J.-F. Rahier8, P. Bossuyt9, J. Dutré10, E. Humblet11, D. Staessen12, H. Peters13, P. Van Hootegem14, E. Louis4, D. Franchimont1, F. Baert15, S. Vermeire2 1Hopital Erasme - ULB, Department of Gastroenterology, Brussels, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 4Centre Hospitalier Universitaire Sart-Tilman - ULG, Department of Gastroenterology, Liège, Belgium, 5Universiteit ziekenhuis Antwerpen - UZA, Department of Gastroenterology, 18:00 - 18:06 Antwerpen, Belgium, 6Universitair ziekenhuis Gent, Department of Gastroenterology, Gent, Belgium, 7AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, 8Centre Hospitalier Universitaire Mont-Godinne - UCL, Department of Gastroenterology, Yvoir, Belgium, 9Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, 10Ziekenhuis Netwerk Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 11Ziekenhuis Oost-Limburg - Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, 12GZA Sint-Vincentius ziekenhuis, Department of Gastroenterology, Antwerpen, Belgium, 13Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Gent, Belgium, 14Algemeen Ziekenhuis Sint- Lucas, Department of Gastroenterology, Brugge, Belgium, 15AZ Delta, Department of Gastroenterology, Roeselare-Menen, Belgium DOP34: Disease activity patterns during the first 5 years after diagnosis in children with Ulcerative Colitis: A population-based study M. Aloi1, M. Bramuzzo2, L. Norsa3, S. Arrigo4, M. Distante5, E. Miele6, A. Agrusti2, C. Romano7, C. Giobbi5, R. Panceri8, L. D‘Antiga3, S. Cucchiara5, P. Alvisi9, SIGENP IBD Working Group 1Sapienza University of Rome, Department of Pediatrics, Pediatric Gastroenterology Unit, Rome, Italy, 2Institute for Maternal and Child 18:06 - 18:12 Health IRCCS Burlo Garofolo, Trieste, Italy, 3Ospedale Papa Giovanni XXIII, Pediatric Gastroenterology Hepatology and Nutrition, Bergamo, Italy, 4Istituto Giannina Gaslini, Department of Gastroenterology and Endoscopy, Genoa, Italy, 5Sapienza University of Rome, Department of Pediatric Gastroenterology, Rome, Italy, 6University of Naples „Federico II“, Department of Translational Medical Science, Section of Pediatrics, Naples, Italy, 7University of Messina, Department of Pediatric Gastroenterology and Endoscopy, Messina, Italy, 8San Gerardo Hospital, Monza, Italy, 9Maggiore Hospital, Bologna, Italy DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s Disease, is significantly amplified in patients with a complicated phenotype R. S. Choung1, F. Petralia2, J. Torres3, 4, T. Sato5, X.-J. Li6, P. Wang2, S. Telesco5, C. Porter7, R. Laird7, R. Gutierrez7, F. Princen6, S. Plevy5, R. Strauss5, M. Riddle7, J. Murray1, J. F. Colombel3, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects) 18:12 - 18:18 study group 1Mayo Clinic, Gastroenterology and Hepatology, Rochester, United States, 2Icahn School of Medicine, Genetics and Genomic Sciences, New York, United States, 3Icahn School of Medicine at Mount Sinai, New York, United States, 4Hospital Beatriz Ângelo, Lisbon, Portugal, 5Janssen R&D, Spring House, United States, 6Prometheus Laboratories Inc., San Diego, United States, 7Naval Medical Research Center, Silver Spring, United States
March 6-9, 2019 • Copenhagen, Denmark 49 Digital oral presentations
Thursday, March 7, 2019, cont. DOP36: Gut microbial variations in patients with quiescent Crohns Disease predict subsequent disease flare T. Braun1, A. Di Segni1, M. BenShoshan1, S. Neuman1, O. Picard1, K. Sosnovski1, G. Efroni1, B. Weiss1, D. Yablecovitch1, A. Lahat1, R. Eliakim1, 18:18 - 18:24 U. Kopylov1, S. Ben-Horin1, Y. Haberman1, 2, On behalf of Israeli IBD Research Nucleus (IIRN) 1Sheba Medical Center, Tel Hashomer, Israel, 2Cincinnati Children Hospital Medical Center, Cincinnati, United States
Digital Oral Presentation Session 5 – Old and new treatment Room: C1 M4-5 17:30 - 18:30 Paolo Gionchetti, Bologna, Italy Anne Strik, Amsterdam, The Netherlands DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: A large single centre experience B. Verstockt1, 2, E. Mertens1, A. Outtier1, G. Van Assche1, 2, S. Vermeire1, 2, 17:30 - 17:36 M. Ferrante1, 2 1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with Inflammatory Bowel Disease B. Verstockt1, 2, S. Verstockt3, P. Sudahakar2, 4, 5, J. Dehairs6, H. Blevi2, G. Van Assche1, 2, S. Vermeire1, 2, M. Ferrante1, 2 1University Hospitals Leuven, Department of Gastroenterology and 17:36 - 17:42 Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Y-ECCO Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3KU Leuven, Abstract Award Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium, 4Earlham Institute, Norwich, United Kingdom, 5Quadram Institute, Norwich, Belgium, 6Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium DOP39: Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with Inflammatory Bowel Disease: London Ontario experience S. Al Draiweesh1, 2, C. Ma1, 3, M. Alkhattabi1, 4, N. Chande1, B. G. Feagan1,5, J. C. Gregor1, R. Khanna1, P. Marotta1, A. Sandhu1, K. Qumosani1, A. Teriaky1, M. Brahmania1, V. Jairath1, 5 1Western University, Department of Medicine, Division of 17:42 - 17:48 Gastroenterology, London, Ontario, Canada, 2King Fahad Specialist Hospital, Department of Medicine, Division of Gastroenterology, Dammam, Saudi Arabia, 3University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Alberta, Canada, 4King Abdulaziz University, Department of Medicine, Rabigh, Saudi Arabia, 5Western University, Department of Epidemiology and Biostatistics, London, Ontario, Canada DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s Disease: A French equivalence study A. Meyer1, J. Rudant2, J. Drouin2, A. Weill2, F. Carbonnel3, J. Coste2 17:48 - 17:54 1Caisse Nationale Assurance Maladie, Paris, France, 2Caisse Nationale de l’Assurance Maladie, Paris, France, 3Hopital Bicetre, Le Kremlin Bicetre, France
50 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Thursday, March 7, 2019, cont. DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with Ulcerative Colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: Data from the OCTAVE studies M. Chiorean1, C. Su2, K. Matsuoka3, A. Orlando4, A. J. Thorpe2, C. I. Nduaka2, D. S. Chapman5, D. A. Woodworth2, N. Lawendy2, G. S. 17:54 - 18:00 Friedman2, R. D. Cohen6 1Virginia Mason Medical Center, Seattle, WA, United States, 2Pfizer Inc, Collegeville, PA, United States, 3Toho University Sakura Medical Center, Sakura, Chiba, Japan, 4University of Palermo, IBD Unit, Palermo, Italy, 5Pfizer Inc, New York, NY, United States,6 University of Chicago Medicine, Chicago, IL, United States DOP42: Dietary therapies induce rapid response and remission in Active Paediatric Crohn’s Disease R. Sigall Boneh1, 2, J. Van Limbergen3, A. Assa4, R. Shaoul5, E. Wine6, P. Milman7, S. Cohen8, M. Kori9, S. Peleg10, A. On11, H. Shamaly12, L. Abramas1, A. Levine1, 2 1Wolfson Medical Center, Pediatric Gastroenterology, Holon, Israel, 2Tel 18:00 - 18:06 Aviv University, Tel Aviv, Israel, 3Dalhousie University, Halifax, Canada, 4Schneider Hospital, Petach Tikva, Israel, 5Meyer Hospital, Haifa, Israel, 6University of Alberta, Edmonton, Canada, 7Hadassah Hospital, Jerusalem, Israel, 8Tel Aviv Medical Center, Tel Aviv, Israel, 9Kaplan Hospital, Rehovot, Israel, 10HaEmek Hospital, Afula, Israel, 11Poriah hospital, Tiberias, Israel, 12French Hospital, Nazareth, Israel DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: Results of the OCTAVE Open study for tofacitinib delayed responders D. T. Rubin1, M. C. Dubinsky2, M. Lukas3, D. Quirk4, C. I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, H. Fan4, D. A. Woodworth4, G. Chan4, 18:06 - 18:12 C. Su4 1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, United States, 2Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, United States, 3Charles University, Prague, Czech Republic, 4Pfizer Inc, Collegeville, PA, United States
March 6-9, 2019 • Copenhagen, Denmark 51 Digital oral presentations
Thursday, March 7, 2019, cont. DOP44: Efficacy and safety of tacrolimus in Ulcerative Colitis: A nationwide, multicentric study from GETECCU I. Rodriguez-Lago1, J. Castro-Poceiro2, A. Fernández-Clotet2, F. Mesonero3, A. López-Sanromán3, A. López-García4, L. Márquez4, A. Clos-Parals5, F. Cañete5, M. Vicuña6, Ó. Nantes6, O. Merino7, V. Matallana Royo8, J. Gordillo9, A. Elorza1, R. Vicente10, M. J. Casanova11, 12, R. Ferreiro- Iglesias13, P. Pérez-Galindo14, J. M. Benítez15, 16, C. Taxonera17, M. J. García García18, E. Martín Arranz19, M. Calafat20, A. Martín-Cardona21, 22, F. Muñoz Núñez23, J. O. Miquel-Cusachs24, E. Sáinz Arnau25, J. P. Gisbert11, Young IBD Group from GETECCU 1Hospital de Galdakao, Gastroenterology, Galdakao, Spain, 2Hospital Clinic, Gastroenterology, Barcelona, Spain, 3Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 4Hospital del Mar, Gastroenterology, Barcelona, Spain, 5Hospital Universitario Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 6Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, 7Hospital de Cruces, Gastroenterology, Bilbao, Spain, 8Hospital Universitario Puerta de Hierro, Gastroenterology, Majadahonda, Spain, 9Hospital 18:12 - 18:18 de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 10Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, 11Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 12Instituto de Investigación Sanitaria Princesa (IIS-IP) Y-ECCO and Centro de Investigación Biomédica en Red de Enfermedades Abstract Award Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, 13Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain, 14Hospital Montecelo, Gastroenterology, Pontevedra, Spain, 15Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, 16IMIBIC, Córdoba, Spain, 17Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, 18Hospital Marqués de Valdecilla, Gastroenterology, Santander, Spain, 19Hospital Universitario La Paz, Gastroenterology, Madrid, Spain, 20Hospital Son Llàtzer, Gastroenterology, Palma, Spain, 21Hospital Universitari Mutua Terrassa, Gastroenterology, Terrassa, Spain, 22Centro de Investigación biomédica en red de enfermedades hepáticas y digestivas (CIBERehd), Terrassa, Spain, 23Hospital de Salamanca, Gastroenterology, Salamanca, Spain, 24Hospital Universitario de Girona, Gastroenterology, Girona, Spain, 25Hospital Arnau de Vilanova, Gastroenterology, Lérida, Spain DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with Fistulising Crohn’s Disease: A post-hoc analysis of the ACCENT-2 trial N. Vande Casteele1, 2, K. Papamichael3, J. Jeyarajah2, M. T. Osterman4, A. S. Cheifetz3 18:18 - 18:24 1University of California San Diego, Department of Medicine, La Jolla, United States, 2Robarts Clinical Trials, Inc., London, Canada, 3Beth- Israel Deaconess Medical Center, Harvard Medical School, Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Boston, United States, 4University of Pennsylvania, Department of Medicine, Perelman School of Medicine, Philadelphia, United States
52 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Friday, March 8, 2019 Digital Oral Presentation Session 6 – Novel treatments Room: C1 M4-5 17:05 - 18:05 Marc Ferrante, Leuven, Belgium Gionata Fiorino, Rome, Italy DOP46: Extended induction treatment with mirikizumab in patients with Moderately to Severely Active Ulcerative Colitis: Results from a phase 2 trial W. J. Sandborn1, M. Ferrante2, B. R. Bhandari3, E. Berliba4, T. Hibi5, G. Geert R. D‘Haens6, J. Tuttle7, K. Krueger8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9 1University California San Diego, La Jolla, California, United States, 2UZ Leuven, KU Leuven, Department of Gastroenterology and 17:05 - 17:11 Hepatology, Leuven, Belgium, 3Delta Research Partners, LLC, Bastrop, LA, United States, 4Nicolae Testemițanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, 5Kitasato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, 6Amsterdam University Medical Centers, Amsterdam, Netherlands, 7Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, 8Eli Lilly and Company, Indianapolis, Indiana, United States, 9Western University, Robarts Clinical Trials Inc, London, Ontario, Canada DOP47: Sustained remission in patients with Moderate to Severe Ulcerative Colitis: Results from the phase 3 UNIFI maintenance study G. Van Assche1, S. R. Targan2, T. Baker3, C. D. O‘Brien3, H. Zhang3, J. Johanns3, P. Szapary3, C. Marano3, R. W. Leong4, 5, D. Rowbotham6, 7, T. Hisamatsu8, S. Danese9, B. E. Sands10, L. Peyrin-Biroulet11 1University of Leuven, Leuven, Belgium, 2Cedars-Sinai Medical Center, 17:11 - 17:17 Los Angeles, United States, 3Janssen Research and Development, Spring House, United States, 4Concord Hospital, Sydney, Australia, 5Macquarie University Hospital, Sydney, Australia, 6Auckland City Hospital, Auckland, New Zealand, 7University of Auckland, Auckland, New Zealand, 8Kyorin University, Tokyo, Japan, 9Humanitas Research Hospital, Milan, Italy, 10Icahn School of Medicine at Mount Sinai, New York, United States, 11Nancy University Hospital, Vandœuvre-lès-Nancy, France DOP48: Amiselimod, a selective S1P receptor modulator in Crohn’s Disease patients: A proof of concept study G. D‘Haens1, S. Danese2, M. Davies3, M. Watanabe4, T. Hibi5 1Academic Medical Centre, Amsterdam, Netherlands, 2Humanitas 17:17 - 17:23 Research Hospital, Gastroenterology, Milano, Italy, 3Mitsubishi Tanabe Europe Ltd, London, United Kingdom, 4Tokyo Medical and Dental University, Gastroenterology, Tokyo, Japan, 5University Kitasato Hospital, Gastroenterology, Tokyo, Japan
March 6-9, 2019 • Copenhagen, Denmark 53 Digital oral presentations
Friday, March 8, 2019, cont. DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in Ulcerative Colitis: Results from the open-label extension study TURANDOT II W. Reinisch1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16 1Medical University of Vienna, Vienna, Austria, 2University of California San Diego, La Jolla, CA, United States, 3Humanitas University, Milan, Italy, 4University of Nice Sophia Antipolis, Hospital l‘Archet, Nice, 17:23 - 17:29 France, 5Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 6Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 7Charles University Hospital, Hradec Králové, Czech Republic, 8Gastroenterology Center, Nitra, Slovakia, 9Nature Coast Clinical Research, Inverness, FL, United States, 10Seoul National University College of Medicine, Seoul, South Korea, 11Alfred Hospital, Melbourne, VIC, Australia, 12Zymo Consulting Group, Newtown Square, PA, United States, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, United States, 15Cytel Inc., Cambridge, MA, United States, 16University Hospitals Leuven, Leuven, Belgium DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with Moderate to Severe Crohn’s Disease: Data from the CELEST study L. Peyrin-Biroulet1, S. Danese2, E. Louis3, P. D.R. Higgins4, M. Dubinsky5, F. Cataldi6, Q. Zhou6, W.-J. Lee6, K. Kligys6, A. P. Lacerda6 17:29 - 17:35 1University of Lorraine, Nancy, France, 2Istituto Clinico Humanitas, Milan, Italy, 3CHU de Liège et Université de Liège, Liège, Belgium, 4University of Michigan, Ann Arbor, United States, 5Icahn School of Medicine at Mount Sinai, New York, United States, 6AbbVie Inc., North Chicago, United States DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with Ulcerative Colitis W. Reinisch1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16 1Medical University of Vienna, Vienna, Austria, 2University of California San Diego, La Jolla, CA, United States, 3Humanitas University, Milan, Italy, 4University of Nice Sophia Antipolis, Hospital l‘Archet, Nice, 17:35 - 17:41 France, 5Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 6Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 7Charles University Hospital, Hradec Králové, Czech Republic, 8Gastroenterology Center, Nitra, Slovakia, 9Nature Coast Clinical Research, Inverness, FL, United States, 10Seoul National University College of Medicine, Seoul, South Korea, 11Alfred Hospital, Melbourne, VIC, Australia, 12Zymo Consulting Group, Newtown Square, PA, United States, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, United States, 15Cytel Inc., Cambridge, MA, United States, 16University Hospitals Leuven, Leuven, Belgium
54 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Friday, March 8, 2019, cont. DOP52: Reduction in inflammatory biomarkers in a phase 2 study of mirikizumab in patients with Moderately to Severely Active Ulcerative Colitis W. J. Sandborn1, B. Sands2, T. Kobayashi3, J. Tuttle4, J. Schmitz5, M. Durante5, R. Higgs5, J. B. Canavan5, R. Siegel5, M. Ferrante6 1University California San Diego, La Jolla, California, United States, 17:41 - 17:47 2Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, New York, United States, 3Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 4Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, 5Eli Lilly and Company, Indianapolis, Indiana, United States, 6UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium DOP53: Clinical, endoscopic, histologic and biomarker activity following treatment with the gut-selective, pan-JAK Inhibitor TD- 1473 in Moderately to Severely Active Ulcerative Colitis W. Sandborn1, D. Nguyen2, B. Ferslew2, L.-Y. Hao3, T. Kanno3, L. Tomsho3, 17:47 - 17:53 D. Boyle1, R. Graham2, B. Abhyankar2, J. Panes4 1University of California San Diego, Medicine, San Diego, United States, 2Theravance Biopharma US, Inc, South San Francisco, United States, 3Janssen R&D, Springhouse, United States, 4Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain DOP54: Efficacy and safety of ustekinumab through week 16 in patients with Moderate to Severe Ulcerative Colitis randomised to ustekinumab: Results from the UNIFI induction trial S. Danese1, B. E. Sands2, C. D. O‘Brien3, H. Zhang3, J. Johanns3, S. Sloan3, J. Izanec4, P. Szapary3, C. Marano3, R. W. Leong5, 6, D. Rowbotham7, 8, S. R. Targan9, G. Van Assche10 1Humanitas Research Hospital, Milan, Italy, 2Icahn School of Medicine 17:53 - 17:59 at Mount Sinai, New York, United States, 3Janssen Research & Development, LLC, Spring House, United States, 4Janssen Scientific Affairs, LLC, Horsham, United States,5 Concord Hospital, Sydney, Australia, 6Macquarie University Hospital, Sydney, Australia, 7Auckland City Hospital, Auckland, New Zealand, 8University of Auckland, Auckland, New Zealand, 9Cedars-Sinai Medical Center, Los Angeles, United States, 10University of Leuven, Leuven, Belgium
Digital Oral Presentation Session 7 – Recent advances of biologic therapies Room: C1 M3 17:05 - 18:05 Filip Baert, Roeselare, Belgium Shomron Ben-Horin, Ramat Gan, Israel DOP55: ZNF133 is associated with infliximab responsiveness in patients with Inflammatory Bowel Diseases using whole-exome sequencing E. S. Jung1, 2, K.-W. Choi3, S. W. Kim2, M. Hübenthal1, S. Mucha1, J. Park2, Z. Park3, D. Ellinghaus1, S. Schreiber1, A. Franke1, W. Y. Oh3, J. H. Cheon2 17:05 - 17:11 1Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany, 2Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea, 3National Institute of Food and Drug Safety Evaluation, Clinical Research Division, Cheongju, South Korea
March 6-9, 2019 • Copenhagen, Denmark 55 Digital oral presentations
Friday, March 8, 2019, cont. DOP56: Dashboard driven versus conventional dosing of infliximab in Inflammatory Bowel Disease patients: The PRECISION trial A. Strik1, 2, S. Berends3, D. Mould4, R. Mathôt3, C. Ponsioen2, J. van den Brande5, J. Jansen6, D. Hoekman7, J. Brandse8, M. Löwenberg2, G. D‘Haens2 1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2Amsterdam UMC, location AMC, 17:11 - 17:17 Gastroenterology and Hepatology, Amsterdam, Netherlands, 3Amsterdam UMC, location AMC, Hospital Pharmacy, Amsterdam, Netherlands, 4Projections Research Inc., Phoenixville, United States, 5Tergooi Hospital, Blaricum, Netherlands, 6Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, 7Amsterdam UMC, location AMC, Clinical Genetics, Amsterdam, Netherlands, 8Amsterdam UMC, location VuMc, Gastroenterology and Hepatology, Amsterdam, Netherlands DOP57: Monitoring response to anti-TNF therapy in Ulcerative Colitis patients by gastrointestinal ultrasound: Sub-analysis from TRUST&UC C. Maaser1, F. Petersen1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, D. Lang4, T. Kucharzik1 17:17 - 17:23 1University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany, 2Gastroenterology Practice, Oldenburg, Germany, 3Biostatistik Tuebingen, Tuebingen, Germany, 4AbbVie Deutschland GmbH & Co.KG, Medical Department Gastroenterology, Wiesbaden, Germany DOP58: IDeaL – a multi-center prospective infliximab dose to level pharmacokinetic study during induction in Paediatric Crohn’s Disease G. H. Huynh1, M. W. Carroll1, A. M. Griffiths2, W. El-Matary3, A. Petrova4, C. Prosser5, C. Kluthe6, J. C. deBruyn7, D. Tomalty2, D. R. Mould8, E. Wine4, H. Q. Huynh4 1University of Alberta, Paediatrics, Edmonton, Canada, 2Hospital for 17:23 - 17:29 Sick Children, University of Toronto, Paediatrics, Toronto, Canada, 3The Children‘s Hospital University of Manitoba, Paediatrics, Winnipeg, Canada, 4Stollery Children‘s Hospital University of Alberta, Paediatrics, Edmonton, Canada, 5Alberta Health Services, Biochemistry, Edmonton, Canada, 6Alberta Health Services, Paediatrics, Edmonton, Canada, 7Alberta Children‘s Hospital University of Calgary, Paediatrics and Community Health Sciences, Calgary, Canada, 8Projections Research, Phoenixville, United States DOP59: Proactive infliximab drug monitoring is superior to conventional management in Inflammatory Bowel Disease S. Raimundo Fernandes, S. Bernardo, C. Simões, L. Correia, P. Moura 17:29 - 17:35 Santos, A. Rita Gonçalves, A. Valente, C. Baldaia, R. Tato Marinho Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Gastrenterology and Hepatology Unit, Lisbon, Portugal DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non response in Crohn’s P. Pavlidis1, A. Tsakmaki1, U. Niazi2, J. Digby-Bell1, G. Lombardi1, B. 17:35 - 17:41 Hayee3, G. Bewick1, N. Powell1 1King‘s College London, London, United Kingdom, 2BRC Bioinformatics core, London, United Kingdom, 3King‘s College Hospital, London, United Kingdom
56 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Friday, March 8, 2019, cont. DOP61: A nationwide cohort study of colectomy rates for Ulcerative Colitis during the introduction of biologic therapy G. Worley1, 2, A. Almoudaris1, 2, P. Bassett3, 4, J. Segal1, 2, A. Akbar2, 4, P. Aylin5, O. Faiz1, 2 1St Mark‘s Hospital and Academic Institute, Surgical Epidemiology 17:41 - 17:47 Trials and Outcome Centre, London, United Kingdom, 2Imperial College London, Department of Surgery and Cancer, London, United Kingdom, 3Statsconsultancy Ltd, Buckinghamshire, United Kingdom, 4St Mark‘s Hospital and Academic Institute, London, United Kingdom, 5Imperial College London, Dr Foster Unit, Department of Primary Care and Public Health, London, United Kingdom DOP62: A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open- label randomised controlled trial in patients with Active Crohn’s Disease W. Reinisch1, B. I. Jang2, V. Borzan3, A. Lahat4, 5, A. Pukitis6, M. Osipenko7, Y. Mostovoy8, S. Schreiber9, S. Ben-Horin10, S. J. Lee11, J. H. Suh11, S. G. Lee11, J. H. Lee11, B. D. Ye12 1Medical University Vienna, Vienna, Austria, 2Yeungnam University 17:47 - 17:53 Hospital, Daegu, South Korea, 3Clinical Hospital Center Osijek, Osijek, Croatia, 4Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 5Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Pauls Stradins Clinical University Hospital, Rīga, Latvia, 7Novosibirsk State Medical University, Novosibirsk, Russian Federation, 8Private Small_ Scale Enterprise Medical Centre „Pulse“, Vinnytsya, Ukraine, 9University Hospital Schleswig-Holstein, Kiel, Germany, 10Sheba Medical Center, Tel Hashomer, Israel, 11Celltrion, Inc., Incheon, South Korea, 12Asan Medical Center, Seoul, South Korea 17:53 - 17:59 DOP63: Late-breaking Abstract
Digital Oral Presentation Session 8 – Intestinal healing Room: C1 M2 17:05 - 18:05 Raja Atreya, Erlangen, Germany Marietta Iacucci, Birmingham, United Kingdom DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with Inflammatory Bowel Disease 17:05 - 17:11 L.-Y. Mak1, L. Chen2, T. Tong2, S. Lau2, W.-K. Leung2 1Queen Mary Hospital, Medicine, Hong Kong, Hong Kong, 2The University of Hong Kong, Medicine, Hong Kong, Hong Kong DOP65: The association of faecal calprotectin level and combined mucosal and transmural healing in patients with Crohn’s Disease S. Noh1, E. H. Oh1, S. H. Park2, 3, J. B. Lee4, J. Y. Kim1, J. C. Park1, J. Kim1, N. Ham1, E. M. Song1, S. H. Park1, 3, S. W. Hwang1, 3, D. H. Yang1, J. S. Byeon1, 17:11 - 17:17 S. J. Myung1, S. K. Yang1, 3, B. D. Ye1, 3 1Asan medical center, Gastroenterology, Seoul, South Korea, 2Asan medical center, Radiology, Seoul, South Korea, 3Asan medical center, Inflammatory Bowel Disease Center, Seoul, South Korea,4 Asan medical center, Clinical Epidemiology & Biostatistics, Seoul, South Korea DOP66: Surveillance colonoscopies are associated with improved prognosis and survival in patients with Ulcerative Colitis A. Hu1, G. Nguyen2, J. Rangrej3, J. Marshall1, N. Narula1 1McMaster University, Division of Gastroenterology, Department of 17:17 - 17:23 Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, Canada, 2University of Toronto, Division of Gastroenterology, Mount Sinai Hospital, Toronto, Canada, 3Ministry of Health and Long- Term Care, Health Analytics Branch, Toronto, Canada
March 6-9, 2019 • Copenhagen, Denmark 57 Digital oral presentations
Friday, March 8, 2019, cont. DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histologic inflammation in patients with Inflammatory Bowel Disease E. Klenske1, R. Atreya1, A. Hartmann2, S. Fischer1, S. Hirschmann1, S. 17:23 - 17:29 Zundler1, M. Iacucci3, M. Neurath1, T. Rath1 1University Hospital of Erlangen, Department of Medicine 1, Division of Gastroenterology, Erlangen, Germany, 2University Hospital of Erlangen, Institute of Pathology, Erlangen, Germany, 3University of Birmingham, Institute of Translational Medicine, Birmingham, United Kingdom DOP68: Histological remission (NANCY index) is superior to endoscopic mucosal healing in predicting relapse free survival in patients with Ulcerative Colitis in clinical and endoscopic remission H. Wang1, I. Fewings2, L. Bornman1, B. Shadbolt3, M. Fadia2, K. Subramaniam1, 4 17:29 - 17:35 1Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia, 2ACT Pathology, Canberra Hospital, Canberra, Australia, 3Health Analytics Research Centre, Canberra Hospital, Canberra, Australia, 4ANU Medical School, Australian National University, Canberra, Australia DOP69: The detection with targeted biopsy and characterisation of neoplastic lesions by magnifying chromoendoscopy and NBI in surveillance colonoscopy of patients with Ulcerative Colitis: A sub- analysis of the Navigator Study K. Watanabe1, 2, M. Esaki3, S. Oka4, F. Shimamoto5, M. Nishishita2, T. Fukuchi6, S. Fujii7, F. Hirai8, K. Kakimoto9, T. Inoue9, H. Kashida10, K. Takeuchi11, N. Ohmiya12, M. Saruta13, S. Saito14, Y. Saito15, S. Tanaka16, Y. Ajioka17, H. Tajiri13 1Hyogo College of Medicine, Intestinal Inflammation Research, Nishinomiya, Japan, 2Nishishita GI Hospital, Osaka, Japan, 3Saga 17:35 - 17:41 University, Saga, Japan, 4Hiroshima University, Hiroshima, Jamaica, 5Prefectural University of Hiroshima, Hiroshima, Japan, 6Osakafu Saiseikai Nakatsu Hospital, Osaka, Japan, 7Kyoto Katsura Hospital, Kyoto, Japan, 8Fukuoka University Chikushi Hospital, Fukuoka, Japan, 9Osaka Medical College, Osaka, Japan, 10Kinki University, Osaka, Japan, 11Toho University Sakura Medical Center, Chiba, Japan, 12Fujita Medical University, Aichi, Japan, 13The Jikei University School of Medicine, Tokyo, Japan, 14The Cancer Institute Hospital Of JFCR, Tokyo, Japan, 15National Cancer Center Hospital, Tokyo, Japan, 16Hiroshima University, Hiroshima, Japan, 17Niigata University, Niigata, Japan DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn’s Disease B. Verstockt1, 2, P. Sudahakar2, 3, 4, B. Creyns5, S. Verstockt6, J. Cremer5, W.-J. Wollants2, S. Organe2, T. Korcsmaros3, 4, M. Madgwick3, G. Van Assche1,2, C. Breynaert5, S. Vermeire1, 2, M. Ferrante1, 2 1University Hospitals Leuven, Department of Gastroenterology and 17:41 - 17:47 Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3Earlham Institute, Norwich, United Kingdom, 4Quadram Institute, Norwich, Belgium, 5KU Leuven, Department of Microbiology and Immunology, Laboratory of Clinical Immunology, Leuven, Belgium, 6KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium
58 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Friday, March 8, 2019, cont. DOP71: Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in Ulcerative Colitis K. Li1, J. R. Friedman1, C. Marano1, H. Zhang1, F. Yang1, B. G. Feagan2, L. 17:47 - 17:53 Peyrin-Biroulet3, G. De Hertogh4 1Janssen Research & Development, LLC, Spring House, United States, 2Robarts Research Institute, Robarts Clinical Trials, London, Canada, 3Nancy University Hospital, Université de Lorraine, Nancy, France, 4University Hospitals KU, Leuven, Belgium DOP72: Increased risk of advanced neoplasia in Inflammatory Bowel Disease patients with recurrent low-grade dysplasia M. de Jong1, H. Kanne1, L. Nissen2, I. Nagtegaal3, J. Drenth1, L. Derikx1, 2, F. Hoentjen1 17:53 - 17:59 1Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, Netherlands, 2Jeroen Bosch Hospital, Gastroenterology and Hepatology, s‘Hertogenbosch, Netherlands, 3Radboud University Medical Center, Pathology, Nijmegen, Netherlands Digital Oral Presentation Session 9 – Surgery and IBD Room: C1 M1 17:05 - 18:05 Paulo Kotze, Curitiba, Brazil Andre D‘Hoore, Leuven, Belgium DOP73: Treatment of perianal fistulas in Crohn’s Disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): A randomised controlled trial K. Wasmann1, E. J. de Groof2, M. Stellingwerf1, G. D‘Haens3, C. Ponsioen3, K. Gecse3, M. Dijkgraaf4, W. Bemelman2, C. Buskens2 1Amsterdam UMC, Department of Surgery and Gastroenterology, 17:05 - 17:11 Amsterdam, Netherlands, 2Amsterdam UMC, Department of Surgery, Amsterdam, Netherlands, 3Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 4Amsterdam UMC, Clinical Research Unit & Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam, Netherlands
March 6-9, 2019 • Copenhagen, Denmark 59 Digital oral presentations
Friday, March 8, 2019, cont. DOP74: Efficacy of ustekinumab in perianal Crohn’s Disease: The BioLAP multicentre observational study C. Biron1, P. Seksik2, M. Nachury3, Y. Bouhnik4, A. Amiot5, S. Viennot6, M. Serrero7, M. Fumery8, M. Allez9, L. Siproudhis10, A. Buisson11, G. Pineton de Chambrun12, V. Abitbol13, S. Nancey14, L. Caillo15, L. Plastaras16, L. Armengol-Debeir17, E. Chanteloup18, M. Simon19, N. Dib20, S. Rajca21, M. Amil22, L. Peyrin-Biroulet23, L. Vuitton24 1CHU Jean Minjoz, Gastroenterology, Besançon, France, 2Hôpital Saint-Antoine, Gastroentérologie, Paris, France, 3CHRU Lille, Gastroentérologie, Lille, France, 4Hôpital Beaujon, AP- HP, Gastroentérologie, Paris, France, 5Hôpital Henri-Mondor, Gastroentérologie, Paris, France, 6CHRU Caen, Gastroentérologie, Caen, France, 7APHM Hôpital Nord, Gastroentérologie, Marseille, France, 8CHRU Amiens, Gastroentérologie, Amiens, France, 9Hôpital 17:11 - 17:17 Saint-Louis, AP-HP, Gastroentérologie, Paris, France, 10CHRU Rennes, Gastroentérologie, Rennes, France, 11CHRU Clermont-Ferrand, Gastroentérologie, Clermont-Ferrand, France, 12CHRU Montpellier, Gastroentérologie, Montpellier, France, 13Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, 14Groupement Hospitalier Sud Hospices Civils de Lyon, Gastroentérologie, Lyon, France, 15CHU Nîmes, Gastroentérologie, Nîmes, France, 16Hôpital Pasteur, Gastroentérologie, Colmar, France, 17CHRU Rouen, Gastroentérologie, Rouen, France, 18Hôpital Saint-Joseph, Gastroentérologie, Paris, France, 19Institut Mutualiste Monsouris, Gastroentérologie, Paris, France, 20CHRU Angers, Gastroentérologie, Angers, France, 21Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, 22CHD Vendée, Gastroentérologie, La Roche-sur-Yon, France, 23CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, 24CHRU Jean Minjoz, Gastroentérologie, Besançon, France DOP75: Surgery and hospitalisations rates in Inflammatory Bowel Disease patients in the Québec provincial database from 1996 - 2015 C. Verdon1, J. Reinglas1, J. Coulombe2, L. Gonczi3, T. Bessissow1, W. Afif1, M. Vutcovici4, G. Wild1, E. Seidman1, A. Bitton1, P. Brassard5, 6, P. Lakatos1 1McGill University Health Center, Division of Gastroenterology, 17:17 - 17:23 Montreal, Canada, 2Lady Davis Research Institute, Jewish General Hospital, Centre for Clinical Epidemiology, Montreal, Canada, 3Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, 4McGill University Health Centre, Division of Gastroenterology, Montreal, Canada, 5Biostatistics and Occupational Health, Department Of Epidemiology, Montreal, Canada, 6McGill University, Department of Medicine, Montreal, Canada DOP76: Prevalence and health-care costs of perianal fistulas in Crohn’s Disease in a nationwide cohort A. Nordholm-Carstensen1, N. Qvist2, B. Højgaard3, C. Halling3, M. Carstensen4, N.-P. Ipland4, J. Burisch5 1Zealand University Hospital, Department of Surgery, Roskilde, 17:23 - 17:29 Denmark, 2Odense University Hospital, Department of Surgery, Odense, Denmark, 3VIVE - The Danish Center for Social Science Research, Copenhagen, Denmark, 4Takeda Pharma A/S, Taastrup, Denmark, 5Danish Centre for eHealth & Epidemiology, Frederikssund, Denmark DOP077: The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn’s Disease O. Knyazev, A. Kagramanova, A. Lishchinskaya, M. Zvyaglova, D. 17:29 - 17:35 Kulakov, A. Parfenov Moscow Clinical Scientific Center named after A. S. Loginov, Department of inflammatory bowel diseases, Moscow, Russian Federation
60 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Friday, March 8, 2019, cont. DOP78: Efficacy of vedolizumab in perianal Crohn’s Disease: The BioLAP multicentre observational study C. Biron1, P. Seksik2, M. Nachury3, S. Nancey4, Y. Bouhnik5, M. Serrero6, L. Armengol-Debeir7, A. Buisson8, M.-L. Tran Minh9, C. Zallot10, M. Fumery11, G. Bouguen12, V. Abitbol13, S. Viennot14, E. Chanteloup15, S. Rajca16, N. Dib17, L. Peyrin-Biroulet10, L. Vuitton18 1CHU Jean Minjoz, Gastroenterology, Besançon, France, 2Hôpital Saint-Antoine, Gastroentérologie, Paris, France, 3CHRU Lille, Gastroentérologie, Lille, France, 4Groupement Hospitalier Sud Hospices Civils de Lyon, Gastroentérologie, Lyon, France, 5Hôpital Beaujon, AP-HP, Gastroentérologie, Paris, France, 6APHM Hôpital Nord, 17:35 - 17:41 Gastroentérologie, Marseille, France, 7CHRU Rouen, Gastroentérologie, Rouen, France, 8CHRU Clermont-Ferrand, Gastroentérologie, Clermont- Ferrand, France, 9Hôpital Saint-Louis, AP-HP, Gastroentérologie, Paris, France, 10CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, 11CHRU Amiens, Gastroentérologie, Amiens, France, 12CHRU Rennes, Gastroentérologie, Rennes, France, 13Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, 14CHRU Caen, Gastroentérologie, Caen, France, 15Hôpital Saint-Joseph, Gastroentérologie, Paris, France, 16Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, 17CHRU Angers, Gastroentérologie, Angers, France, 18CHRU Jean Minjoz, Gastroentérologie, Besançon, France DOP79: Effect of vedolizumab on surgical rates in IBD: Post hoc analysis from the GEMINI trials B. G. Feagan1, B. E. Sands2, R. Lirio3, T. Lissoos3, J. Wang3, D. Feng3, K. Lasch3 17:41 - 17:47 1Robarts Clinical Trials, Western University, London, Ontario, Canada, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, NY, United States, 3Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, United States DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn’s Disease treated with concomitant thiopurines: The POPCUR trial A. Buisson1, D. Laharie2, S. Nancey3, X. Hébuterne4, X. Roblin5, M. Nachury6, L. Peyrin-Biroulet7, M. Fumery8, F. Goutorbe1, D. Coban1, 17:47 - 17:53 C. Allimant1, M. Reymond1, E. Vazeille1, B. Pereira1, M. Goutte1, G. Bommelaer1 1University Hospital Estaing, IBD unit, Clermont-Ferrand, France, 2CHU Bordeaux, Bordeaux, France, 3HCL Lyon-Sud, Lyon, France, 4CHU Nice, Nice, France, 5CHU Saint-Etienne, Saint-Etienne, France, 6CHU Lille, Lille, France, 7CHU Nancy, Nancy, France, 8CHU Amiens, Amiens, France DOP81: Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s Disease A. L. Hamilton1, P. P. De Cruz1, 2, E. K. Wright3, L. Okada4, M. Hale4, L. Mimms4, A. Jain4, M. A. Kamm1 1The University of Melbourne and St Vincent‘s Hospital, Melbourne, 17:53 - 17:59 Department of Medicine and Department of Gastroenterology, Melbourne, Australia, 2Austin Health, Department of Gastroenterology, Melbourne, Australia, 3St Vincent‘s Hospital, Department of Gastroenterolgy, Melbourne, Australia, 4Prometheus Laboratories Inc, San Diego, United States
March 6-9, 2019 • Copenhagen, Denmark 61 Digital oral presentations
Friday, March 8, 2019, cont. Digital Oral Presentation Session 10 – Clinical Epidemiology Room: C1 M0 17:05 - 18:05 Stefanos Bonovas, Milan, Italy Johan Burisch, Copenhagen, Denmark DOP82: Direct and indirect costs of Inflammatory Bowel Disease in the biological era; ten years of follow up in a Danish population- based inception cohort 17:05 - 17:11 B. Lo1, I. Vind1, M. K. Vester-Andersen1, 2, F. Bendtsen1, J. Burisch1 1Copenhagen University Hospital Hvidovre, The Gastro Unit, Hvidovre, Denmark, 2Zealand University Hospital, Medical Department, Koege, Denmark DOP83: Association of FUT2 and ABO with Crohn’s Disease in Koreans H.-S. Lee1, 2, B. M. Kim2, S. Jung2, M. Hong2, K. Kim2, J. W. Moon2, J. Baek2, S. W. Hwang3, S. H. Park3, S.-K. Yang3, K. Song2, B. D. Ye3 1KU Leuven, Department of Human Genetics, Laboratory of Complex 17:11 - 17:17 Genetics, Leuven, Belgium, 2University of Ulsan College of Medicine, Department of Biochemistry and Molecular Biology, Seoul, South Korea, 3Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology and Inflammatory Bowel Disease Center, Seoul, South Korea DOP84: Nationwide incidence and prevalence of Paediatric Inflammatory Bowel Disease in Scotland 2015-2017 demonstrates the highest paediatric prevalence rate recorded worldwide C. Burgess1, 2, P. Henderson1, 2, I. Chalmers3, R. Harris4, R. Hansen4, R. Russell4, D. Wilson1, 2 17:17 - 17:23 1University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom, 2Royal Hospital for Sick Children, Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom, 3Royal Aberdeen Children‘s Hospital, Paediatric Gastroenterology and Nutrition, Aberdeen, United Kingdom, 4Royal Hospital for Children, Paediatric Gastroenterology and Nutrition, Glasgow, United Kingdom DOP85: Rising depression and antidepressant use amongst Inflammatory Bowel Disease patients J. Blackwell1, S. Saxena2, C. Alexakis1, E. Cecil2, A. Bottle2, I. Petersen3, 4, M. Hotopf5, R. Pollok1 1St George‘s Healthcare NHS Trust, Gastroenterology, London, United 17:23 - 17:29 Kingdom, 2Imperial College London, School of Public Health, London, United Kingdom, 3University College London, Epidemiology and Health Informatics, London, United Kingdom, 4Aarhus University, Biostatistics, Aarhus, Denmark, 5King‘s College London, Institute of Psychiatry, London, United Kingdom DOP86: Risk for development of Inflammatory Bowel Disease under inhibition of interleukin 17 in psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis: A review and meta-analysis 17:29 - 17:35 W. Eigner1, J. Burisch2, W. Reinisch1 1Medical University of Vienna, Medicine III, Division Gastroenterology and Hepatology, Vienna, Austria, 2Danish Centre for eHealth & Epidemiology, Department of Gastroenterology, Frederikssund, Denmark DOP87: Multi-parameter data-sets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR) G.-R. Jones1, 2, M. Lyons2, N. Plevris1, P. Jenkinson1, C. Bisset1, J. Fulforth1, C. S. Chuah1, S. Minnis1, S.-L. Gillespie1, W. Brindle1, C. Burgess3, P. 17:35 - 17:41 Henderson3, D. Wilson3, C. Lees1 1Western General Hospital, Gastroenterology, Edinburgh, United Kingdom, 2University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, 3Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, United Kingdom
62 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations
Friday, March 8, 2019, cont. DOP88: Thiopurine and allopurinol combination therapy and the risk of adverse outcomes and step-up medical therapy in Inflammatory Bowel Disease patients: A nationwide Danish cohort study S. B. Thomsen1, K. H. Allin2, J. Burisch2, C. B. Jensen2, S. Hansen2, L. L. 17:41 - 17:47 Gluud1, K. Theede1, M. Kiszka-Kanowitz1, A. M. Nielsen1, T. Jess2 1Copenhagen University Hospital Hvidovre, Gastrounit, Medical Division, Copenhagen, Denmark, 2Bispebjerg and Frederiksberg Hospital, Center for Clinical Research and Prevention, Copenhagen, Denmark DOP89: Final growth in Paediatric Crohn’s Disease is impaired also in the era of biologics: A population based analysis from the epiIIRN administrative cohort A. Assa1, S. Cohen2, N. Asayag3, N. Dan4, G. Focht4, O. Ledder4, N. Lederman5, E. Matz6, A. Cahan7, R. Balicer8, B. Feldman8, I. Brufman8, D. Turner4 1Schneider Children‘s Medical Center of Israel Hospital for Children, 17:47 - 17:53 Petah Tikva, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel, 4Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel, 5Meuhedet Health Services, Tel Aviv, Israel, Tel Aviv, Israel, 6Leumit Health Services, Tel Aviv, Israel, Tel Aviv, Israel, 7Maccabi Healthcare Services, Tel Aviv, Israel, Tel Aviv, Israel, 8Clalit Research Institute, Chief’s Office, Clalit Health Services, Tel Aviv, Israel, Tel Aviv, Israel DOP90: The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD. Results after 20 years of follow-up in the IBSEN study A. Ossum1, 2, Ø. Palm3, M. Cvancarova4, B. Moum1, 2, M. L. Høivik1, The 17:53 - 17:59 IBSEN study group 1Oslo University Hospital, Ullevaal, Gastroenterology, Oslo, Norway, 2University of Oslo, Faculty of Medicine, Oslo, Norway, 3Oslo University Hospital, Rikshospitalet, Rheumatology, Oslo, Norway, 4OsloMet, Faculty of Public Health, Oslo, Norway
March 6-9, 2019 • Copenhagen, Denmark 63 New ECCO Guidelines & Topical Reviews
Stay tuned with JCC online 2019
ECCO Guidelines ECCO Topical Reviews • ECCO - ESGAR Consensus Guidelines on • Complementary Medicine and Psychotherapy Diagnostic Techniques and Monitoring • Perioperative Dietary Therapy
ECCO is looking forward to your visit to JCC online, which also provides free access to all Guideline and Topical Review publications! • Christian Maaser • Laurence Egan • ECCO GuiCom Chair • JCC Editor-in-Chief
Scan and contact the ECCO Office www.ecco-ibd.eu
2019_Poster_New ECCO Guidelines & Topical Reviews.indd 1 21.12.2018 16:23:41 Poster exhibition
Hard copy poster presentations/Poster exhibition Opening Hours Industry and Poster exhibition Wednesday, March 6, 2019 Closed Thursday, March 7, 2019 13:00 - 19:00 Friday, March 8, 2019 08:30 - 19:00 Saturday, March 9, 2019 08:00 - 13:00 Guided poster session The guided poster session is on Friday, March 8, 2019 from 12:30 to 13:30 in Hall B.
In pairs, poster session chairs will guide groups through the poster exhibition and presenting authors will have the opportunity to share the major findings of their abstracts in 1-2 minutes. In that time, delegates will have the chance to engage with the abstract authors and directly ask any questions.
To join the guided poster session, please choose one of poster groups listed below and find the respective poster chairs near the poster exhibition at 12:30 on Friday, March 8, 2019. All poster chairs carry an “ECCO Poster Chair” button and also hold a sign that states the poster group number as well as the scientific category.
Guided poster sessions are chaired by: (i) Basic Science: Group 1 (starts at P001): Franco Scaldaferri, Rome, Italy Michael Scharl, Zurich, Switzerland Group 2 (starts at P026): Azucena Salas, Barcelona, Spain Gerhard Rogler, Zurich, Switzerland Group 3 (starts at P051): Jesús Cosín-Roger, Valencia, Spain Monika Tripathi, Cambridge, United Kingdom Group 4 (starts at P076): Charlotte Hedin, Solna, Sweden Dror Shouval, Ramat-Gan, Israel (ii) Clinical: Diagnosis & outcome: Group 5 (starts at P100): Laurent Beaugerie, Paris, France Christianne Buskens, Amsterdam, The Netherlands Group 6 (starts at P131): Lissy de Ridder, Rotterdam, The Netherlands David Wilson, Edinburgh, United Kingdom Group 7 (starts at P161): Janneke van der Woude, Rotterdam, The Netherlands Gert De Hertogh, Leuven, Belgium Group 8 (starts at P191): Marina Aloi, Rome, Italy Jimmy Limdi, Manchester, United Kingdom
March 6-9, 2019 • Copenhagen, Denmark 65 Poster exhibition
Group 9 (starts at P221): Arie Levine, Tel Aviv, Israel Giulia Roda, Milan, Italy Group 10 (starts at P251): Roger Feakins, London, United Kingdom Tim Raine, Cambridge, United Kingdom Group 11 (starts at P281): Gerassimos Mantzaris, Athens, Greece Patrick van Rheenen, Groningen, The Netherlands (iii) Clinical: Therapy and observation: Group 12 (starts at P311): Loris Riccardo Lopetuso, Rome, Italy John Mansfield, Newcastle, United Kingdom Group 13 (starts at P342): Willem Bemelmann, Amsterdam, The Netherlands Yves Panis, Clichy, France Group 14 (starts at P373): Raja Atreya, Erlangen, Germany Janindra Warusavitarne, London, United Kingdom Group 15 (starts at P404): Ailsa Hart, London, United Kingdom Fabrizio Michelassi, New York, United States Group 16 (starts at P435): Dominik Bettenworth, Münster, Germany Ebbe Langholz, Copenhagen, Denmark Group 17 (starts at P466): Boris Vucelic, Zagreb, Croatia Ran Zhihua, Shanghai, China Group 18 (starts at P497): Fernando Magro, Porto, Portugal Sophie Restellini, Geneva, Switzerland Group 19 (starts at P528): Jaroslaw Kierkus, Warsaw, Poland Shaji Sebastian, Hull, United Kingdom Group 20 (starts at P558): Mark Löwenberg, Amsterdam, The Netherlands Bram Verstockt, Leuven, Belgium Group 21 (starts at P588): Krisztina Gecse, Amsterdam, The Netherlands Piotr Eder, Poznan, Poland Group 22 (starts at P618): Javier Gisbert, Madrid, Spain Nik Sheng Ding, Melbourne, Australia Group 23 (starts at P648): Uri Kopylov, Tel Aviv, Israel Pascal Juillerat, Bern, Switzerland Group 24 (starts at P678): David Laharie, Pessac, France Valerie Pittet, Lausanne, Switzerland Group 25 (starts at P708): Pierre Michetti, Lausanne, Switzerland Pär Myrelid, Linköping, Sweden (iv) Epidemiology: Group 26 (starts at P738): Nynne Nyboe Andersen, Copenhagen, Denmark Naila Arebi, London, United Kingdom Group 27 (starts at P777): Julien Kirchgesner, Paris, France Peter Lakatos, Budapest, Hungary (v) Genetics: Group 28 (starts at P815): Richard Russell, Glasgow, United Kingdom Magali Svrcek, Paris, France (vi) Microbiology: Group 29 (starts at P829): James Lindsay, London, United Kingdom TBD
66 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Poster exhibition
Poster exhibition
In order to view the list with abstracts presented at ECCO’19 as hard copy posters, please follow the links stated or scan the QR-codes in each category.
(i) Basic Science Poster P001-P099 ecco-ibd.eu/bs
(ii) Clinical: Diagnosis and outcome Poster P100-P310 ecco-ibd.eu/cd
(iii) Clinical: Therapy and observation Poster P311-P737 ecco-ibd.eu/ct
(iv) Epidemiology Poster P738-P814 ecco-ibd.eu/epi
March 6-9, 2019 • Copenhagen, Denmark 67 Poster exhibition
(v) Genetics Poster P815-P828 ecco-ibd.eu/gen
(vi) Microbiology Poster P829-P861 ecco-ibd.eu/mb
(vii) Nurses abstracts Poster N01-N24 ecco-ibd.eu/np
68 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 17th IBD Intensive Advanced Course
Educational programme ECCO aims to promote education and improve the quality of care for IBD patients throughout Europe. Thus, ECCO offers the following educational activities prior to as well as during the 14th Congress of ECCO in Copenhagen.
17 th IBD Intensive Advanced Course
Date: Wednesday-Thursday, March 6-7, 2019 Time: Wednesday, March 6: 08:00-16:45 Thursday, March 7: 07:30-12:00 Organisation: EduCom Target audience: Junior gastroenterologists Registration: Upon invitation only. No onsite registration. CME accreditation: 10 CME Credits; prerequisite: completion of the online evaluation form. Wednesday, March 6, 2019 Programme overview (as of February 1, 2019) HB4 M1-2, Hall B, Bella Center 08:00 - 08:15 Arrival & distribution of voting pads 1: Welcome 08:15 - 08:30 Silvio Danese, Milan, Italy James Lindsay, London, United Kingdom Session 1: Pathogenesis 08:30 - 09:15 Lead discussant: Yehuda Chowers, Haifa, Israel 2: Exposome 08:30 - 08:45 Jonas Halfvarson, Örebrö, Sweden 3: Genetics 08:45 - 09:00 Siew Ng, Hong Kong, China 4: Inflammatory pathways 09:00 - 09:15 Yehuda Chowers, Haifa, Israel 09:15 - 09:35 Coffee break Session 2: Part I: Case-based management of IBD therapies 09:35 - 11:20 Lead discussant: Peter Irving, London, United Kingdom 5: 5-ASA compounds 09:35 - 10:05 Gerhard Rogler, Zurich, Switzerland 6: Thiopurines 10:05 - 10:20 Peter Irving, London, United Kingdom 7: Methotrexate 10:20 - 10:35 Pascal Juillerat, Bern, Switzerland 8: Steroids 10:35 - 10:50 Fernando Gomollón Garcia, Zaragoza, Spain 9: Anti-TNF agents 10:50 - 11:05 Filip Baert, Roeselare, Belgium 10: Anti-integrines 11:05 - 11:20 James Lindsay, London, United Kingdom
March 6-9, 2019 • Copenhagen, Denmark 69 17th IBD Intensive Advanced Course
Wednesday, March 6, 2019, cont. Programme overview (as of February 1, 2019) HB4 M1-2, Hall B, Bella Center Session 2: Part II: New biologics and small molecules 11:20 - 12:05 Lead discussant: Axel Dignass, Frankfurt, Germany 11: Ustekinumab 11:20 - 11:35 Marc Ferrante, Leuven, Belgium 12: Tofacitinib 11:35 - 11:50 Florian Rieder, Cleveland, United States 13: Other small molecules (apremilast/ozanimod) 11:50 - 12:05 Laurent Peyrin Biroulet, Vandœuvre-lès-Nancy , France 12:05 - 13:25 Lunch break 13:25 - 14:55 Session 3: Seminars: Part I: Special clinical situations EITHER: 14a. Managing IBD and pregnancy (HB4 M1-2, Hall B, Bella Center) Iris Dotan, Petah Tikva, Israel Janneke van der Woude, Rotterdam, The Netherlands 13:25 - 14:10 OR: 14b. Managing extraintestinal manifestations of IBD (B4 M10, Hall B, Bella Center) Peter Lakatos, Budapest, Hungary; Montreal, Canada Stephan Vavricka, Zurich, Switzerland EITHER: 14a. Managing IBD and pregnancy (B4 M10, Hall B, Bella Center) Iris Dotan, Petah Tikva, Israel Janneke van der Woude, Rotterdam, The Netherlands 14:10 - 14:55 OR: 14b. Managing extraintestinal manifestations of IBD (HB4 M1-2, Hall B, Bella Center) Peter Lakatos, Budapest, Hungary; Montreal, Canada Stephan Vavricka, Zurich, Switzerland 14:55 - 15:15 Coffee break 15:15 - 16:45 Session 3: Seminars: Part II : Long term management EITHER: 15a. Managing complications associated with anti-TNF therapy (HB4 M1-2, Hall B, Bella Center) Shomron Ben-Horin, Ramat Gan, Israel Joana Torres, Lisbon, Portugal 15:15 - 16:00 OR: 15b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation (B4 M10, Hall B, Bella Center) Pierre Michetti, Lausanne, Switzerland Henit Yanai, Petah Tikva, Israel EITHER: 15a. Managing complications associated with anti-TNF therapy (B4 M10, Hall B, Bella Center) Shomron Ben-Horin, Ramat Gan, Israel Joana Torres, Lisbon, Portugal 16:00 - 16:45 OR: 15b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation (HB4 M1-2, Hall B, Bella Center) Pierre Michetti, Lausanne, Switzerland Henit Yanai, Petah Tikva, Israel
70 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 17th IBD Intensive Advanced Course
Thursday, March 7, 2019 Programme overview (as of February 1, 2019) HB4 M1-2, Hall B, Bella Center Session 4: Interactive case discussions 07:30 - 09:30 Lead discussants: Pascal Juillerat, Bern, Switzerland Antonio López-Sanromán, Madrid, Spain 16: Investigation and management of early Mild/Moderate Crohn’s Disease 07:30 - 08:00 Case presentation: Tim Raine, Cambridge, United Kingdom Discussion: Larry Egan, Galway, Ireland 08:00 - 08:05 Discussion 17: Management of perianal CD 08:05 - 08:40 Paulo Kotze, Curitiba, Brazil Antonio López-Sanromán, Madrid, Spain 08:40 - 08:45 Discussion/Questions 18: Optimal management of patient with Severe Crohn’s Disease treated with anti-TNF agents 08:45 - 09:30 Case presentation: Dominik Bettenworth, Münster, Germany Discussion: Pascal Juillerat, Bern, Switzerland Paulo Kotze, Curitiba, Brazil 09:30 - 09:45 Coffee break Session 5: Special case scenarios 09:45 - 11:45 Lead discussant: Gerassimos Mantzaris, Athens, Greece 09:45 - 10:15 19: Medical management of Acute Severe Ulcerative Colitis David Laharie, Bordeaux, France 20: Pre- and postoperative management of Crohn’s Disease 10:15 - 10:45 Glen Doherty, Dublin, Ireland 21: Management of refractory pouchitis 10:45 - 11:15 Iris Dotan, Petah Tikva, Israel 11:15 - 11:45 Discussion / Q&A Session 22: Feedback and closing remarks 11:45- 12:00 Pascal Juillerat, Bern, Switzerland
March 6-9, 2019 • Copenhagen, Denmark 71 3rd School for Clinical Trialists
3rd School for Clinical Trialists
Date: Wednesday, March 6, 2019 Time: 08:00 -11:30 Organisation: ClinCom Target audience: Clinical trial coordinators, IBD Nurses and Allied health professionals Registration: For online registered participants only. No onsite registration. CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form.
Wednesday, March 6, 2019 Programme overview (as of February 1, 2019) Auditorium 15, Hall A, Bella Center 3rd School for Clinical Trialists: Clinical Trial Evolution and Recruitment in IBD 1: Welcome & Introduction 08:00 - 08:15 Marc Ferrante, Leuven, Belgium Session 1: Evolution of trial design 08:15 - 09:30 Javier Gisbert, Madrid, Spain 2: What did we achieve with the past IBD trials until now? 08:15 - 08:45 Laurent Peyrin-Biroulet, Vandœuvre-lès-Nancy, France 3: What are the unmet needs and how can new type/innovative 08:45 - 09:15 trials meet these? Gert van Assche, Leuven, Belgium 09:15 - 09:30 4: General Discussion 09:30 - 10:00 Coffee break Session 2: How to optimise recruitment 10:00 - 11:20 Uri Kopylov, Tel Aviv, Israel 5: Clinical trial coordinator’s view 10:00 - 10:20 Martin Thomas, Cambridge, United Kingdom 6: Patient’s view / IBD nurse’s view (together) 10:20 - 10:40 Carina Blixt, Hvidovre, Denmark Annette Munk Happel, Hvidovre, Denmark (IBD Patient) 7: PI’s view 10:40 - 11:00 Laurent Beaugerie, Paris, France 7: Group Discussion Laurent Beaugerie, Paris, France Carina Blixt, Hvidovre, Denmark 11:00 - 11:20 Krisztina Gecse, Amsterdam, The Netherlands Martin Thomas, Cambridge, United Kingdom Annette Munk Happel, Hvidovre, Denmark (IBD Patient) Wulf Böcher, Ingelheim, Germany (Boehringer Ingelheim) 9: Summary & closing remarks 11:20 - 11:30 John Mansfield, Newcastle upon Tyne, United Kingdom
72 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 10th N-ECCO School
10th N-ECCO School
Date: Wednesday, March 6, 2019 Time: 08:30-16:15 Organisation: N-ECCO Target audience: IBD Nurses, Dietitians Registration: Upon invitation only. No onsite registration. CME accreditation: N/A
Wednesday, March 6, 2019 Programme overview (as of February 1, 2019) B3 M5-6, Hall B, Bella Center 1: Welcome & Introduction 08:30 - 08:45 Petra Hartmann, Minden, Germany Session 1: Diagnosis and assessment 08:45 - 12:15 Marjo Campmans-Kuijpers, Groningen, The Netherlands Petra Hartmann, Minden, Germany 2: Diagnosis, anatomy and physiology in IBD 08:45 - 09:30 Marc Ferrante, Leuven, Belgium 3: Psychosocial implications of living with IBD 09:30 - 10:00 Kay Greveson, London, United Kingdom 4: Nutritional assessment in IBD 10:00 - 10:30 Konstantinos Gerasimidis, Glasgow, United Kingdom 10:30 - 10:45 Coffee break 5: Surgery in IBD 10:45 - 11:15 Michel Adamina, Winterthur, Switzerland 6: Medical treatment 11:15 - 11:45 Dominik Bettenworth, Münster, Germany 7: Adherence 11:45 - 12:15 Susanna Jäghult, Stockholm, Sweden 12:15 - 13:15 Lunch break
March 6-9, 2019 • Copenhagen, Denmark 73 10th N-ECCO School
Wednesday, March 6, 2019, cont. Programme overview (as of February 1, 2019) B3 M5-6, Hall B, Bella Center Session 2: Case studies – Disease management 13:15 - 14:45 Wladyslawa Czuber-Dochan, London, United Kingdom Catherine Wall, London, United Kingdom EITHER: 8a: Workshop 1 – UC Management (Group A) (B3 M5-6, Hall B, Bella Center) Nik Sheng Ding, Melbourne, Australia 13:15 - 14:00 OR: 8b: Workshop 2 – CD Management (Group B) (B3 M9-10, Hall B, Bella Center) Marieke Pierik, Maastricht, The Netherlands EITHER: 8a: Workshop 1 – UC Management (Group B) (B3 M9-10, Hall B, Bella Center) Nik Sheng Ding, Melbourne, Australia 14:00 - 14:45 OR: 8b: Workshop 2 – CD Management (Group A) (B3 M5-6, Hall B, Bella Center) Marieke Pierik, Maastricht, The Netherlands 14:45 - 15:00 Coffee break Session 3: Multidisciplinary management in IBD 15:00 - 16:05 Wladyslawa Czuber-Dochan, London, United Kingdom Catherine Wall, London, United Kingdom 9: Nutritional management in IBD 15:05 - 15:35 Catherine Wall, London, United Kingdom 10: Nursing roles in IBD management 15:35 - 16:05 Susanna Jäghult, Stockholm, Sweden 11: Closing remarks 16:05 - 16:15 Petra Hartmann, Minden, Germany
74 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 6th ECCO-ESGAR Ultrasound Workshop – Advanced
6th ECCO-ESGAR Ultrasound Workshop – Advanced
Date: Wednesday, March 6, 2019 Time: 09:30-13:40 Organisation: EduCom in collaboration with ESGAR Target audience: Physicians, Radiologists, Surgeons, Paediatricians Registration: For registered participants only. No onsite registration. CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form.
Wednesday, March 6, 2019 Programme overview (as of February 1, 2019) B3 M1-2, Hall B, Bella Center 1: Welcome & Introduction 09:30 - 09:40 Antonio López-Sanromán, Madrid, Spain Giovanni Maconi, Milan, Italy Session 1: Assessment of IBD activity 09:40 - 11:40 Antonio López-Sanromán, Madrid, Spain Jordi Rimola, Barcelona, Spain 2: How to monitor activity in Crohn’s Disease 09:40 - 10:00 Torsten Kucharzik, Lüneburg, Germany 3: Interactive video presentation 1 10:00 - 10:20 Torsten Kucharzik, Lüneburg, Germany 4: Assessing and grading postoperative recurrence 10:20 - 10:40 Stephan Vavricka, Zurich, Switzerland 5: Interactive video presentation 2 10:40 - 11:00 Stephan Vavricka, Zurich, Switzerland 6: The contribution of ultrasound in Ulcerative Colitis 11:00 - 11:20 Christian Maaser, Lüneburg, Germany 7: Interactive video presentation 3 11:20 - 11:40 Christian Maaser, Lüneburg, Germany 11:40 - 12:10 Light lunch Session 2: Assessment of complications in Crohn’s Disease 12:10 - 13:20 Giovanni Maconi, Milan, Italy 8: Elastography and CEUS to characterize strictures and abdominal 12:10 - 12:30 masses in Crohn’s Disease Rune Wilkens, Copenhagen, Denmark 9: Interactive video presentation 12:30 - 12:50 Rune Wilkens, Copenhagen, Denmark 10: Transperineal ultrasound to detect, assess and monitor perianal 12:50 - 13:00 Crohn’s Disease Giovanni Maconi, Milan, Italy 11: Interactive video presentation 13:00 - 13:20 Giovanni Maconi, Milan, Italy 12: Post course test 13:20 - 13:40 Summary and closing remarks Giovanni Maconi, Milan, Italy
March 6-9, 2019 • Copenhagen, Denmark 75 4th Advanced ECCO: EduCational COurse for Industry
4th Advanced ECCO: EduCational COurse for Industry
Date: Wednesday, March 6, 2019 Time: 14:00-18:00 Organisation: ClinCom Target audience: Corporate Members & Non-Corporate Members Registration: For online registered participants only. No onsite registration. CME accreditation: N/A
Wednesday, March 6, 2019 Programme overview (as of February 1, 2019) Auditorium 15, Hall A, Bella Center 1: Welcome & Introduction 14:00 - 14:05 Silvio Danese, Milan, Italy 2: Session 1: Individualised therapy: The role of prognostic biomarkers Shomron Ben-Horin, Ramat Gan, Israel Panel discussion and interaction with the audience: Shomron Ben-Horin, Ramat Gan, Israel 14:05 - 14:55 Silvio Danese, Milan, Italy Brihad Abhyankar, Dublin, Ireland (Theravance) Mark Ainsworth, Copenhagen, Denmark (Danish Medicines Agency) Swati Tole, San Francisco, United States (Roche) 3: Session 2: From phase 3 to first-line use Laurent Peyrin-Biroulet, Vandœuvre-lès-Nancy, France Panel discussion and interaction with the audience: Brian Feagan, London, Canada 14:55 - 15:45 Laurent Peyrin-Biroulet, Vandœuvre-lès-Nancy, France Fabio Cataldi, Cambridge, United States (AbbVie) Scott Plevy, Spring House, United States (Johnson & Johnson) Elmer Schabel, Bonn, Germany (Federal Institute of Drugs and Medical Products) 15:45 - 16:15 Coffee break 4: Session 3: Challenges in paediatric study design Anne Griffiths, Toronto, Canada Panel discussion and interaction with the audience: Lissy de Ridder, Rotterdam, The Netherlands 16:15 - 17:05 Anne Griffiths, Toronto, Canada Laurence D’Agay, Boudry, Switzerland (Celgene) Peter Szitanyi, Prague, Czech Republic (Charles University) William Treem, Cambridge, United States (Takeda) 5: Session 4: EMA recommendations for clinical trial design in IBD Mark Ainsworth, Copenhagen, Denmark (Danish Medicines Agency) Panel discussion and interaction with the audience: Mark Ainsworth, Copenhagen, Denmark 17:05 - 17:55 John Mansfield, Newcastle Upon Tyne, United Kingdom Julián Panés, Barcelona, Spain Wulf Böcher, Ingelheim, Germany (Boehringer Ingelheim) Freddy Cornillie, Kriens, Switzerland (MSD International) 6: Closing remarks 17:55 - 18:00 Krisztina Gecse, Amsterdam, The Netherlands
76 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 5th Y-ECCO Basic Science Workshop
5th Y-ECCO Basic Science Workshop
Date: Wednesday, March 6, 2019 Time: 12:30-16:30 Organisation: Y-ECCO Target audience: Basic scientists, Physicians, Paediatricians, Surgeons, IBD Nurses Registration: For online registered participants only. No onsite registration. CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form. Wednesday, March 6, 2019 Programme overview (as of February 1, 2019) B3 M7-8, Hall B, Bella Center 1: Welcome & Introduction 12:30 - 12:35 Demystifying complex molecular techniques Nuha Yassin, Birmingham, United Kingdom Session 1: Complex genetics and functional epigenetics 12:35 - 13:50 Charlotte Hedin, Stockholm, Sweden Dermot McGovern, Los Angeles, United States 2: Complex genetics and functional epigenetics 12:35 - 13:05 Dermot McGovern, Los Angeles, United States 3: Abstract 1: Distinct and common gene expression profiles between inflamed ileum and colon of newly diagnosed CD patients 13:05 - 13:20 Sare Verstockt, Leuven, Belgium Presented as P821 in the poster exhibition 4: Abstract 2: Signalling and transcriptional network propagation uncovers novel Ulcerative Colitis pathogenetic pathways from 13:20 - 13:35 single nucleotide polymorphisms Dezso Modos, Cambridge, United Kingdom Presented as P011 in the poster exhibition 5: Abstract 3: The regulatory landscape of intestinal cells – investigating the transcriptional effect of autophagy impairment observed in Crohn’s 13:35 - 13:50 disease using organoid and network biology approaches Agatha Treveil, Norwich, United Kingdom Presented as DOP08 in DOP Session 1 13:50 - 14:15 Meet the speakers break Session 2: Understanding and integrating the ‘omics’ in IBD 14:15 - 15:30 Elaine Holmes, London, United Kingdom Nuha Yassin, Birmingham, United Kingdom 6: Understanding and integrating the ‘omics’ in IBD 14:15 - 14:45 Elaine Holmes, London, United Kingdom 7: Abstract 4: Supplementation with butyrate producing bacteria 14:45 - 15:00 reduces tumor load in a mouse model of colitis associated cancer Ana Montalbar-Arques, Zurich, Switzerland 8: Abstract 5: Myenteric plexitis and post-operative recurrence in 15:00 - 15:15 Crohn’s disease: the role of enteric glial cells and ICAM-1 Catherine Le Berre, Nantes, France 9: Abstract 6: The cytokine milieu in patients with Inflammatory 15:15 - 15:30 Bowel Disease impacts the phenotype of mesenchymal stromal cells Marieke Barnhoorn, Leiden, The Netherlands Session 3: Group session – Which methods should you choose? Moderators: Dominik Bettenworth, Münster, Germany Johan Burisch, Copenhagen, Denmark 15:30 - 16:25 Nik Sheng Ding, Melbourne, Australia Expert panel: Isabelle Cleynen, Leuven, Belgium Elaine Holmes, London, United Kingdom Dermot McGovern, Los Angeles, United States 10: Closing remarks and Y-ECCO best abstract awards 16:25 - 16:30 Nuha Yassin, Birmingham, United Kingdom
March 6-9, 2019 • Copenhagen, Denmark 77 11th Y-ECCO Career Workshop
11th Y-ECCO Career Workshop
Date: Wednesday, March 6, 2019 Time: 17:00-19:00 Organisation: Y-ECCO Target audience: Physicians, Paediatricians, Surgeons, IBD Nurses Registration: For registered participants only. No onsite registration. CME accreditation: 2 CME Credits; prerequisite: completion of the online evaluation form.
Wednesday, March 6, 2019 Programme overview (as of February 1, 2019) B3 M7-8, Hall B, Bella Center Modern career enhancing skills 1: Welcome & Introduction 17:00 - 17:05 Johan Burisch, Copenhagen, Denmark Session 1: Keys to the IBD kingdom – fellowships and beyond 17:05 - 18:00 Dominik Bettenworth, Münster, Germany Charlotte Hedin, Stockholm, Sweden 2: The view of the fellow 17:05 - 17:30 Pieter Hindryckx, Ghent, Belgium 3: The view of the host 17:30 - 18:00 Siew Ng, Hong Kong, China Session 2: Optimising your career using modern technology 18:00 - 19:00 Nik Sheng Ding, Melbourne, Australia Nuha Yassin, Birmingham, United Kingdom 4: Science and social media – why bother? 18:00 - 18:30 Charlie Lees, Edinburgh, United Kingdom 5: Living like an academic athlete 18:30 - 19:00 Florian Rieder, Cleveland, United States 6: Closing remarks 19:00 Johan Burisch, Copenhagen, Denmark
78 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 1st ECCO-ESGAR Basic Imaging Workshop
1st ECCO-ESGAR Basic Imaging Workshop
Date: Wednesday-Thursday, March 6-7, 2019 Time: Wednesday, March 6: 14:30-19:00 Thursday, March 7: 07:30-12:00 Organisation: EduCom in collaboration with ESGAR Target audience: Physicians, Radiologists, Surgeons, Paediatricians Registration: For registered participants only. No onsite registration. CME accreditation: 7 CME Credits; prerequisite: completion of the online evaluation form.
Wednesday, March 6, 2019 Programme overview (as of February 1, 2019) B3 M1-2, Hall B, Bella Center 1: Day 1. Welcome & pre-course test 14:30 - 14:45 Marietta Iacucci, Birmingham, United Kingdom James Lindsay, London, United Kingdom Session 1: Endoscopy – Endoscopic assessment and scoring systems in IBD: “The simpler the better” 14:45 - 16:30 Krisztina Gecse, Amsterdam, The Netherlands Marietta Iacucci, Birmingham, United Kingdom 2a: Presentation: Endoscopic scoring systems in IBD: When and How 14:45 - 15:05 can I EXIT? Raf Bisschops, Leuven, Belgium 2b: Video case: Endoscopic scoring systems in IBD: When and How 15:05 - 15:20 can I EXIT? Krisztina Gecse, Amsterdam, The Netherlands 2c: Panel discussion: Endoscopic scoring systems in IBD: When and How can I EXIT? Filip Baert, Roeselare, Belgium Raf Bisschops, Leuven, Belgium 15:20 - 15:45 James East, Oxford, United Kingdom Marietta Iacucci, Birmingham, United Kingdom Taku Kobayashi, Tokyo, Japan Matt Rutter, North Tees, United Kingdom 3a: Presentation: How to write a great IBD endoscopy report? 15:45 - 16:05 Matt Rutter, North Tees, United Kingdom 3b: Panel discussion: How to write a great IBD endoscopy report? Filip Baert, Roeselare, Belgium Raf Bisschops, Leuven, Belgium 16:05 - 16:30 James East, Oxford, United Kingdom Marietta Iacucci, Birmingham, United Kingdom Taku Kobayashi, Tokyo, Japan Matt Rutter, North Tees, United Kingdom 16:30 - 17:00 Coffee break
March 6-9, 2019 • Copenhagen, Denmark 79 1st ECCO-ESGAR Basic Imaging Workshop
Wednesday, March 6, 2019, cont. Programme overview (as of February 1, 2019) B3 M1-2, Hall B, Bella Center Session 2: Endoscopy – Surveillance and dysplasia management in IBD 17:00 - 18:30 Matt Rutter, North Tees, United Kingdom Raf Bisschops, Leuven, Belgium 4a: Presentation: Surveillance colonoscopy and dysplasia characterisation: How do I do and manage it? 17:00 - 17:20 James East, Oxford, United Kingdom Marietta Iacucci, Birmingham, United Kingdom 4b: Video case: Surveillance colonoscopy and dysplasia characterisation: How do I do and manage it? 17:20 - 17:35 Federica Furfaro, Milan, Italy Paulo Kotze, Curitiba, Brazil 4c: Panel discussion: Surveillance colonoscopy and dysplasia characterisation: How do I do and manage it? Raf Bisschops, Leuven, Belgium James East, Oxford, United Kingdom 17:35 - 18:00 Marietta Iacucci, Birmingham, United Kingdom Taku Kobayashi, Tokyo, Japan Matt Rutter, North Tees, United Kingdom Henit Yanai, Petah Tikva, Israel 5: Small bowel Crohn’s Disease – is MRE enough? Do we still need 18:00 - 18:30 enteroscopy? Taku Kobayashi, Tokyo, Japan 6: Day 1: Post-course test and Closing remarks 18:30 - 19:00 Marietta Iacucci, Birmingham, United Kingdom
80 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 1st ECCO-ESGAR Basic Imaging Workshop
Thursday, March 7, 2019 Programme overview (as of February 1, 2019) B3 M3-4, Hall B, Bella Center 7: Day 2: Welcome & Introduction 07:30 - 07:40 Andrea Laghi, Rome, Italy Giovanni Maconi, Milan, Italy Session 3: Ultrasound and MRI – Introductory Lectures 07:40 - 08:30 Giovanni Maconi, Milan, Italy 8: Intestinal Ultrasound 07:40 - 08:05 Christian Maaser, Lüneburg, Germany 9: Entero-MRI 08:05 - 08:30 Jordi Rimola, Barcelona, Spain Session 4: Ultrasound and MRI – Hands-on bowel ultrasonography and interactive 08:30 - 11:30 discussion on Ultrasound MRI workstations 10: Management of suspected IBD Torsten Kucharzik, Lüneburg, Germany Francesca Maccioni, Rome, Italy 11: Assessment of Crohn’s Disease activity Stephan Vavricka, Zurich, Switzerland Pasquale Paolantonio, Rome, Italy 12: Intestinal complications of Crohn’s Disease Rune Wilkens, Copenhagen, Denmark Arun Gupta, London, United Kingdom 08:30 - 11:30 13: Post-operative recurrence of Crohn’s Disease Britta Siegmund, Berlin, Germany Cristiana Bonifacio, Rozzano, Italy 14: Perianal Crohn’s Disease Giovanni Maconi, Milan, Italy Guiseppe Lo Re, Palermo, Italy 15: Ulcerative Colitis Christian Maaser, Lüneburg, Germany Michael Torkzad, London, United Kingdom 16: Day 2: Post-course test and Closing remarks 11:30 - 12:00 Andrea Laghi, Rome, Italy Giovanni Maconi, Milan, Italy
March 6-9, 2019 • Copenhagen, Denmark 81 Copenhagen Denmark ECCO IBD Curriculum
ECCO’s Framework of Education
• Concise yet complete: What • Close to 500 items from the e-CCO Learning gastroenterologists need to know to Platform are already mapped to the ECCO develop expertise in the IBD field IBD Curriculum • Developed in part by ECCO Officers and • e-Courses ECCO National Representatives • Talking Heads • Provides a future framework for ECCO • Educational Podcasts Educational Activities • Skills Videos • Webcasts from the ECCO Congress Scientific Programme and Educational Activities
Scan and visit www.e-learning.ecco-ibd.eu
2019_POSTER_IBD Curriculum.indd 1 04.01.2019 18:29:47 7th SciCom Workshop
7th SciCom Workshop: Mechanisms and therapeutic modulation of mucosal healing in IBD
Date: Thursday, March 7, 2019 Time: 08:45-12:00 Organisation: SciCom Target audience: Basic scientists and interested clinicians Registration: For online registered participants only. No onsite registration. CME accreditation: 2 CME Credits; prerequisite: completion of the online evaluation form.
Thursday, March 7, 2019 Programme overview (as of February 1, 2019) B3 M9-10, Hall B, Bella Center Mechanisms and therapeutic modulation of mucosal healing in IBD Session 1: Intestinal regeneration and its disruption in IBD 08:45 - 10:10 Jesús Rivera-Nieves, San Diego, United States Janneke Van der Woude, Rotterdam, The Netherlands 1: Welcome & Introduction 08:45 - 08:55 Shomron Ben-Horin, Ramat Gan, Israel 2: Epithelial barrier defects in the pathogenesis of IBD 08:55 - 09:20 Sebastian Zeissig, Dresden, Germany 3: Intestinal immunity – friend or foe in regeneration? 09:20 - 09:45 Michael Scharl, Zurich, Switzerland 4: The extracellular matrix as a central regulator of intestinal 09:45 - 10:10 regeneration TBD 10:10 - 10:30 Coffee break Session 2: Clinical assessment and therapeutic modulation of intestinal regeneration in IBD 10:30 - 11:45 Gerhard Rogler, Zurich, Switzerland Sebastian Zeissig, Dresden, Germany 5: Epithelial transplantation to facilitate mucosal healing 10:30 - 10:55 Mamoru Watanabe, Tokyo, Japan 6: Novel endoscopic approaches for the assessment of mucosal 10:55 - 11:20 healing Maximillian Waldner, Erlangen, Germany 7: New drugs to support tissue healing – insights from other fields 11:20 - 11:45 Florian Rieder, Cleveland, United States 8: Closing remarks 11:45 - 12:00 Sebastian Zeissig, Dresden, Germany
March 6-9, 2019 • Copenhagen, Denmark 83 1st Guideline Methodology and GRADE Workshop
1st Guideline Methodology and GRADE Workshop
Date: Thursday, March 7, 2019 Time: 08:00-12:00 Organisation: GuiCom Target audience: All health care professionals interested in guidelines and guideline development Registration: For online registered participants only. No onsite registration. CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form.
Thursday, March 7, 2019 Programme overview (as of February 1, 2019) B3 M7-8, Hall B, Bella Center Session 1 08:00 - 10:15 Gionata Fiorino, Milan, Italy Joana Torres, Lisbon, Portugal 1: Welcome & Introduction 08:00 - 08:15 Gionata Fiorino, Milan, Italy 2: What you need to know to understand the GRADE methodology 08:15 - 09:45 Stefanos Bonovas, Milan, Italy 3: Patient perspectives of guidelines – why should patients be involved Ciara Drohan, Dublin, Ireland (EFCCA patient representative) 09:45 - 10:05 Evelyn Groß, Graz, Austria (EFCCA patient representative) Sanna Lönnfors, Pyhtää, Finland (EFCCA patient representative) Marko Perovic, Belgrade, Serbia (EFCCA patient representative) 4: What is the role of patients in the GRADE methodology 10:05 - 10:15 Stefanos Bonovas, Milan, Italy 10:15 - 10:45 Coffee break Session 2 10:45 - 12:00 Gionata Fiorino, Milan, Italy Tim Raine, Cambridge, United Kingdom 5: How to perform a scientifically sound literature research – the 10:45 - 11:00 new ECCO SOP Joana Torres, Lisbon, Portugal 6: The pros and cons of using the GRADE vs. Oxford methodology 11:00 - 11:45 Marien González Lorenzo, Milan, Italy Theodore Lytras, Athens, Greece 7: Discussion and conclusion 11:45 - 12:00 Gionata Fiorino, Milan, Italy Joana Torres, Lisbon, Portugal
84 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 6th P-ECCO Educational Course
6th P-ECCO Educational Course
Date: Thursday, March 7, 2019 Time: 08:00-10:00 Organisation: P-ECCO in collaboration with N-ECCO Target audience: Advanced IBD Nurses; Paediatricians, Physicians, Surgeons Registration: For online registered participants only. No onsite registration. CME accreditation: 2 CME Credits; prerequisite: completion of the online evaluation form.
Thursday, March 7, 2019 Programme overview (as of February 1, 2019) C1 M0, Hall C, Bella Center Dealing with challenging adolescents with IBD 08:00 - 10:00 Kay Greveson, London, United Kingdom David Wilson, Edinburgh, United Kingdom 1: Welcome 08:00 - 08:05 David Wilson, Edinburgh, United Kingdom 2: I am not a challenging patient: I want to live a normal life! 08:05 - 08:35 Rosie Campbell, London, United Kingdom 3: Non-adherence and motivational interviewing 08:35 - 09:05 Ailsa Hart, London, United Kingdom 4: Helping adolescents to thrive 09:05 - 09:30 Vikki Garrick, Glasgow, United Kingdom 5: Transitional care and sexuality 09:30 - 10:00 Patrick van Rheenen, Groningen, The Netherlands
March 6-9, 2019 • Copenhagen, Denmark 85 13th N-ECCO Network Meeting
13th N-ECCO Network Meeting
Date: Thursday, March 7, 2019 Time: 10:30-16:45 Organisation: N-ECCO Target audience: IBD Nurses - advanced level Registration: For registered participants only. No onsite registration. CME accreditation: N/A
Thursday, March 7, 2019 Programme overview (as of February 1, 2019) C1 M0, Hall C, Bella Center 1: Welcome & Introduction 10:30 - 10:45 Announcement of the N-ECCO Research Grant Award 2019 Kay Greveson, London, United Kingdom Session 1: New research and developments in IBD 10:45 - 12:00 Wladyslawa Czuber-Dochan, London, United Kingdom Susanna Jäghult, Stockholm, Sweden 2: New model of e-health – “IBD Home” 10:45 - 11:15 Susanna Jäghult, Stockholm, Sweden 3: Nurse Abstract 1: Fatigue and physical activity in individuals with Inflammatory Bowel Disease: A feasibility cross-sectional, 11:15 - 11:30 correlational study Dawn Farrell, Tralee, Ireland Presented as N01 in poster exhibition 4: Nurse Abstract 2: Inflammatory Bowel Disease and pregnancy: The impact of education in knowledge and attitude of women in 11:30 - 11:45 reproductive age. One-year follow-up study Triantafyllia Tsavdaroglou, Athens, Greece Presented as N02 in poster exhibition 5: Nurse Abstract 3: Can post biologic infusion monitoring be reduced? A multi-centred retrospective study 11:45 - 12:00 Lisa Younge, London, United Kingdom Presented as N03 in poster exhibition 12:00 - 13:30 Lunch break N-ECCO Network Meeting Lunch Satellite Symposium 12:15 - 13:15 See page 113.
86 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 13th N-ECCO Network Meeting
Thursday, March 7, 2019, cont. Programme overview (as of February 1, 2019) C1 M0, Hall C, Bella Center Session 2: Clinical and practical IBD – how to work together with the patient 13:30 - 15:00 Petra Hartmann, Minden, Germany Else Mikkelsen, Herning, Denmark 6: How to implement biosimilars 13:30 - 14:00 Kay Greveson, London, United Kingdom 7: The importance of shared care in IBD – a tandem talk 14:00 - 15:00 Anne Carol Elisabeth Jørgensen, Herlev, Denmark Büsra Nergiz, Søborg, Denmark (IBD Patient) 15:00 - 15:30 Coffee break Session 3: Different views of IBD care 15:30 - 16:30 Kay Greveson, London, United Kingdom 8: Different ways to work with IBD patients – Descriptions from South Africa, Germany, Denmark, Sweden Palle Bager, Aarhus, Denmark 15:30 - 16:30 Karin Davidson, Cape Town, South Africa Petra Hartmann, Minden, Germany Susanna Jäghult, Stockholm, Sweden 9: Closing remarks, N-ECCO in 2019 and beyond 16:30 - 16:45 Kay Greveson, London, United Kingdom
March 6-9, 2019 • Copenhagen, Denmark 87 8th S-ECCO IBD Masterclass in collaboration with ESCP
8th S-ECCO IBD Masterclass in collaboration with ESCP Date: Thursday, March 7, 2019 Time: 08:00-17:15 Organisation: S-ECCO in collaboration with ESCP Target audience: Surgeons, Physicians, IBD Nurses Registration: For online registered participants only. No onsite registration. CME accreditation: 6 CME Credits; prerequisite: completion of the online evaluation form.
Thursday, March 7, 2019 Programme overview (as of February 1, 2019) C1 M2, Hall C, Bella Center 1: Welcome 08:00 - 08:10 Willem Bemelman, Amsterdam, The Netherlands Session 1: Hot debates in IBD surgery 08:10 - 10:00 Geert D’Haens, Amsterdam, The Netherlands André D’Hoore, Leuven, Belgium 08:10 - 08:55 Debate 1: Perforating form of ileal Crohn’s Disease 2: What about the radiology? 08:10 - 08:20 Andrea Laghi, Rome, Italy 3: Only medical treatment can solve the problem! 08:20 - 08:30 Julián Panés, Barcelona, Spain 4: No! Surgery is the only solution! 08:30 - 08:40 Antonino Spinelli, Milan, Italy 08:40 - 08:55 Discussion 08:55 - 09:40 Debate 2: The failed pouch 5: Diverting stoma is enough! 08:55 - 09:05 Dieter Hahnloser, Lausanne, Switzerland 6: Pouch excision and definitive stoma is much better! 09:05 - 09:15 Pär Myrelid, Linköping, Sweden 7: No! Redo pouch is fantastic! 09:15 - 09:25 Conor Delaney, Cleveland, United States 09:25 - 09:40 Discussion 8: Tandem talk: Outcome measures in IBD surgery 09:40 - 10:00 Michel Adamina, Winterthur, Switzerland Laurent Beaugerie, Paris, France 10:00 - 10:30 Coffee break
88 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 8th S-ECCO IBD Masterclass in collaboration with ESCP
Thursday, March 7, 2019, cont. Programme overview (as of February 1, 2019) C1 M2, Hall C, Bella Center Session 2: The scientific IBD surgeon: Trial updates and free papers 10:30 - 12:00 Michel Adamina, Winterthur, Switzerland Conor Delaney, Cleveland, United States Trial updates 9: Rectal stump or not after laparoscopic subtotal colectomy: 10:30 - 10:40 Results of a 5-center European study Diane Mège, Clichy, France 10: Stoma rates in the biological era 10:40 - 10:50 Paulo Kotze, Curitiba, Brazil 11: Early biomarkers for surgical complications in 250 CD patients 10:50 - 11:00 Michele Carvello, Milan, Italy Free papers 12: Abstract 1: Iterative ileocolonic resection for Crohn’s Disease: A prospective multicentric cohort study of the GETAID Chirurgie 11:00 - 11:10 Solafah Abdalla, Paris, France Presented as P558 in the poster exhibition 13: Abstract 2: Treatment of perianal fistulas in Crohn’s Disease, seton versus anti-TNF versus surgical closure following anti-TNF 11:10 - 11:20 (PISA): A randomised controlled trial Karin Wasmann, Amsterdam, The Netherlands Presented as DOP73 in DOP Session 9 14: Abstract 3: Long-term function after transanal versus transabdominal ileal pouch-anal anastomosis for Ulcerative Colitis: 11:20 - 11:30 A multicenter cohort study Antonino Spinelli, Milan, Italy Presented as P468 in the poster exhibition 15: Pregnancy and delivery in IBD patients 11:30 - 11:45 Hagit Tulchinsky, Tel Aviv, Israel 16: Faecal diversion in severe anoperineal Crohn’s Disease: Does it 11:45 - 12:00 really work? Yves Panis, Clichy, France 12:00 - 13:25 Lunch break 12:15 - 13:15 Lunchtime Satellite Symposium (see pg. 113) Session 3: Difficult decisions in IBD surgery 13:25 - 15:25 Fabrizio Michelassi, New York, United States Yves Panis, Clichy, France 13:25 - 13:55 Debate 3: Can we prevent recurrence after surgery for CD? 17: Postoperative medical prevention after ileocecal resection for 13:25 - 13:35 CD Pierre Michetti, Lausanne, Switzerland 18: Prevention by surgery is possible 13:35 - 13:45 Christianne Buskens, Amsterdam, The Netherlands 13:45 - 13:55 Discussion
March 6-9, 2019 • Copenhagen, Denmark 89 8th S-ECCO IBD Masterclass in collaboration with ESCP
Thursday, March 7, 2019, cont. Programme overview (as of February 1, 2019) C1 M2, Hall C, Bella Center 13:55 - 14:45 Surgery is not always easy – Session 19: Open surgery for IBD patients: Never? 13:55 - 14:05 Fabrizio Michelassi, New York, United States 20: Upper GI CD: What are the surgical options? 14:05 - 14:15 Paulo Kotze, Curitiba, Brazil 21: Subtotal colectomy first for all UC patients? 14:15 - 14:25 André D’Hoore, Leuven, Belgium 22: Oncologic decisions in IBD surgery 14:25 - 14:35 Phillip Fleshner, Los Angeles, United States 14:35 - 14:45 Discussion 14:45 - 15:25 Surgical technique video session 23: Laparoscopic subtotal colectomy for Acute Colitis 14:45 - 14:55 Janindra Warusavitarne, London, United Kingdom 24: Long side-to-side stricturoplasty 14:55 - 15:05 Fabrizio Michelassi, New York, United States 25: Flap for anoperineal fistula complicating CD 15:05 - 15:15 Phil Tozer, London, United Kingdom 26: Gracilis muscle interposition for rectovaginal fistula 15:15 - 15:25 complicating CD Oded Zmora, Tel Aviv, Israel 15:25 - 15:45 Coffee break Session 4: Surgery in the era of biologics 15:45 - 16:15 André D’Hoore, Leuven, Belgium Paulo Kotze, Curitiba, Brazil 27: Good news! Less surgery 15:45 - 16:00 Jean-Frédéric Colombel, New York, United States 28: No! Biologics only delay surgery 16:00 - 16:15 Willem Bemelman, Amsterdam, The Netherlands Session 5: Consultants’ corner on challenging cases Willem Bemelman, Amsterdam, The Netherlands Jean-Frédéric Colombel, New York, United States 16:15 - 17:00 Conor Delaney, Cleveland, United States André D’Hoore, Leuven, Belgium Dieter Hahnloser, Lausanne, Switzerland Challenging cases 29: A refractory proctitis complicating CD 16:15-16:30 Laura Beyer-Berjot, Marseille, France 30: A rectovaginal fistula complicating CD 16:30-16:45 Diane Mège, Clichy, France 31: A chronic fistula after IPAA for UC 16:45-17:00 Michele Carvello, Milan, Italy Closing remarks 17:00 - 17:15 Yves Panis, Clichy, France
90 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 4th ECCO-AOCC Forum: East meets West
4th ECCO-AOCC Forum: East meets West
Date: Thursday, March 7, 2019 Time: 08:50-11:40 Organisation: ECCO Governing Board Target audience: Physicians, Surgeons Registration: For online registered participants only. No onsite registration. CME accreditation: N/A
Thursday, March 7, 2019 Programme overview (as of February 1, 2019) C1 M3, Hall C, Bella Center Session 1 08:50 - 10:00 Glen Doherty, Dublin, Ireland Jiaming Qian, Beijing, China 1: Welcome & Introduction 08:50 - 09:00 Silvio Danese, Milan, Italy 2: Tandem Talk: Surgical and medical approach for Fistulising Crohn’s Disease 09:00 - 10:00 Christianne Buskens, Amsterdam, The Netherlands Byong Duk Ye, Seoul, Korea 10:00 - 10:30 Coffee break Session 2 10:30 - 11:40 Peter Irving, London, United Kingdom Yoon Tae Jeen, Seoul, Korea 3: Tandem Talk: When to start and when to stop biologics 10:30 - 11:30 Taku Kobayashi, Tokyo, Japan Edouard Louis, Liège, Belgium 4: Closing remarks 11:30 - 11:40 Akira Andoh, Shiga, Japan
March 6-9, 2019 • Copenhagen, Denmark 91 We keep you informed at all times!
Volume 12 Issue 12 December, 2018 12-12 December, 2018
JOURNAL of CROHN’S and COLITIS Journal of Crohn’s and Colitis
AB Pages 1383–1508 Abdominal ultrasound in ulcerative colitis – see editorial and article pages 1383–1391
Ulcers
www.ecco-ibd.eu More reasons to join the ECCO Family!
JCC ECCO News • 2017 Impact Factor: 6.637 • All the inside stories of ECCO • ECCO Guidelines and Topical Reviews • ECCO Calls, Elections and Activities • ECCO Scientific Workshop Reviews • Literature Reviews • ECCO Position statements • JCC online only (website) e-CCO Learning • Printed copies to be purchased at OUP • ECCO IBD Curriculum • e-Courses and e-Library ECCO Website • Congress abstracts • ECCO Activities & Events • Scientific articles • Congress abstracts • Congress webcasts • Educational Audio Podcasts • Skills videos
Scan and contact the ECCO Office www.ecco-ibd.eu
2019_POSTER_We keep you informed at all times.indd 1 29.01.2019 18:50:36 4th H-ECCO IBD Masterclass
4th H-ECCO IBD Masterclass
Date: Thursday-Friday, March 7-8, 2019 Time: Thursday, March 7: 13:30-17:15 Friday, March 8: 08:00-12:00 Organisation: H-ECCO, endorsed by ESP Target audience: Histopathologists, Clinicians Registration: For registered participants only. No onsite registration. CME accreditation: 6 CME Credits; prerequisite: completion of the online evaluation form.
Thursday, March 7, 2019 Programme overview (as of February 1, 2019) B3 M9-10, Hall B, Bella Center 1: Welcome & Introduction 13:30 - 13:35 Roger Feakins, London, United Kingdom Session 1: Basic 13:35 - 15:15 Paula Borralho Nunes, Lisbon, Portugal James Lindsay, London, United Kingdom 2: Clinical diagnosis of IBD 13:35 - 13:55 James Lindsay, London, United Kingdom 3: Biopsy diagnosis and classification of IBD 13:55 - 14:15 Gert de Hertogh, Leuven, Belgium 4: How to deal with an IBD resection specimen 14:15 - 14:35 Monika Tripathi, Cambridge, United Kingdom 5: Histological differential diagnosis of IBD 14:35 - 14:55 Roger Feakins, London, United Kingdom 6: Acute and fulminant colitis 14:55 - 15:15 Francesca Rosini, London, United Kingdom 15:15 - 15:45 Coffee break Session 2: Treatment and its effects 15:45 - 17:15 Roger Feakins, London, United Kingdom Francesca Rosini, London, United Kingdom 7: Specific effects of IBD drugs on the mucosa 15:45 - 16:05 Gert de Hertogh, Leuven, Belgium 8: Diversion proctocolitis 16:05 - 16:25 Monika Tripathi, Cambridge, United Kingdom 9: Pouch and pre-pouch pathology: Does it matter? 16:25 - 16:50 Shaun Walsh, Dundee, United Kingdom 10: Hot topics in IBD 16:50 - 17:15 Magali Svrcek, Paris, France
March 6-9, 2019 • Copenhagen, Denmark 93 4th H-ECCO IBD Masterclass
Friday, March 8, 2019 Programme overview (as of February 1, 2019) B3 M9-10, Hall B, Bella Center Session 3: Age and demographics 08:00 - 09:45 Gert de Hertogh, Leuven, Belgium Magali Svrcek, Paris, France 11: Demographics of IBD 08:00 - 08:15 Johan Burisch, Copenhagen, Denmark 12: Paediatric IBD – clinical aspects 08:15 - 08:35 Patrick van Rheenen, Groningen, The Netherlands 13: Paediatric IBD – pathological features 08:35 - 08:55 Paula Borralho Nunes, Lisbon, Portugal 14: Older onset IBD – clinical aspects 08:55 - 09:15 Guillaume Savoye, Rouen, France 15: Histology of IBD and related colitides in older patients 09:15 - 09:35 Vincenzo Villanacci, Brescia, Italy 16: Slide seminar case 1 09:35 - 09:45 Roger Feakins, London, United Kingdom 09:45 - 10:15 Coffee break Session 4: Tumours 10:15 - 11:55 Monika Tripathi, Cambridge, United Kingdom Vincenzo Villanacci, Brescia, Italy 17: Serrated lesions in IBD 10:15 - 10:35 Roger Feakins, London, United Kingdom 18: Clinical features of IBD-related tumours 10:35 - 10:55 Laurent Beaugerie, Paris, France 19: Pathology of colorectal cancer in IBD 10:55 - 11:15 Magali Svrcek, Paris, France 20: Other tumours in IBD 11:15 - 11:35 Paula Borralho Nunes, Lisbon, Portugal 21: Slide seminar cases 2 and 3 11:35 - 11:55 Paula Borralho Nunes, Lisbon, Portugal Monika Tripathi, Cambridge, United Kingdom 22: Closing remarks 11:55 - 12:00 Roger Feakins, London, United Kingdom
94 14th Congress of ECCO - European Crohn‘s and Colitis Organisation ECCO Educational Workshops 2019
ECCO Workshops st 61 ECCO Workshop 65 LATVIA Lancara, Cyprus - June 15, 2019 62nd ECCO Workshop Tel Aviv, Israel - June 19, 2019 63rd ECCO Workshop Santiago, Chile - July 3, 2019 64th ECCO Workshop New Delhi, India - November 9, 2019 65th ECCO Workshop Riga, Latvia - December 6, 2019 Congress special: Call for similar cases Learning Platform 64byINDIA ECCO 61 CYPRUS – ECCO63 CONFERCHILE Round 2 62 ISRAEL
Spreading standards in IBD: Your presence counts!
Scan and contact the ECCO Office www.ecco-ibd.eu
2019_POSTER_Educational Workshops.indd 1 21.12.2018 16:25:08 4th D-ECCO Workshop
4th D-ECCO Workshop
Date: Friday, March 8, 2019 Time: 08:15-12:25 Organisation: D-ECCO Target audience: Dietitians, IBD Nurses, Physicians Registration: For registered participants only. No onsite registration. CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form.
Friday, March 8, 2019 Programme overview (as of February 1, 2019) HB4 M1-2, Hall B, Bella Center 1: Welcome 08:15 - 08:20 Marjo Campmans-Kuijpers, Groningen, The Netherlands Session 1: Science, diet and IBD 08:20 - 09:30 Rotem Sigall-Boneh, Tel Aviv, Israel Catherine Wall, London, United Kingdom 2: Breastfeeding and risk of IBD 08:20 - 08:38 Joana Torres, Lisbon, Portugal 3: Diet and microbiome in IBD 08:38 - 08:56 Marjo Campmans-Kuijpers, Groningen, The Netherlands 4: Immunological effects of nutritional interventions in IBD 08:56 - 09:15 Dror Shouval, Tel Hashomer, Israel 5: Growth and bone health in patients with IBD 09:15 - 09:30 David Wilson, Edinburgh, United Kingdom 09:30 - 09:50 Coffee break Session 2: Practical clinical nutrition in IBD 09:50 - 10:50 Marjo Campmans-Kuijpers, Groningen, The Netherlands Arie Levine, Tel Aviv, Israel 6: Patients’ and carers’ perception about the role of diet in IBD 09:50 - 10:10 Konstantinos Gerasimidis, Glasgow, United Kingdom 7: Novel dietary treatments for IBD – how to advise the patient 10:10 - 10:30 Rotem Sigall-Boneh, Tel Aviv, Israel 8: Tandem talk: The future IBD clinic – the role of dietitian and nurse in the management of IBD patients 10:30 - 10:50 Kay Greveson, London, United Kingdom Catherine Wall, London, United Kingdom 10:50 - 11:10 Coffee break
96 14th Congress of ECCO - European Crohn‘s and Colitis Organisation 4th D-ECCO Workshop
Friday, March 8, 2019, cont. Programme overview (as of February 1, 2019) HB4 M1-2, Hall B, Bella Center Session 3: Panel discussion – Cases & questions from the audience Konstantinos Gerasimidis, Glasgow, United Kingdom (Moderator) Jackie Falconer, London, United Kingdom 11:10 - 12:20 Arie Levine, Tel Aviv, Israel James Lindsay, London, United Kingdom Miranda Lomer, London, United Kingdom Lisa Younge, London, United Kingdom Abstract presentations 9: Abstract 1: Development of an inflammatory bowel disease specific nutrition screening tool (IBD-NST) 11:10 - 11:20 Catherine Wall, London, United Kingdom Presented as P599 in the poster exhibition 10: Abstract 2: Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with Inflammatory Bowel Disease mimicking prebiotic activity and proving effects on the 11:20 - 11:30 treatment of the disease Sonia Facchin, Padova, Italy Presented as P655 in the poster exhibition Case presentations and panel discussion 11: Nutritional factors in transitional IBD 11:30 - 11:37 Shameer Mehta, London, United Kingdom 11:37 - 11:47 Panel discussion 12: Pre-operative nutritional optimisation in stricturing Crohn’s 11:47 - 11:54 Disease Dearbhaile O’Hanlon, London, United Kingdom 11:54 - 12:04 Panel discussion 13: Complications secondary to intravenous iron infusion in PIBD 12:04 - 12:11 patient Richard Russell, Glasgow, United Kingdom 12:11 - 12:20 Panel discussion 14: Closing remarks 12:20 - 12:25 Konstantinos Gerasimidis, Glasgow, United Kingdom
March 6-9, 2019 • Copenhagen, Denmark 97 Congress information
Congress information Badges Keep your badge visible at all times throughout the entire Congress and social events. The coloured stripes on your name badge represent the following:
Congress delegates, Faculty members, Press Exhibitors, Participants of educational activities only Congress day ticket holders Congress Organiser, Staff
Banks and ATM Most banks in Copenhagen are open from Monday to Friday from 10:00 to 16:00. There are ATMs (Automatic Teller Machine) at Bella Center and all over the city of Copenhagen. At the airport and main station and along the main streets, you will find currency exchange offices as well. Certificate of attendance After the Congress, registered delegates can download and print their certificates of attendance from the online registration system’s individual user area. Cloakroom The cloakroom is located in Hall E of Bella Center. Neither Bella Center nor the congress organisers are liable for any loss of belongings dropped off at the cloakroom. Coffee breaks Coffee breaks are always served in the Exhibition Hall (Hall C) at Bella Center. ECCO invites delegates to enjoy coffee and pastries free of charge. Water fountains are available throughout the congress venue. Lunch and other snacks are also available at cash catering stations. Delegates attending Satellite Symposia may be offered food and beverages prior to or after the symposium. Congress bags Registered delegates with a badge indicating eligibility, excluding exhibitors, can collect an ECCO’19 congress bag produced by Township. ECCO fully supports Township’s mission of creating sustainable economic opportunity for women in South Africa’s township communities and their production of fair trade, environmentally-friendly products.
98 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Congress information
Congress documentation Abstract USB drives Claim your USB drive by presenting your personal USB drive voucher, which you have received by email. If you have not received the USB drive voucher, please visit the Registration desk for assistance. Abstracts – Online access All abstracts of the ECCO’19 Congress can also be found online at www.ecco-ibd.eu and the online editions of the Journal of Crohn’s and Colitis. Alternatively, delegates can also look up abstracts online at the Internet Lounge in Hall B. Online streaming (post-event) Members of ECCO can access the presentations of the 14th Congress of ECCO after the event – online at www.ecco-ibd.eu in the e-Library of the e-CCO Learning platform. Presentation availability is subject to speaker authorisation. Congress organiser OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH* ECCO Office Ungargasse 6/13 1030 Vienna, Austria Phone: +43-(0) 1-710 22 42 Fax: +43-(0) 1-710 22 42-001 E-mail: [email protected] Web: www.ecco-ibd.eu/ecco19 *service provider fully owned by European Crohn’s and Colitis Organisation Congress venue Bella Center Center Boulevard 5 DK-2300 Copenhagen, Denmark www.bellacentercopenhagen.dk Credit cards and cheques All major credit cards, including Visa, MasterCard, Diners and American Express are accepted in most of the establishments as restaurants, hotels and shopping-centres and stores. Travel checks can be cashed in most of the banks and exchange offices. When paying by credit card for your shopping, you will be asked to show identification or your pin code. Please have your ID card or passport with you all the time, otherwise they may refuse to accept your credit card as payment. Currency The official currency in Denmark is the Danish Krone (DKK). The exchange rate is approximately 1.5 Kroner to 1 Euro. You can exchange your currency at all banks as well as many exchange offices in Copenhagen. When you are exchanging your currency, you need your passport or official ID card. If you do not have it with you, the bank may refuse to exchange your currency. Payment at cash catering onsite is also possible in Euro.
March 6-9, 2019 • Copenhagen, Denmark 99 Congress information
Disclaimer Please note that in the event of a cancellation of the congress by the organisers in case of force majeure, the registration fee, hotel deposit and any other service ordered through the registration will be partially refunded or forfeited, subject to the commitments of the congress organiser at that time. You may wish to insure yourself directly against such a risk.
ECCOlogical Congresses and exhibitions are commonly known for producing excessively high volumes of waste. ECCO believes that continued commitment to eco- friendly and sustainable meetings benefits host destinations and elevates the delegate experience.
At the 14th Congress of ECCO, we are dedicated in our commitment to leaving a minimal ecological footprint as we strive for greener meetings. For details, visit the ECCO Congress website at www.ecco-ibd.eu/ecco19. Face-to-face with ECCO Following its success in past congresses, the Congress will again hold the “Face-to-face with ECCO” during the coffee breaks at the ECCO Booth in the entrance hall. You are welcome to stop by to have a chat with ECCO Officers in an informal atmosphere. Engage in lively discussions about IBD and ECCO’s Initiatives! Floor plans Please refer to page 119-121. General regulations Visitors of the 14th Congress of ECCO must fully comply with the following regulations: ■■ Entrance to the 14th Congress of ECCO and affiliated events is granted only with the congress badge. ■■ Entrance to the “ECCO Interaction: Hearts and Minds” is only granted with an entrance ticket which needs to be collected at the Registration desk. ■■ The congress organiser may not be held liable for any theft and/or loss of a visitor’s individual property. It is the visitor’s sole responsibility to keep their belongings safe. Industry exhibition Please refer to pg. 117. Information on Copenhagen For information on Copenhagen, such as tours, restaurants, museums, churches/synagogues/ mosques, stop by the “Copenhagen information” desk at the Registration area in Hall E. Insurance and liability Neither the congress organiser nor Bella Center will assume any responsibility whatsoever for damage or injury to persons or property during the Congress. Participants are recommended to arrange their personal travel and health insurance.
100 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Congress information
Internet access Use the network “ECCO2019”, no password required, to access free WiFi throughout the congress venue. Internet access is also provided in the Internet Lounge located in Hall B. The ECCO Office asks delegates to respect the viewing time of max. 5 minutes per person. Language The official language of the Congress is English. No simultaneous translation will be provided.
Lost and found For lost and found service at Bella Center, please stop by the ECCO Booth in Hall E. For help in locating property lost outside Bella Center, please inform the registration desk.
Medical facilities Medical assistance can be provided by qualified staff onsite. If you need immediate assistance with first aid, please contact the security/first aid personnel found in every hall. Members‘ Lounge Exclusive for ECCO Members, the Members’ Lounge is located in the Exhibition Hall (Hall C), and is ideal for delegates who want to hold private meetings, or even just sit and relax. All electronic devices can be charged here, and Members can enjoy an open buffet to fuel the busy day.
Members’ Lounge opening hours: Thursday, March 7, 2019 10:30 - 19:45 Friday, March 8, 2019 07:15 - 19:45 Saturday, March 9, 2019 08:00 - 13:00 Photos, Filming and Recording The recording of any sort of a presentation without the consent of the organiser, including but not limited to audio/video recording and photography, is strictly prohibited at the ECCO’19 Scientific programme, Educational programme and all hard copy poster presentations. This regulation encompasses the use of (smartphones) mobile devices and any professional recording device. The entire scientific programme and selected educational activities are officially recorded by the organiser and will be published open access on the ECCO e-Learning platform after the Congress accessible to the entire IBD Community for a limited period of time. All ECCO Members however can view these official recordings at no cost throughout the entire year. All abstracts and presentations (subject to speaker authorisation) are archived in the e-Library. Poster exhibition Please refer to pg. 65. Programme changes ECCO cannot assume liability for any changes in the ECCO’19 Congress programme and programmes of the educational activities due to external or unforeseen circumstances.
March 6-9, 2019 • Copenhagen, Denmark 101 Congress information
Public transportation The congress center is well served by Copenhagen’s metro system with the station “Bella Center” on the green line M1.
To get to Øksnehallen, take the green metro line M1 from “Bella Center st. (Metro)” headed towards “Vestamager st.” and get off at “Ørestad st.”. From there, take the regional train headed towards “Helsingør st.”, and get off at “Hovedbanegården København H” (Copengahen Central Station). Then, continue straight ahead walking via Reventlowsgade to Halmtorvet until you reach Øksnehallen. (Time travel: approx. 29 min)
Visit www.rejseplanen.dk to plan your travel in detail. Registration and accommodation All registration procedures for the 14th Congress of ECCO have been conducted online. Should you wish to register onsite, visit the registration desk in Hall E for assistance. Registration desk and ECCO Congress Office The Registration Area is located in Hall E of Bella Center. You will find the ECCO Congress Office in Office 18-19 on stthe 1 floor of Bella Center.
ECCO Congress Office and the Registration desk opening hours: Wednesday, March 6, 2019 07:00 - 19:00 Thursday, March 7, 2019 07:00 - 19:00 Friday, March 8, 2019 07:00 - 19:00 Saturday, March 9, 2019 08:00 - 13:00
102 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Congress information
Registration fees Early registration Late registration Onsite registration Fee in EURO until November 14, until February 19, after February 19, (including 25% Danish VAT) 2018 2019 2019 ECCO Member Congress registration fees: Regular/Regular (Y-ECCO) Member Congress fee 250.- 320.- 400.- Nurse Member Congress fee 55.- 95.- 145.- Affiliate Member Congress fee1 55.- 95.- 145.- Non-Member Congress registration fees: Non-Member Congress fee 605.- 685.- 770.- Nurse Non-Member Congress fee2 355.- 395.- 545.- Affiliate Non-Member Congress fee3 355.- 395.- 545.- Patient Advocate Congress fee4 55.- 55.- 55.- 1Students/PhD Students registering at the Affiliate Member Congress fee must upload a certificate of their Student/PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed. 2 Nurses registering at the Nurse Non-Member Congress fee must upload a certificate of their current nurse status and registration number during the registration process. If no certificate is being uploaded, the registration process cannot be completed. 3 Students/PhD Students and delegates with the following professions may register for the Affiliate Non-Member Congress fee: Dietitian, Pharmacist, Psychologist. All delegates registering at this fee must upload a certificate of their professional status/Student or PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed. 4 Patient Advocates registering at this fee must upload a proof of their membership of a Patient Advocate Association during the registration process. If no certificate is being uploaded, the registration process cannot be completed. Please note that you might not have access to industry sponsored satellite symposia.
Registration fee for delegates includes: ■■ Access to all scientific sessions ■■ Access to poster exhibition ■■ Access to industry exhibition (HCP only) ■■ Free copy of all congress documentation ■■ Certificate of attendance ■■ Access to congress abstracts ■■ Congress bag ■■ Coffee breaks In order to pick-up a pre-paid ticket, the delegate must present a passport or ID at the Registration Area.
Speakers’ Centre The Speakers’ Centre is located in Hall E of Bella Center. Three hours prior to the presentation, speakers must submit their PowerPoint presentations at the Speakers’ Centre. The submitted presentation is saved on our central congress server and then made available on a provided congress notebook in each presentation hall respectively. For technical reasons, speakers may not use their own notebook for presentations. Specialised technical staff onsite will gladly assist delegates and answer all pertinent questions.
March 6-9, 2019 • Copenhagen, Denmark 103 Congress information
All conflicts are to be disclosed on the nd2 slide of each PowerPoint presentation. To facilitate and reinforce the 2nd slide policy, faculty speakers are reminded to disclose their potential Conflicts of Interest in their presentation in line with UEMS regulations.
A draft CoI slide has been prepared for each speaker based on the submitted CoI form, and will be available in the Speakers’ Centre to include in the presentation. Please be reminded that if the respective presentation does not yet include a disclosure form, the slide draft should be checked and amended before it is inserted into the presentation.
All speakers are kindly asked to personally sign the publication consent form on their talks directly at the Speakers’ Centre. If you are participating in a tandem talk or panel discussion, both/all speaking are asked to visit the Speaker Center onsite in order to sign off their respective publication consent forms.
Speakers’ Centre opening hours: Wednesday, March 6, 2019 07:30 - 18:00 Thursday, March 7, 2019 07:00 - 19:30 Friday, March 8, 2019 06:30 - 19:45 Saturday, March 9, 2019 08:00 - 13:00
104 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Copenhagen Denmark UR-CARE Training Centre Stop by for a try in Hall E
The IBD Database for your patient records and your research studies
• Visit the UR-CARE Training Centre in Hall E • Test the database and discover all of the functionalities • Open during Congress opening hours on Wednesday through Saturday • Ask questions and get answers directly from the UR-CARE team
Scan and visit www.ecco-ibd.eu/ur-care
2019_POSTER_UR-CARE Training Centre.indd 1 29.01.2019 15:17:27 Industry sponsored satellite symposia
Industry sponsored satellite symposia
Industry sponsored satellite symposia organised by pharmaceutical companies are open to all congress participants. The programmes of symposia are not affiliated with ECCO and sponsors hold responsibility for the content of their respective programmes.
ECCO has scheduled parallel satellite symposia on: Thursday, March 7, 2019 at 11:00-12:00 and 18:45-19:45 Friday, March 8, 2019 at 07:15-08:15 and 18:35-19:35
Parallel lunchtime satellite symposia will take place on: Friday, March 8, 2019 at 12:40-13:20.
Kindly note that satellite symposia take place in various halls on the Ground Floor of Bella Center. Please be advised that due to Danish compliance laws, access may be restricted to health care professionals only.
Industry sponsored satellite symposia – Scientific programme Thursday, March 7, 2019 Satellite symposium 1a – Organiser: Takeda Meeting room: Plenary hall, Hall A, Bella Center Treatment decisions with advanced therapies: Comparative evidence in Ulcerative 11:00 - 12:00 Colitis Jean-Frédéric Colombel, New York, United States Introduction 11:00 - 11:10 Jean-Frédéric Colombel, New York, United States Key learnings from indirect comparisons of randomised controlled 11:10 - 11:25 trials William J. Sandborn, California, United States What do real-world comparative effectiveness studies tell us? 11:25 - 11:40 Parambir S. Dulai, California, United States Our evolving understanding of gut-selective vs advanced systemic 11:40 - 11:55 therapy Jean-Frédéric Colombel, New York, United States Panel Discussion/Q&A 11:55 - 12:00 All
106 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Industry sponsored satellite symposia
Industry sponsored satellite symposia – Scientific programme Thursday, March 7, 2019, cont. Satellite symposium 1b – Organiser: AbbVie Meeting room: Hall C, C1 M4-5, Bella Center Future targets and endpoints in IBD – an informed discussion 11:00 - 12:00 Brian Feagan, London, Canada Welcome and Introduction 11:00 - 11:05 Brian Feagan, London, Canada Evolving endpoints in clinical trials 11:05 - 11:25 Brian Feagan, London, Canada Exploring the value of biomarkers and endoscopic targets 11:25 - 11:40 Peter Bossuyt, Bonheiden, Belgium Interpreting patient-reported outcomes 11:40 - 11:55 Reena Khanna, London, Canada Concluding remarks and close 11:55 - 12:00 Brian Feagan, London, Canada
Satellite symposium 1c – Organiser: Celltrion Meeting room: Auditorium 15, Bella Center Redesigning the Future of IBD Treatment with Infliximab SC 11:00 - 12:00 Walter Reinisch, Vienna, Austria Welcome remarks 11:00 - 11:05 Walter Reinisch, Vienna, Austria Personalised Anti-TNF therapy in Crohn’s Disease (PANTS) 11:05 - 11:15 Tariq Ahmad, Exeter, United Kingdom Clinical findings on Infliximab SC 11:15 - 11:25 Shomron Ben-Horin, Ramat Gan, Israel Earlier introduction of biologics 11:25 - 11:35 Iris Dotan, Petah Tikva, Israel Future of IBD treatment with Infliximab SC 11:35 - 11:45 Stefan Schreiber, Kiel, Germany Panel discussion 11:45 - 12:00 All
Satellite symposium 2a – Organiser: Pfizer Meeting room: Plenary hall, Hall A, Bella Center Tofacitinib in Ulcerative Colitis: A practical guide 18:45 - 19:45 Simon Travis, Oxford, United Kingdom Welcome and Introduction 18:45 - 18:50 Simon Travis, Oxford, United Kingdom Tofacitinib: An effective option for moderate-to-severe Ulcerative 18:50 - 19:05 Colitis Simon Travis, Oxford, United Kingdom Exploring the Tofacitinib safety profile 19:05 - 19:20 Axel Dignass, Frankfurt am Main, Germany The practicalities of using Tofacitinib in the clinic 19:20 - 19:40 Peter Irving, London, United Kingdom Q&A 19:40 - 19:45 All
March 6-9, 2019 • Copenhagen, Denmark 107 Industry sponsored satellite symposia
Industry sponsored satellite symposia – Scientific programme Thursday, March 7, 2019, cont. Satellite symposium 2b – Organiser: Amgen Meeting room: Hall C, C1 M4-5, Bella Center IBD management puzzle: Do we have all the pieces? 18:45 - 19:45 Stefan Schreiber, Kiel, Germany Welcome and Introduction 18:45 - 18:50 Stefan Schreiber, Kiel, Germany Putting the pieces together: When should anti-TNFs be introduced? 18:50 - 19:05 Stefan Schreiber, Kiel, Germany Solving the riddle: How do we implement TDM to maximise 19:05 - 19:20 treatment success? Walter Reinisch, Vienna, Austria Unravelling the problem: How can biomarkers be used to guide 19:20 - 19:35 clinical management? Gionata Fiorino, Milan, Italy Summary and close 19:35 - 19:45 Stefan Schreiber, Kiel, Germany
Satellite symposium 2c – Organiser: Janssen Meeting room: Auditorium 15, Bella Center IL-12/23 in IBD: Making the best use of available evidence 18:45 - 19:45 Alessandro Armuzzi, Rome, Italy Welcome and Introduction 18:45 - 18:50 Alessandro Armuzzi, Rome, Italy Current developments in IBD 18:50 - 19:00 Subrata Gosh, Birmingham, United Kingdom Clinical insights in IBD Moderator: Tim Raine, Cambridge, United Kingdom 19:00 - 19:30 Speakers: Alessandro Armuzzi, Rome, Italy Subrata Gosh, Birmingham, United Kingdom Future treatment options in IBD 19:30 - 19:35 Alessandro Armuzzi, Rome, Italy Conclusion and close of meeting 19:35 - 19:45 Tim Raine, Cambridge, United Kingdom
108 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Industry sponsored satellite symposia
Industry sponsored satellite symposia – Scientific programme Friday, March 8, 2019 Satellite symposium 3b – Organiser: Nestle Health Science Meeting room: Hall C, C1 M4-5, Bella Center Why do we need dietary therapy in Crohn’s Disease? 07:15 - 08:15 Iris Dotan, Petah Tikva, Israel Michael Kamm, Melbourne, Australia Why do we need nutrition therapy in an era of biologics? 07:15 - 07:30 Michael Kamm, Melbourne, Australia What are the targets for dietary therapy? 07:30 - 07:45 Arie Levine, Tel Aviv, Israel Present state of the art on dietary management in Crohn’s Disease 07:45 - 08:00 Johan van Limbergen, Halifax, Canada The new kid on the block: The Crohn’s Disease Exclusion Diet for 08.00 - 08:15 induction of remission Rotem Sigall-Boneh, Tel Aviv, Israel
Satellite symposium 3c – Organiser: Pfizer Meeting room: Auditorium 15, Bella Center The Psychology of Change in IBD: Working with the mind when the gut needs a 07:15 - 08:15 change David Rubin, Chicago, United States Welcome and Introductions 07:15 - 07:20 David Rubin, Chicago, United States Understanding the psychological drivers of decision making in IBD 07:20 - 07:35 Lyndsay Hughes, London, United Kingdom The psychology of IBD management: Challenging ourselves to 07:35 - 07:50 change David Rubin, Chicago, United States Preparing our patients when the gut needs a change 07:50 - 08:05 Tariq Ahmad, Exeter, United Kingdom 08:05 - 08:15 Q&A
March 6-9, 2019 • Copenhagen, Denmark 109 Industry sponsored satellite symposia
Lunchtime Satellite symposia – Scientific programme Friday, March 8, 2019 Satellite symposium LS1 – Organiser: AbbVie Meeting room: Plenary hall, Hall A, Bella Center Rapid control of Ulcerative Colitis: Can we optimise treatment? 12:40 - 13:20 Jean-Frédéric Colombel, New York, United States Welcome and Introduction 12:40–12:45 Jean-Frédéric Colombel, New York, United States Understanding the inflammatory and symptomatic picture of 12:45–12:55 Ulcerative Colitis Johan Burisch, Copenhagen, Denmark Timely management of Ulcerative Colitis 12:55–13:05 Jean-Frédéric Colombel, New York, United States Optimising therapy – approaches to enhance clinical outcomes 13:05–13:15 Edouard Louis, Liège, Belgium Concluding remarks and close 13:15-13:20 Jean-Frédéric Colombel, New York, United States
Lunch symposium LS2 – Organiser: Celgene Meeting room: Hall C, C1 M4-5, Bella Center 12:40 - 13:20 How will evolving therapies illuminate your practice? How will evolving therapies illuminate your practice? 12:40 - 13:20 Remo Panaccione, Calgary, Canada Jonas Halfvarsson, Örebro, Sweden
Lunch symposium LS3 – Organiser: Tillotts Meeting room: Auditorium 15, Bella Center Smart Simplicity - Simplifying treatment options and processes 12:40 - 13:20 Geert D’Haens, Amsterdam, The Netherlands Welcome and Introduction 12:40 - 12:45 Geert D’Haens, Amsterdam, The Netherlands Difference between textbook and reality in IBD 12:45 - 13:00 Ala Sharara, Beirut, Lebanon Confusing terminology in IBD 13:00 - 13:15 Hugh Mulcahy, Dublin, Ireland Closing remarks 13:15 - 13:20 All
Lunch symposium LS4 – Organiser: MSD Meeting room: Hall C, C1 M1, Bella Center Treat-to-Target in Ulcerative Colitis: Challenges in real-life practice 12:40 - 13:20 Glen Doherty, Dublin, Ireland Targets and outcome measures in Ulcerative Colitis: IOIBD 12:40 - 12:55 consensus vs real-life practice Alexander Moschen, Innsbruck, Austria Effective early control of inflammation in patients with active 12:55 - 13:10 Ulcerative Colitis Glen Doherty, Dublin, Ireland Summary and Q&A 13:10 - 13:20 All
110 14th Congress of ECCO - European Crohn‘s and Colitis Organisation International Symposia and Workshops
Scientific Dialogue in the Interest of Therapeutic Progress
Workshop Symposium 216 From Viral Hepatitis to Chronic Building Bridges in IBD Inflammation and Liver Cancer Brussels, Belgium Heidelberg, Germany September 13–14, 2019 February 21–22, 2019 Symposium 217 Symposium 214 West Meets East: IBD: From Pathophysiology Functional Meets Organic to Personalized Medicine Gastrointestinal Diseases Oxford, Great Britain Singapore March 29–30, 2019 November 29–30, 2019
Symposium 215 IBD: From Diagnosis to Therapy St. Petersburg, Russia July 5–6, 2019
Congress Department paid advertisement Pharma by Falk Dr. Tel.: +49 (0)761/1514-125 Fax: +49 (0)761/1514-359 E-Mail: [email protected] www.falk-foundation-symposia.org Congress Department Tel.: +49 (0)761/1514-125 Fax: +49 (0)761/1514-359 E-Mail: [email protected] www.falk-foundation-symposia.org 2019 Industry sponsored satellite symposia
Industry sponsored satellite symposia – Scientific programme Friday, March 8, 2019 Satellite symposium 4a – Organiser: Takeda Meeting room: Plenary Hall, Hall A, Bella Center Evolving models of care in Crohn’s disease: Identifying and treating patients at risk 18:35 - 19:35 of disease progression Remo Panaccione, Alberta, Canada Introduction 18:35 - 18:40 Remo Panaccione, Alberta, Canada Early disease control: Identifying patients at risk of disease 18:40 - 18:55 progression Edouard Louis, Liège, Belgium Practical approaches for the management of Crohn’s Disease 18:55 - 19:15 according to risk stratification Remo Panaccione, Alberta, Canada Challenging patient cases: Low risk or high risk – what would you do? 19:15 - 19:35 (panel discussion) Subrata Ghosh, Birmingham, United Kingdom
Satellite symposium 4c – Organiser: Biogen and Samsung Bioepis Meeting room: Auditorium 15, Bella Center The IBD pathway – from a patient perspective 18:35 - 19:35 Geert D’Haens, Amsterdam, The Netherlands Welcome and Introduction 18:35 - 18:45 Geert D’Haens, Amsterdam, The Netherlands Patient perspectives, such as their expectations and concerns as they experience a switch in treatment, will be discussed with the audience by a multidisciplinary team: Raja Atreya, Erlangen, Germany 18:45 - 19:30 Luisa Avedano, Brussels, Belgium Yoram Bouhnik, Paris, France Maria de Jong, Amsterdam, The Netherlands Geert D’Haens, Amsterdam, The Netherlands Closing Remarks 19:30 - 19:35 Geert D’Haens, Amsterdam, The Netherlands
Satellite symposium 4d – Organiser: Sandoz Meeting room: Hall C, C1 M1, Bella Center Defining the future of IBD care: The pivotal role of personalised treatment 18:35 - 19:35 Peter Irving, London, United Kingdom The myth of the typical IBD patient (introduction) 18:35 - 18:40 Peter Irving, London, United Kingdom IBD subgroups: The secret of hitting the mark Chair: Peter Irving, London, United Kingdom 18:40 - 19:00 Speakers: Marieke Pierik, Maastricht, The Netherlands Jonas Halfvarson, Örebro, Sweden Hidden gems of rheumatology 19:00 - 19:15 Frank Behrens, Frankfurt, Germany Personalised treatment for IBD: Of course, but why and how? 19:15 - 19:30 Claudio Fiocchi, Cleveland, United States Closing remarks 19:30 - 19:35 Peter Irving, London, United Kingdom
112 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Industry sponsored satellite symposia
Industry sponsored satellite symposia – Educational programme Thursday, March 7, 2019 – N-ECCO Network Meeting Satellite symposium Organiser: Takeda Meeting room: Hall C, C1 M0, Bella Center 12:15 - 13:15 Bon voyage! Preparing our patients for confident travel with IBD Stepping out of your comfort zone: You can travel with IBD! Video from Hannah Witton (Vlogger with IBD) Welcome and Introductions Stephan Vavricka, Zurich, Switzerland Travelling with IBD, from research to reality Stephan Vavricka, Zurich, Switzerland 12:15 - 13:15 How to advise patients: Practical tips to help travellers with IBD Shomron Ben-Horin, Ramat Gan, Israel Kay Greveson, London, United Kingdom Q&A Moderator: Stephan Vavricka, Zurich, Switzerland All Summary of key learning points and closing Shomron Ben-Horin, Ramat Gan, Israel
Thursday, March 7, 2019 – S-ECCO IBD Masterclass Satellite symposium Organiser: Takeda Meeting room: Hall C, C1 M2, Bella Center The future is now: Improved management of complex perianal fistulas in Crohn’s 12:45 - 13:15 disease Welcome and speaker introductions Antonino Spinelli, Milan, Italy Discussion and introduction to the cases: Goal-setting in complex perianal fistula Antonino Spinelli, Milan, Italy Henit Yanai, Petah Tikva, Israel Matching the patient to the procedure choice for complex perianal 12:15 - 13:15 fistula Antonino Spinelli, Milan, Italy Optimising long-term strategies for complex perianal fistula in Crohn’s Disease Henit Yanai, Petah Tikva, Israel Discussion: Key learnings Antonino Spinelli, Milan, Italy Henit Yanai, Petah Tikva, Israel
March 6-9, 2019 • Copenhagen, Denmark 113 Copenhagen Denmark
Highlights of ECCO’19
Congress special: Call for similar cases –The ECCO ECCO’19 CONFER Congress Round in 2 a nutshell
Take-home messages from the Scientific Programme: • Watch a summary of selected top abstracts • Recorded just for you and your colleagues at home • Available in the eLibrary right after the Congress
Scan and visit www.ecco-ibd.eu/highlights
2019_POSTERHighlights.indd 1 21.12.2018 16:17:59 ECCO Interaction: Hearts and Minds
ECCO Interaction: Hearts and Minds ECCO Interaction: Hearts and Minds is THE event at ECCO to see and be seen, to network and engage. Anyone who has been to a previous ECCO Congress knows that it is a must and everyone is welcome, but places are limited.
This year’s edition of the ECCO Interaction: Hearts and Minds will be held at the famous Øksnehallen in Copenhagen.
Date: Friday, March 8, 2019 Start time: 20:30 Venue: Øksnehallen, Halmtorvet 11, 1700 Copenhagen
How to get to Øksnehallen from Bella Center using public transportation From “Bella Center St. (Center Østvej)”, take bus 250S headed towards “Buddinge st.” and get off at “Hovedbanegården København H” (Copengahen Central Station). From there on you can continue walking straight ahead on Bernstorffsgade via Halmtorvet until you reach Øksnehallen. (Time travel: approx. 34 min)
Alternatively, take the green metro line M1 from “Bella Center st. (Metro)” headed towards “Vestamager st.” and get off at “Ørestad st.”. From there, take the regional train headed towards “Helsingør st.”, and get off at “Hovedbanegården København H” (Copengahen Central Station). Then, continue straight ahead walking via Reventlowsgade to Halmtorvet until you reach Øksnehallen. (Time travel: approx. 29 min) Visit www.rejseplanen.dk to plan your travel in detail.
Tickets need to be picked up at the registration desk “ECCO Interaction: Hearts and Minds” located in Hall E at Bella Center. Access to the event is strictly granted with ECCO Interaction tickets only. Please make sure to bring your ticket with you. No ticket sale onsite at Øksnehallen! Y-ECCO Networking Corner ■■ Unique opportunity to meet key opinion leaders from the Governing Board and Operational Board of ECCO and to network with fellow Y-ECCO Members ■■ Where/When • At the ECCO Interaction: Hearts and Minds 2019 • Øksnehallen, Halmtorvet 11, 1700 Copenhagen • 20:30-21:30 ■■ Welcome drinks and food will be served ■■ Join the main interaction following this great event ■■ Make sure you are registered and have your ticket with you!
March 6-9, 2019 • Copenhagen, Denmark 115 Corporate sponsors
Corporate sponsors (as of February 1, 2019) ECCO gratefully acknowledges the support of the following ECCO Corporate Members:
116 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Industry exhibition
Industry exhibition Opening hours Thursday, March 7, 2019 10:30 – 19:45 Friday, March 8, 2019 07:15 – 19:45 Saturday, March 9, 2019 08:00 – 13:00 List of exhibitors & sponsors
Company Booth Booth number Company number AbbVie 8 Mauna Kea Technologies 35 AbbVie 9 Mendes S.A. 34 Allergan 36 MSD 32 Amgen 4 Nanjing FMT Medical 44 Arena Pharmaceuticals 40 Nestle Health Science 23 Biogen 25 Nikkiso 33 Bühlmann Laboratories 2 Norgine 43 Calpro AS 16 Pfizer 1 Celgene 18 Pfizer 3 Celltrion 26 Pharmacosmos 42 Diversigen 28 Dr. Falk Pharma 37 Pharmanovia 46 EFCCA E1 Predictimmune 20 Eli Lilly 24 R-Biopharm 15 Eurospital 29 Reprocell Inc. 11 Roche 19 Robarts Clinical Trials 10 Ferring 6 Sandoz 31 Fresenius Kabi 38 Shire International 39 Gilead 17 Takeda 13 Grifols 30 Takeda 14 Immundiagnostik 27 Tani Medikal 45 Janssen 5 Theradiag 21 Janssen R&D 7a Thermo Fisher Scientific 12 Janssen 7b Tillotts 22 La Lettre de l' Hepato- gastroenterologue (EDIMARK) E2 Wisepress E3
March 6-9, 2019 • Copenhagen, Denmark 117 Exhibition plan
Exhibition plan
10 11 12 44 45 46 E N T R A C 2
E1 14 15 33 35 E2 16 Members‘ Lounge 34
E3 E N T R A C 1
13
32
1 2 9 36
37
3 31
17
38
C O U R S E M 27 28 29 30
18 26 39 4 8
40 19 20 7a 7b 25 21 5 42 6
C O U R S E M 23 24 22 T E R I N G 43 C A
CATERING CATERING C O U R S E M
118 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Floor plans
Floor plans Bella Center Hall A, Ground Floor Hall E, Ground Floor ■■ Plenary Hall ■■ ECCO Booth ■■ Auditorium 15 ■■ Registration • 3rd School for Clinical Trialists ■■ Cloakroom • 4 th Advanced ECCO: EduCational COurse ■■ Bag distribution for Industry ■■ UR-CARE Training Centre ■■ Office 60-181 ■■ Speakers’ Centre ■■ Cash Catering Hall B, Ground Floor ■■ Course Rooms Level 1 ■■ Meeting Rooms ■■ ECCO Congress Office ■■ Poster Exhibition and Internet Lounge ■■ Meeting rooms Hall C, Ground Floor ■■ Exhibition Hall ■■ Members’ Lounge ■■ C1 M0-5
Hall B
Course Rooms & Meeting Rooms Poster Exhibition & Internet Lounge
Registration Cloakroom ECCO Booth Hall E UR-CARE Training Centre Bag Distribution Members’ Lounge 60-181 Plenary Hall Speakers’ Centre C1 M0 Hall A
C1 M1 Auditorium 15 Hall C C1 M2 Exhibition Hall
C1 M3 Entrance
C1 M4-5
March 6-9, 2019 • Copenhagen, Denmark 119 Floor plans
Hall B, Bella Center
Hall B • 1st ECCO-ESGAR Basic Imaging Workshop (B3 M1-2) • 1st Guideline Methodology and GRADE Workshop (B3 M7-8) • 4th D-ECCO Workshop (HB4 M1-2) • 4th H-ECCO IBD Masterclass (B3 M9-10) • 5th Y-ECCO Basic Science Workshop (B3 M7-8) • 6th ECCO-ESGAR Ultrasound Workshop – Advanced (B3 M1-2) • 7th SciCom Workshop (B3 M9-10) • 10th N-ECCO School (B3 M5-6) • 11th Y-ECCO Career Workshop (B3 M7-8) • 17th IBD Intensive Advanced Course (HB4 M1-2) • Satellite Symposia • Poster Exhibition and Internet Lounge
HB4 M1-2
M6-10 M6-10
Hall B
Poster Exhibition M1-4 M1-4 M1-4 & Internet Lounge
B1 B2 B3 B4 B5 B6
120 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Floor plans
Hall C, Bella Center
Hall C • 4th ECCO-AOCC Forum (C1 M3) • 6th P-ECCO Educational Course (C1 M0) • 8th S-ECCO IBD Masterclass (C1 M2) • 13th N-ECCO Network Meeting (C1 M0) • Basic Science Session (C1 M4-5) • Digital Oral Presentations Sessions 1-10 (C1 Rooms) • Satellite Symposia • Members’ Lounge • Exhibition Hall • Cash Catering
Members’ Lounge
C1 M0
C1 M1 Hall C
Exhibition Hall C1 M2
C1 M3
C1 M4-5
March 6-9, 2019 • Copenhagen, Denmark 121 Index of authors
Index of speakers and abstract authors
Assa, A. OP05, OP18, DOP31, Bendele, A. DOP21 Abdelaal, T. OP27 DOP42, DOP89 Bender, A. OP10 Abhyankar, B. 4th Advanced ECCO: Atia, O. DOP31 Bendtsen, F. DOP82 EduCational COurse Atreja, A. OP17 Ben-Shoshan, M. DOP36 for Industry, DOP53 Atreya, R. DOP67 Benítez, J. M. DOP44 Abitbol, V. DOP74, DOP78 Atrott, K. DOP02, DOP14, DOP19 Berends, S. DOP56 Abramas, L. OP05, DOP42 Aylin, P. DOP61 Bergemalm, D. DOP10 Abreu, M. T. OP37 Azana, S. N03 Berliba, E. OP38, DOP46 Adams, A. DOP10 Azevedo, L. OP04 Bernardo, S. DOP59 Adamina, M. 10th N-ECCO School Berti, G. DOP20 Afhim, S. DOP30 Bessissow, T. DOP75 Afif, W. DOP75 Bettenworth, D. 5th Y-ECCO Agrusti, A. DOP34 Bae, D. OP23 Basic Science Workshop, Ainsworth, M. 4th Advanced ECCO: Bäbler, K. DOP14, DOP19, DOP24 10th N-ECCO School EduCational COurse Baek, J.-Y. OP23 Bewick, G. DOP60 for Industry Baek, J. DOP83 Beyer-Berjot, L. 8th S-ECCO Ajioka, Y. DOP69 Baert, F. 1st ECCO-ESGAR Basic IBD Masterclass Akbar, A. DOP61 Imaging Workshop, Beyrend, G. OP27 Al Draiweesh, S. DOP39 17th IBD Intensive Advanced Bhagat, S. OP13 Alberts, E. DOP06 Course, OP25, OP35, DOP33 Bhandari, B. R. OP38, DOP46 Aldelemi, S. DOP20 Bager, P. 13th N-ECCO Network Biedermann, L. OP06 Alexakis, C. DOP85 Meeting Biron, C. DOP74, DOP78 Algaba-Chueca, F. DOP05 Baines, J. F. DOP12 Bisschops, R. 1st ECCO-ESGAR Basic Alkhattabi, M. DOP39 Baker, T. DOP47 Imaging Workshop Allez, M. OP20, DOP74 Baldaia, C. DOP59 Bisset, C. DOP87 Allimant, C. DOP80 Balicer, R. DOP89 Bitton, A. DOP75 Allin, K. H. DOP88 Ballet, V. DOP26 Blackwell, J. DOP85 Almoudaris, A. DOP61 Banerjee, A. OP08 Bleich, A. DOP12 Aloi, M. DOP34 Banerjee, R. Scientific Session 5 Blevi, H. DOP38 Altwegg, R. OP24 Bar-Gil Shitrit, A. DOP29, DOP31 Bliss, C. DOP49, DOP51 Alves, I. OP04 Baribaud, F. OP36 Blixt, C. 3rd School for Alvisi, P. DOP34 Barnhoorn, M. 5th Y-ECCO Basic Clinical Trialists Alzinaty, M. DOP29 Science Workshop, OP22 Bloom, S. OP16 Amil, M. DOP74 Barrachina, M. D. OP03 Boivineau, L. OP24 Amiot, A. DOP74 Barreton, G. DOP12 Bommelaer, G. DOP80 Andersen, V. OP15 Basic, M. DOP12 Bonifacio, C. 1st ECCO-ESGAR Basic Andoh, A. 4th ECCO-AOCC Forum Bassett, P. DOP61 Imaging Workshop Angin, M. DOP07 Bassolas-Molina, H. DOP25 Bonovas, S. 1st Guideline Anzai, S. DOP22 Beaugerie, L. 3rd School for Methodology and Arancibia, C. OP28, DOP11 Clinical Trialists GRADE Workshop Arebi, N. OP15, DOP29 Behren, A. DOP17 Bornman, L. DOP68 Argmann, C. OP17 Beigel, F. OP12 Borzan, V. DOP62 Armengol-Debeir, L. DOP74, DOP78 Belousova, E. OP15 Bos, E. OP22 Armstrong, S. OP07 Bemelman, W. 8th S-ECCO Bossard, C. DOP23 Armuzzi, A. OP29, OP35, DOP20 IBD Masterclass, DOP73 Bossuyt, P. OP25, OP35, Arnauts, K. OP11 Ben-Horin, S. 17th IBD Intensive DOP29, DOP33 Arora, V. OP38, DOP46 Advanced Course,, 4th Advanced Bottle, A. DOP85 Arrigo, S. DOP34 ECCO: EduCational COurse Bouguen, G. OP24, DOP78 Arroyes, M. DOP25 for Industry, 7th SciCom Bouhnik, Y. OP25, DOP74, DOP78 Asayag, N. DOP89 Workshop, DOP36, DOP62 Bourreille, A. OP21, DOP23
122 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Index of authors
Boyle, D. DOP53 Cataldi, F. 4th Advanced ECCO: D’Antiga, L. DOP34 Bozon, A. OP24 EduCational COurse for D’Alessio, S. Scientific Session 9 Böcher, W. 3rd School for Clinical Industry, OP08, OP14, D’Haens, G. Scientific Session 1, Trialists, 4th Advanced DOP49, DOP50, DOP51 OP08, OP25, OP35, ECCO: EduCational Cañete, F. DOP44 DOP48, DOP56, DOP73 COurse for Industry Cecil, E. DOP85 D’Hoore, A. 8th S-ECCO IBD Brahmania, M. DOP39 Ceuppens, J. DOP26 Masterclass, OP30 Bramuzzo, M. DOP34 Chalmers, I. DOP84 D’Inca, R. OP15 Brandse, J. DOP56 Chan, G. DOP43 Dahlerup, J. F. OP15 Brassard, P. DOP75 Chande, N. DOP39 Daly, M. OP01 Braun, T. OP19, DOP36 Chang, D. K. DOP04 Dan, N. DOP89 Brazier, F. OP24 Chanteloup, E. DOP74, DOP78 Danese, S. Scientific Session 1, Breiteneicher, S. OP12 Chapman, D. S. DOP41 Scientific Session 12, Breynaert, C. DOP26, DOP70 Cheifetz, A. S. DOP45 4th Advanced ECCO: Brignone, C. DOP07 Chen, H. DOP21 EduCational COurse for Brindle, W. DOP87 Chen, K. DOP17 Industry, 4th ECCO-AOCC Brodmerkel, C. OP17, OP36 Chen, L. DOP64 Forum, OP26, OP35, OP37, Broide, E. OP18 Cheon, J. H. DOP55 DOP47, DOP48, DOP49, Brokalaki, H. N02 Chiorean, M. OP09, DOP41 DOP50, DOP51, DOP54 Brooks, J. OP10 Choi, K.-W. DOP55 Dart, R. J. OP32 Brufman, I. DOP89 Choi, Y. I. OP23 Davani, N. OP30 Buck, J. OP07 Choung, R. S. DOP35 Davidson, K. 13th N-ECCO Buisson, A. OP24, OP25, DOP74, Chuah, C. S. DOP87 Network Meeting DOP78, DOP80 Clark, M. M. OP20 Davies, M. DOP48 Burgess, C. DOP84, DOP87 Cleynen, I. 5th Y-ECCO Basic Davis Thomas, S. OP19 Burisch, J. Scientific Session 5, Science Workshop Dawn, F. N01 5th Y-ECCO Basic Clos-Parals, A. DOP44 De Cruz, P. P. DOP81 Science Workshop, Coban, D. DOP80 de Groof, E. J. DOP73 OP15, DOP76, DOP82, Cohen, R. D. DOP41 De Hertogh, G. 4th H-ECCO DOP86, DOP88 Cohen, S. OP05, OP18, IBD Masterclass, DOP71 Busenhart, P. DOP14 DOP42, DOP89 de Jong, M. DOP72 Buskens, C. 4th ECCO-AOCC Forum, Collij, V. OP01 de Ridder, L. 4th Advanced ECCO: 8th S-ECCO IBD Collins, M. OP19 EduCational COurse Masterclass, DOP73 Colombel, J.-F. Scientific Session 1, for Industry Byeon, J. S. DOP65 8th S-ECCO IBD Masterclass, De Salvo, C. OP29 Byron, C. N01 OP17, OP26, OP35, DOP35 De Vallière, C. DOP24 Colombo, G. DOP01 De Vos, M. DOP33 Constable, L. DOP06 deBruyn, J. C. DOP58 Cornillie, F. 4th Advanced ECCO: Deceneux, C. DOP17 Cabell, C. OP09 EduCational COurse Dedman, H. DOP21 Caesar, J. OP12 for Industry Dehairs, J. DOP38 Cahan, A. DOP89 Corraliza, A. M. DOP25 Delaney, C. 8th S-ECCO IBD Caillo, L. DOP74 Correia, A. OP04 Masterclass Calafat, M. DOP44 Correia, L. DOP59 Denson, L. A. OP19 Calatayud, S. OP03 Cosin-Roger, J. OP03 Derikx, L. DOP72 Campbell, R. 6th P-ECCO Coste, J. DOP40 Dewit, S. DOP29 Educational Course Coulombe, J. DOP75 DeWouters, T. DOP02 Campmans-Kuijpers, M. 4th D-ECCO Cremer, A. DOP29 Dexheimer, P. OP19 Workshop Cremer, J. DOP26, DOP70 Di Martino, L. OP29 Canavan, J. B. OP38, DOP52 Creyns, B. DOP26, DOP70 Di Palma, F. DOP08 Canet, F. OP03 Cucchiara, S. DOP34 Di Segni, A. DOP36 Carbonnel, F. DOP40 Curran, M. OP36 Diab, J. DOP15 Carding, S. OP07, OP10 Cvancarova, M. DOP90 DIAMOND2 Study Group DOP32 Carroll, M. W. DOP58 Dias, A. OP04 Carstensen, M. DOP76 Dib, N. DOP74, DOP78 Carvello, M. 8th S-ECCO IBD Diculescu, M.-M. OP35 Masterclass D’Agay, L. 4th Advanced ECCO: Digby-Bell, J. DOP06, DOP60 Casanova, M. J. DOP44 EduCational COurse Dijkgraaf, M. DOP73 Castro-Poceiro, J. DOP44 for Industry Dijkstra, G. OP01, DOP24
March 6-9, 2019 • Copenhagen, Denmark 123 Index of authors
Dinarello, C. Scientific Session 12 Feagan, B. G. 4th Advanced ECCO: Dinarzo, A. OP17 EduCational COurse Gacesa, R. OP01 Ding, N. S. 5th Y-ECCO Basic for Industry, OP26, García García, M. J. DOP44 Science Workshop, OP38, DOP39, DOP46, Gardner, R. DOP10 10th N-ECCO School DOP71, DOP79 Garrick, V. 6th P-ECCO Distante, M. DOP34 Feakins, R. 4th H-ECCO IBD Educational Course Divekar, D. OP07 Masterclass, DOP20 Garrido, A. DOP25 Dotan, I. 17th IBD Intensive Feldman, B. DOP89 Gasbarrini, A. OP29 Advanced Course, Felice, C. DOP20 Gecse, K. 1st ECCO-ESGAR Basic DOP31 Feng, D. DOP79 Imaging Workshop, Douglas, K. DOP21 Fernandes, D. DOP10 3rd School for Clinical Dreesen, E. OP25 Fernandes, S. R. DOP59 Trialists, DOP73 Drenth, J. DOP72 Fernández-Clotet, A. DOP25, Geert R. D’Haens, G. OP38, Drohan, C. 1st Guideline DOP44 DOP46 Methodology and Fernández-Veledo, S. DOP05 Genazzani, A. A. DOP01 GRADE Workshop Ferrante, M. Scientific Session 4, Gerasimidis, K. 4th D-ECCO Drouin, J. DOP40 17th IBD Intensive Advanced Workshop, 10th N-ECCO School Dubinsky, M. C. OP17, Course, 3rd School for Clinical Geremia, A. OP28, DOP11 DOP43, DOP50 Trialists, 10th N-ECCO School, Giannotta, M. OP15 Durand, T. DOP23 OP11, OP30, OP35, Giannoulatou, E. DOP20 Durante, M. OP38, DOP46, DOP52 OP38, DOP26, DOP29, Gibson, G. OP19 Duricova, D. OP15 DOP37, DOP38, DOP46, Gillespie, S.-L. DOP87 Durieu, E. DOP23 DOP52, DOP70 Gilletta De Saint-Joseph, C. DOP29 Durlik, M. DOP03 Ferreiro-Iglesias, R. DOP44 Gilletta, C. OP24 Dutré, J. DOP33 Ferslew, B. DOP53 Gils, A. OP25, DOP33 Dzyngel, B. OP16 Festen, E. OP01 Gineste, P. OP21 D’Haens, G. OP26 Fewings, I. DOP68 Giobbi, C. DOP34 Filippi, J. OP24 Gisbert, J. P. DOP44 Fischer, I. DOP57 Glanville, T. DOP28 Fischer, S. DOP67 Glauben, R. DOP13 East, J. 1st ECCO-ESGAR Basic Fiorino, G. 1st Guideline Glerup, H. Scientific Session 1 Imaging Workshop Methodology and Gluud, L. L. DOP88 Efroni, G. DOP36 GRADE Workshop Goetsch, M. DOP49, DOP51 Ehrlich, H. OP21 Fleshner, P. 8th S-ECCO IBD Godwin, N. N01 Eigner, W. DOP86 Masterclass Goldis, A. OP15, OP35 Ejarque, M. DOP05 Flint, S. DOP18 Goll, R. DOP15 Elangovan, S. Scientific Session 7 Florholmen, J. DOP15 Golovchenko, O. OP35 El-Matary, W. DOP58 Flourié, B. OP24 Gomollón, F. Scientific Session 2, Eliakim, R. DOP36 Focht, G. DOP31, DOP89 17th IBD Intensive Advanced Ellinghaus, D. DOP55 Forry, M. N01 Course, OP35 Ellul, P. OP15 Forsdahl, G. DOP15 González Lorenzo, M. 1st Guideline Elorza, A. DOP44 Foster, K. DOP18 Methodology and Epi-IBD OP15 Fotos, N. N02 GRADE Workshop Eriksson, C. DOP29 Franchimont, D. DOP33 Gonczi, L. DOP75 Esaki, M. DOP32, DOP69 Franke, A. DOP55 Goodman, W. OP29 Escher, H. OP27 Frey-Wagner, I. DOP24 Gopalakrishnan, S. DOP12 Espin, E. DOP05 Friedman, G. S. DOP41 Gordillo, J. DOP44 Esteller, M. DOP25 Friedman, J. R. OP13, OP17, Gorelick, K. J. OP08, DOP49, DOP51 Esteve, M. DOP25 OP36, DOP71 Gotman, N. OP19 Friedrich, S. OP38, DOP46 Gottier, C. DOP02 Fu, J. OP01 Goutorbe, F. DOP80 Fujii, S. DOP69 Goutte, M. DOP80 Facchin, S. 4th D-ECCO Workshop Fukata, N. DOP32 Govek, S. DOP21 Fadia, M. DOP68 Fukuchi, T. DOP69 Graham, R. DOP53 Faiz, O. DOP61 Fulforth, J. DOP87 Grant, S. OP05 Fan, H. DOP43 Fumery, M. OP15, OP24, OP35, Greenaway, B. DOP11 Farrell, D. 13th N-ECCO Network DOP74, DOP78, DOP80 Greenbaum, L. E. OP36 Meeting, N01 Furfaro, F. 1st ECCO-ESGAR Basic Gregor, J. C. DOP39 Fazekas, D. OP10 Imaging Workshop Greguš, M. DOP49, DOP51
124 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Index of authors
Greveson, K. 10th N-ECCO School, Hebuterne, X. OP14 Ilott, N. OP28 13th N-ECCO Network Hegazy, A. Scientific Session 9 Imai, Y. OP36 Meeting Hellstern, P. A. DOP49, DOP51 Imenez Silva, P. H. DOP24 Griffiths, A. M. Scientific Session 6, Hellström, P. OP35 Inoue, S. DOP32 4th Advanced ECCO: Helwig, U. DOP57 Inoue, T. DOP69 EduCational COurse Henderson, P. DOP84, DOP87 Inspector, Y. Scientific Session 2 for Industry, DOP58 Hering, L. DOP14, DOP19 Ipland, N.-P. DOP76 Grimaud, J.-C. OP35 Hermangild Kottoor, S. DOP06 Iqbal, S. DOP20 Gropp, R. OP12 Hernandez, V. OP15 Iqbal, T. OP16 Groß, E. 1st Guideline Hernandez-Medrano, I. Scientific Irizar, H. OP17 Methodology and Session 11 Irving, P. M. 17th IBD Intensive GRADE Workshop Hertervig, E. OP35 Advanced Course, Gubonina, I. OP35 Hibi, T. OP38, DOP32, OP32, DOP06 Gul, L. OP07 DOP46, DOP48 Izanec, J. DOP54 Gupta, A. 1st ECCO-ESGAR Basic Hibiya, S. OP31 Imaging Workshop Higgins, P. DOP50 Gupta, C. DOP49, DOP51 Higgs, R. DOP52 Gutierrez, R. DOP35 Hindryckx, P. 11th Y-ECCO Career Jäghult, S. 10th N-ECCO School, Guz Mark, A. OP18 Workshop 13th N-ECCO Network Meeting Günther, C. DOP13 Hiraguri, Y. DOP22 Jain, A. DOP81 Hirai, F. DOP32, DOP69 Jairath, V. OP09, DOP39 Hirschmann, S. DOP67 Jang, B. I. DOP62 Hisamatsu, T. OP37, Jansen, B. DOP10 Ha, N. OP23 DOP32, DOP47 Jansen, J. DOP56 Haberman, Y. OP19, DOP36 Hoekman, D. DOP56 Jefferson, M. OP07 Haerty, W. DOP08 Hoentjen, F. DOP29, DOP72 Jeffrey, R. OP20, DOP20 Hahnloser, D. 8th S-ECCO Hollobone, S. DOP30 Jenkinson, P. DOP87 IBD Masterclass Holmes, E. 5th Y-ECCO Basic Jensen, C. B. DOP88 Hale, M. DOP81 Science Workshop Jensen, E. DOP15 Halfvarson, J. Scientific Session 3, Hong, M. DOP83 Jess, T. DOP88 17th IBD Intensive Advanced Hong, S. N. DOP04 Jeyarajah, J. DOP45 Course, OP15, OP35, DOP10 Hotopf, M. DOP85 Jodeleit, H. OP12 Hall, J. OP16 Hu, A. DOP66 Johanns, J. OP37, DOP47, DOP54 Hall, L. DOP08 Hu, S. OP01 John, T. DOP17 Halling, C. DOP76 Huang, B. OP14 Jones, E. OP07, DOP08 Ham, N. DOP65 Huang, R. OP17 Jones, G.-R. DOP87 Hamilton, A. L. DOP81 Hughes, S. DOP11 Jorgensen, A 13th N-ECCO Hampe, J. DOP12 Humbel, F. OP06 Network Meeting Han, S. DOP17 Humblet, E. DOP29, DOP33 Joustra, V. OP35 Hansen, R. DOP84 Huttenhower, C. OP19 Judge, C. N01 Hansen, S. DOP88 Huynh, G. H. DOP58 Juillerat, P. 17th IBD Intensive Hansen, T. DOP15 Huynh, H. Q. DOP58 Advanced Course, OP06 Hao, K. OP17 Hwang, S. W. DOP65, DOP83 Julsgaard, M. DOP29 Hao, L.-Y. DOP53 Hyams, J. S. OP19 Jun, J. H. OP23 Harris, R. DOP84 Hébuterne, X. OP08, OP21, OP35, Jung, E. S. DOP55 Hart, A. Scientific Session 10, DOP49, DOP51, DOP80 Jung, S. DOP83 6th P-ECCO Educational Course Höllt, T. OP27 Hartmann, A. DOP67 Høivik, M. L. DOP90 Hartmann, P. 13th N-ECCO Højgaard, B. DOP76 Network Meeting Hübenthal, M. DOP55 Kagramanova, A. DOP77 Hartwig, J. DOP12 Kaimakliotis, I. OP15 Hasnain, S. DOP09 Kakimoto, K. DOP69 Hausmann, M. DOP24 Kamm, M. A. DOP81 Hautefort, I. OP07, DOP08 Iacucci, M. Scientific Session 6, Kanai, T. DOP32 Hawinkels, L. OP22 1st ECCO-ESGAR Basic Kanne, H. DOP72 Hawkey, C. J. OP20 Imaging Workshop, DOP67 Kanno, T. DOP53 Hayday, A. OP32 IBD-BIOM Consortium DOP10 Kariv, R. DOP31 Hayden, K. OP13, OP36 Ibiza, S. Scientific Session 7 Karns, R. OP19 Hayee, B. DOP60 Ibraheim, H. DOP06 Kasarskis, A. OP17
March 6-9, 2019 • Copenhagen, Denmark 125 Index of authors
Kaser, A. Scientific Session 1 Kurilshikov, A. OP01 Li, J. DOP17 Kashida, H. DOP69 Kłopocka, M. OP08, DOP49, DOP51 Li, K. OP13, OP36, DOP71 Kassam, Z. DOP06 Li, N. OP27 Katkeviciute, E. DOP14, DOP19 Li, X.-J. DOP35 Kato, S. DOP32 Liefferinckx, C. DOP33 Katsanos, K. H. OP15 Lacerda, A. P. OP14, DOP50 Lindsay, J. O. 4th H-ECCO IBD Katsukura, N. OP31 Laghi, A. 8th S-ECCO IBD Masterclass, 17th IBD Intensive Kawai, M. DOP22 Masterclass Advanced Course, Kawamoto, A. DOP22 Lago, P. OP04 OP14, OP20, DOP20 Kayhan, C. DOP43 Laharie, D. OP24, OP25, Lirio, R. A. OP26, DOP79 Keshav, S. DOP11 OP35, DOP80 Lishchinskaya, A. DOP77 Khanna, R. DOP39 Lahat, A. DOP36, DOP62 Lissoos, T. DOP79 Kievit, H. A. L. OP15 Lahiff, C. DOP11 Liu, X. DOP21 Kim, B. M. DOP83 Laird, R. DOP35 Lo, B. DOP82 Kim, E. R. DOP04 Lakatos, P. 17th IBD Intensive Lo Re, G. 1st ECCO-ESGAR Basic Kim, J. DOP65 Advanced Course, DOP75 Imaging Workshop Kim, J. Y. DOP65 Lakatos, P. L. OP15 Loftus, Jr, E. V. OP14, OP26 Kim, J. S. OP23, DOP49, DOP51 Lambrecht, G. OP25 Lombardi, G. DOP60 Kim, K. DOP83 Lang, D. DOP57 Lopetuso, L. R. OP29 Kim, S. W. DOP55 Lang, S. DOP02 Losic, B. OP17 Kim, T. J. DOP04 Langholz, E. OP15 Louis, E. 4th ECCO-AOCC Forum, Kim, Y.-H. DOP04 Lasch, K. DOP79 OP08, OP25, DOP29, Kiss, G. OP21 Lau, S. DOP64 DOP33, DOP50 Kiszka-Kanowitz, M. DOP88 Laukens, D. 7th SciCom Workshop Lönnfors, S. 1st Guideline Klaus, J. OP08 Lavon, E. DOP31 Methodology and Klenske, E. DOP67 Lawendy, N. DOP41, DOP43 GRADE Workshop Kligys, K. DOP50 Le Berre, C. 5th Y-ECCO Basic Lu, N. DOP21 Kluthe, C. DOP58 Science Workshop, DOP23 Lukas, M. DOP43 Knyazev, O. DOP77 Leavens, K. DOP11 Lynch, K. DOP11 Kobayashi, T. 1st ECCO-ESGAR Basic Ledder, O. OP18, DOP89 Lyons, M. DOP87 Imaging Workshop, Lederman, N. DOP89 Lytras, T. 1st Guideline 4th ECCO-AOCC Forum, DOP52 Lee, C. DOP04, DOP04 Methodology and Kok, K. B. DOP29 Lee, H.-S. DOP83 GRADE Workshop Kolterer, S. DOP57 Lee, J. H. DOP62 López-García, A. DOP44 Koning, F. OP27 Lee, J. B. DOP65 López-Sanromán, A. DOP44 Kooy-Winkelaar, Y. OP27 Lee, J. W. OP23 Löwenberg, M. DOP56 Kopylov, U. DOP36 Lee, K.-J. DOP21 Korcsmaros, T. OP07, OP10, Lee, S. J. DOP62 DOP08, DOP70 Lee, S. D. OP08, OP14 Kori, M. OP05, DOP42 Lee, S. G. DOP62 Ma, C. DOP39 Koslowsky, B. DOP31 Lee, S.-M. OP23 Maaser, C. 1st ECCO-ESGAR Basic Kosoy, R. OP17 Lee, W.-J. DOP50 Imaging Workshop, Kotze, P. 1st ECCO-ESGAR Basic Lee, Y. J. OP23 6th ECCO-ESGAR Ultrasound Imaging Workshop, Lees, C. Scientific Session 3, Workshop Advanced, DOP57 8th S-ECCO IBD Masterclass 11th Y-ECCO Career Maccioni, F. 1st ECCO-ESGAR Basic Krause, T. DOP29 Workshop, DOP87 Imaging Workshop Krueger, K. DOP46 Lefevre, J. 8th S-ECCO IBD Machiels, K. OP30 Krznaric, Z. OP15 Masterclass Macken, E. DOP29, DOP33 Kucharzik, T. 1st ECCO-ESGAR Basic Lelieveldt, B. OP27 Maconi, G. 1st ECCO-ESGAR Basic Imaging Workshop, Leong, R. W. DOP47, DOP54 Imaging Workshop, 6th ECCO-ESGAR Ultrasound Letizia, M. DOP13 6th ECCO-ESGAR Ultrasound Workshop Advanced, DOP57 Leung, W.-K. DOP64 Workshop Advanced Kuemmerle, J. OP02, DOP16 Leventhal, G. DOP02 Macpherson, A. OP06 Kugathasan, S. OP19 Lever, G. DOP28 Madgwick, M. DOP70 Kulakov, D. DOP77 Levine, A. Scientific Session 7, Magro, F. OP15 Kumagai, T. OP20 Scientific Session 10, Mahajan, M. OP17 Kunisaki, R. DOP32 OP05, DOP42 Maia, L. OP04 Kunkel, D. DOP13 Lewis, A. OP20, DOP20 Mak, L.-Y. DOP64 Kupcinskas, L. OP15 Li, C. OP02, DOP16 Malavasi, F. DOP01
126 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Index of authors
Maller, E. DOP43 Montalban-Arques, A. 5th Y-ECCO Nielsen, K. R. OP15 Mansfield, J. 4th Advanced ECCO: Basic Science Workshop, DOP02 Nijhuis, A. DOP20 EduCational COurse Moon, J. W. DOP83 Nijs, J. DOP29 for Industry Moritz, T. DOP15 Nishimura, R. OP31 Mantzaris, G. N02 Mostovoy, Y. DOP62 Nishishita, M. DOP69 Marano, C. OP13, OP37, DOP47, Motoya, S. OP35, DOP32 Nissen, L. DOP72 DOP54, DOP71 Mould, D. R. DOP56, DOP58 Nitcheu, J. OP21 Marcos-Pinto, R. OP04 Moum, B. DOP90 Noh, S. DOP65 Marks, D. J. B. DOP11 Moura Santos, P. DOP59 Nojima, M. DOP32 Marotta, P. DOP39 Mucha, S. DOP55 Noman, M. DOP33 Marshall, J. DOP66 Muders, M. DOP12 Nordholm-Carstensen, A. DOP76 Martin, S. W. OP08 Muller-de Jonge, E. OP22 Norsa, L. DOP34 Martí, M. DOP05 Munk Happel, A. 3rd School Novacek, G. OP35 Martín Arranz, E. DOP44 for Clinical Trialists Nwokolo, C. OP16 Martín-Cardona, A. DOP44 Munkholm, P. OP15 Masamunt, M. C. DOP25 Murray, J. DOP35 Matallana Royo, V. DOP44 Muñoz Núñez, F. DOP44 Matar, M. OP18 Myrelid, P. 8th S-ECCO IBD O’Brien, C. D. OP37, Mathôt, R. DOP56 Masterclass DOP47, DOP54 Matsumoto, T. DOP32 Myung, S. J. DOP65 O’Connell, R. DOP21 Matsuoka, K. DOP41 Márquez, L. DOP44 O’Donoghue, D. OP16 Matsuura, M. DOP32 Odes, S. OP15 Matthews, Z. OP07, DOP08 Odukwe, S. DOP06 Matz, E. DOP89 Oh, E. H. DOP65 Mayer, U. OP07 Nachury, M. DOP74, Oh, W. Y. DOP55 Maymó-Masip, E. DOP05 DOP78, DOP80 Ohlsen, C. DOP21 McDonald, T. T. DOP18 Nagahori, M. DOP32 Ohmiya, N. DOP69 McGovern, D. Scientific Session 3, Naganuma, M. DOP32 Ohtsuka, K. DOP22, DOP22 5th Y-ECCO Basic Nagasawa, J. DOP21 Oka, S. DOP69 Science Workshop Nagata, S. DOP22 Okada, L. DOP81 McGuckin, M. DOP09 Nagtegaal, I. DOP72 Okamoto, R. OP31, DOP22 Mearin, L. OP27 Nagy, P. OP08 Oksanen, P. OP15 Mège, D. 8th S-ECCO IBD Naik, S. OP09 Oldenburg, B. OP25 Masterclass Nakamura, T. OP31, Olivares Rivas, I. DOP02 Mehta, S. DOP20 DOP22 Oliver, P. DOP30 Menacho, M. DOP05 Nakase, H. DOP32 On, A. OP05, DOP42 Merino, O. DOP44 Nancey, S. OP24, DOP29, DOP74, Ordás, I. DOP25 Mertens, E. DOP37 DOP78, DOP80 Organe, S. DOP70 Mesonero, F. DOP44 Nangalia, V. Scientific Session 11 Orlando, A. DOP41 Meyer, A. DOP40 Nantes, Ó. DOP44 Ortiz, A. DOP21 Michelassi, F. 8th S-ECCO IBD Napora, P. OP21 Ortiz-Masia, D. OP03 Masterclass Narula, N. DOP66 Osipenko, M. DOP62 Michetti, P. 17th IBD Intensive Naveilhan, P. DOP23 Ossum, A. DOP90 Advanced Course, Nduaka, C. I. DOP41, DOP43 Osterman, M. T. DOP45 8th S-ECCO IBD Masterclass Neuman, S. DOP36 Ouboter, L. OP27 Miele, E. DOP34 Neunlist, M. DOP23 Outtier, A. DOP37 Milenkovic, Z. DOP29 Neurath, M. DOP67 Oxford IBD Cohort study Milik, A. DOP21 Neveu, I. DOP23 investigators OP28 Millan, M. DOP05 Nevin, K. DOP11, DOP18 Milman, P. OP05, DOP42 Neyazi, M. OP28 Mimms, L. DOP81 Ng, S. Scientific Session 5, Minnis, S. DOP87 1th Y-ECCO Career Workshop, Pabois, J. DOP23 Miquel-Cusachs, J. O. DOP44 17th IBD Intensive Palm, Ø. DOP90 Misselwitz, B. OP06 Advanced Course Panaccione, R. OP26, OP35, OP37 Mo, A. OP19 Nguyen, D. DOP53 Panceri, R. DOP34 Modos, D. 5th Y-ECCO Basic Nguyen, G. DOP66 Panés, J. 4th Advanced ECCO: Science Workshop, OP10 Niazi, U. DOP60 EduCational COurse for Industry, Moens, A. DOP29 Niechcial, A. DOP14, DOP19 8th S-ECCO IBD Masterclass, Moniruzzaman, M. DOP09 Nielsen, A. M. DOP88 OP09, DOP25, DOP53
March 6-9, 2019 • Copenhagen, Denmark 127 Index of authors
Panis, Y. Scientific Session 4, Pouillon, L. OP24 Romano, C. DOP34 8th S-ECCO IBD Masterclass Poullenot, F. OP24 Rosen, M. OP19 Paolantonio, P. 1st ECCO-ESGAR Powell, N. DOP06, DOP60 Rosini, F. 4th H-ECCO IBD Basic Imaging Workshop Powell, P. OP07, DOP08 Masterclass Papamichael, K. DOP45 Powrie, F. OP28 Rowbotham, D. DOP47, DOP54 Parfenov, A. DOP77 PREDICTS (PRoteomic Rowse, G. DOP30 Parfionovas, A. OP26 Evaluation and Discovery Rubin, D. T. OP26, DOP43 Pariente, B. OP25, OP35 in an IBD Cohort of Tri-service Rudant, J. DOP40 Park, D. I. OP08 Subjects) study group DOP35 Ruiz, P. DOP24 Park, J. C. DOP65 Princen, F. DOP35 Russell, R. DOP84 Park, J. DOP55 Prosser, C. DOP58 Rutter, M. 1st ECCO-ESGAR Basic Park, J. OP23 PROTECT Study group OP19 Imaging Workshop Park, S. H. DOP65, DOP83 Prymak, O. OP35 Rydzewska, G. OP35 Park, S. H. DOP65 Przemysław, Z. OP21 Ryu, K. H. OP23 Park, Z. DOP55 Pukitis, A. DOP62 Pavlidis, P. DOP06, DOP60 Pérez-Galindo, P. DOP44 Pedersen, N. OP15 Peleg, S. OP05, DOP42 Shouval, D. 4th D-ECCO Pereira, B. DOP80 Workshop, DOP31 Pereira, M. OP04 Qian, J. DOP21 Saito, S. DOP69 Perrigoue, J. OP17 Quirk, D. DOP43 Saito, Y. DOP69 Perovic, M. 1st Guideline Qumosani, K. DOP39 Sakuraba, H. DOP32 Methodology and Qvist, N. DOP76 Salas, A. DOP25 GRADE Workshop Salupere, R. OP15 Peters, H. DOP33 Samaan, M. DOP06 Petersen, F. DOP57 Sandborn, W. J. OP08, OP09, Petersen, I. DOP85 Rahier, J.-F. Scientific Session 5, OP14, OP26, OP37, OP38, Petralia, F. DOP35 DOP29, DOP33 DOP46, DOP49, DOP52, Petrova, A. DOP58 Rajca, S. DOP74, DOP78 DOP51, DOP53 Peyrin-Biroulet, L. 17th IBD Rangrej, J. DOP66 Sanderson, J. DOP06 Intensive Advanced Course, Rath, S. DOP57 Sandhu, A. DOP39 3rd School for Clinical Trialists, Rath, T. DOP67 Sands, B. E. OP17, OP26, OP37, 4th Advanced ECCO: Reiding, K. DOP10 DOP47, DOP52, DOP54, DOP79 EduCational COurse for Industry, Reinglas, J. DOP75 Saruta, M. DOP69 OP09, OP24, OP35, OP37, Reinisch, W. OP08, DOP49, DOP51, Sato, T. OP36, DOP35 DOP47, DOP50, DOP71, DOP62, DOP86 Satsangi, J. OP20, DOP10 DOP74, DOP78, DOP80 Reymond, M. DOP80 Savoye, G. Scientific Session 10 Picard, O. DOP36 Ricart, E. DOP25 Saxena, S. DOP85 Pierik, M. 10th N-ECCO Riddle, M. DOP35 Scaldaferri, F. OP29 School, OP25 Rieder, F. 7th SciCom Workshop, Schabel, E. 4th Advanced ECCO: Pineton de Chambrun, G. DOP74 11th Y-ECCO Career Workshop, EduCational COurse for Industry Pinho, S. OP04 17th IBD Intensive Schadt, E. OP17 Pinto, V. OP04 Advanced Course Scharl, M. 7th SciCom Workshop, Pinzani, M. Scientific Session 1 Rimola, J. 1st ECCO-ESGAR Basic OP06, DOP02, DOP14, DOP19 Pizarro, T. T. OP29 Imaging Workshop Schirmer, M. OP19 Plastaras, L. DOP74 Rinawi, F. OP18 Schmidt, F. DOP13 Plevris, N. DOP87 Rita Gonçalves, A. DOP59 Schmitz, J. DOP52 Plevy, S. 4th Advanced ECCO: Rivera-Nieves, J. 17th IBD Schreiber, S. Scientific Session 9, EduCational COurse Intensive Advanced Course OP08, OP14, OP35, for Industry, OP17, Roblin, X. OP24, DOP80 DOP55, DOP62 OP36, DOP35 Rodriguez Sillke, Y. DOP13 Schreiner, P. OP06 Plug, L. OP22 Rodriguez-Lago, I. DOP44 Schwartz, D. OP15 Podevin, J. DOP23 Rogers, J. OP17 Schwarzfischer, M. DOP14, Pollok, R. DOP85 Rogers, R. OP26 DOP19 Pomeranc, A. B. DOP20 Rogler, G. 17th IBD Intensive Sebastian, S. OP15, DOP29 Ponsioen, C. DOP56, DOP73 Advanced Course, Segal, J. DOP61 Porta, C. DOP01 OP06, OP20, OP35, Seidman, E. DOP75 Porter, C. DOP35 DOP14, DOP24 Seksik, P. DOP74, DOP78 Posen, A. DOP29 Rolli-Derkinderen, M. DOP23 Selinger, C. DOP28
128 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Index of authors
Seo, S.-K. OP23 Suarez-Farinas, M. OP17 Travis, S. Scientific Session 4, Seong, G. DOP04 Subramaniam, K. DOP68 OP28, OP35, DOP11 Serena, C. DOP05 Sudhakar, P. OP07, OP10, DOP08, Treem, W. 4th Advanced ECCO: Serrero, M. DOP74, DOP78 DOP38, DOP70 EduCational COurse Seuwen, K. DOP24 Sugaya, T. DOP32 for Industry Shadbolt, B. DOP68 Suh, D.-H. OP23 Tremelling, M. OP10 Shafran, I. OP26 Suh, J. H. DOP62 Trescoli-Garcia, A. OP03 Shamaly, H. OP05, DOP42 Surowiecka-Pastewka, A. DOP03 Treton, X. OP24 Shamir, R. OP18 Suzuki, K. DOP22 Treveil, A. 5th Y-ECCO Basic Science Shaoul, R. OP05, OP18, Suzuki, Y. DOP32 Workshop, OP07, DOP08 DOP31, DOP42 Svrcek, M. 4th H-ECCO IBD Triantafyllia, T. N02 Sheridan, J. DOP29 Masterclass Triebel, F. DOP07 Shimamoto, F. DOP69 Szapary, P. OP37, DOP47, DOP54 Tripathi, M. 4th H-ECCO IBD Shimizu, H. DOP22 Szitanyi, P. 4th Advanced ECCO: Masterclass Shin, J. OP23 EduCational COurse Tristán, E. DOP25 Shirasaki, T. OP31 for Industry Tsakmaki, A. DOP60 Shubhakar, A. DOP10 Sáinz Arnau, E. DOP44 Tsavdaroglou, A. 13th N-ECCO Siebeck, M. OP12 Network Meeting, N02 Siegel, R. DOP52 Tsuchiya, K. OP31, DOP22 Siegmund, B. 1st ECCO-ESGAR Tulchinsky, H. 8th S-ECCO Basic Imaging Tajiri, H. DOP69 IBD Masterclass Workshop, DOP13 Takahashi, J. DOP22 Turcan, S. OP15 Sigall-Boneh, R. 4th D-ECCO Takeuchi, K. DOP69 Turner, D. OP18, DOP31, DOP89 Workshop, OP05, DOP42 Tan, M. DOP11 Tuttle, J. OP38, DOP46, DOP52 SIGENP IBD Working Group DOP34 Tanaka, S. DOP69 Silver, A. OP20, DOP20 Tannahill, G. DOP18 Simon, M. DOP74 Tarabar, D. OP08, DOP49, DOP51 Simões, C. DOP59 Targan, S. R. OP37, DOP47, DOP54 Ungaro, R. OP35 Siproudhis, L. OP24, DOP74 Tarzi, R. DOP11 Urbanowicz, P. DOP10 Slevin, S. DOP11 Tato Marinho, R. DOP59 Uzzan, M. Scientific Session 7 Sloan, S. DOP54 Taxonera, C. DOP44 Smith, M. OP16 Telesco, S. E. OP36, DOP35 Smith, N. DOP21 Teriaky, A. DOP39 Song, E. M. DOP65 Terrón-Puig, M. DOP05 Valente, A. DOP59 Song, J. H. DOP04 The IBSEN study group DOP90 Valpiani, D. OP15 Song, K. DOP21 Theede, K. DOP88 Van Assche, G. 3rd School for Song, K. DOP83 Thomas, M. 3rd School for Clinical Trialists, OP37, DOP26, Song, W.-M. OP17 Clinical Trialists DOP37, DOP38, DOP47, Sosnovski, K. DOP36 Thomsen, S. B. DOP88 DOP54, DOP70 Spalinger, M. DOP02, DOP14 Thorpe, A. J. DOP41 van den Brande, J. DOP56 Spalinger, M. R. DOP19 Tole, S. 4th Advanced ECCO: van der Meulen-de Jong, A. Sparrow, M. DOP49, DOP51 EduCational COurse OP22, OP27 Spencer, D. DOP10 for Industry van der Woude, C. J. 17th IBD Spinelli, A. Scientific Session 11, Tomalty, D. DOP58 Intensive Advanced 8th S-ECCO IBD Masterclass Tomsho, L. OP36, DOP53 Course, OP25, DOP29 Srinivasan, N. DOP11 Tong, H. DOP09 van Dullemen, H. OP01 Staessen, D. DOP33 Tong, T. DOP64 Van Haaften, W. T. DOP24 Stallhofer, J. OP12 Topf Olivestone, C. OP18 Van Hootegem, A. DOP29 Stanciu, C. OP35 Torkzad, M. 1st ECCO-ESGAR Basic Van Hootegem, P. DOP33 Steens, J.-M. OP21 Imaging Workshop Van Kemseke, C. DOP33 Stellingwerf, M. DOP73 Torres, J. Scientific Session 2, Van Limbergen, J. OP05, DOP42 Stevens, C. OP01 17th IBD Intensive Advanced Van Moerkercke, W. DOP29, DOP33 Stocco, G. DOP01 Course, 1st Guideline Van Rheenen, P. 6th P-ECCO Stojmirovic, A. OP17 Methodology and GRADE Educational Course Strauss, R. DOP35 Workshop, 4th D-ECCO van Unen, V. OP27 Strawn, D. OP13 Workshop, DOP35 Vanasek, T. OP35 Strigli, A. DOP12 Tran Minh, M.-L. DOP78 Vancamelbeke, M. OP11 Strik, A. DOP56 Tozer, P. 8th S-ECCO IBD Masterclass Vande Casteele, N. DOP45 Su, C. DOP41, DOP43 Travelli, C. DOP01 Vantourout, P. OP32
March 6-9, 2019 • Copenhagen, Denmark 129 Index of authors
Vardi, H. OP15 Wang, R. DOP09 Yarur, A. OP09 Vavricka, S. Scientific Session 2, Wang, Y. DOP24 Ye, B. D. DOP62, DOP65, DOP83, 17th IBD Intensive Advanced Wang, Y. OP08 4th ECCO-AOCC Forum Course, 1st ECCO-ESGAR Basic Warren, D. DOP06 Yerushalmi, B. OP18, DOP31 Imaging Workshop, Warusavitarne, J. 8th S-ECCO Yilmaz, B. OP06 6th ECCO-ESGAR Ultrasound IBD Masterclass Youn, G. S. OP23 Workshop Advanced Wasmann, K. 8th S-ECCO Young IBD Group Vazeille, E. DOP80 IBD Masterclass, DOP73 from GETECCU DOP44 Vaňásek, T. DOP49, DOP51 Watanabe, K. DOP32, DOP69 Younge, L. 13th N-ECCO Network Vegh, Z. OP15 Watanabe, M. 7th SciCom Meeting, N03 Vendrell, J. DOP05 Workshop, OP31, Yui, S. DOP22 Ventham, N. DOP10 DOP22, DOP32, DOP48 Yzet, C. OP35 Veny, M. DOP25 Watanabe, S. OP31 Verdon, C. DOP75 Watson, A. OP07, OP10 Verfaillie, C. OP11 Wawrzyniak, M. DOP19 Vermeire, S. OP09, OP10, OP11, Weder, B. DOP24 Zagozda, M. DOP03 OP21, OP25, OP26, OP30, Weersma, R. OP01 Zakościelna, E. DOP03 DOP26, DOP29, DOP33, DOP37, Weidinger, C. DOP13 Zallot, C. DOP78 DOP38, DOP49, DOP51, DOP70 Weill, A. DOP40 Zand, A. Scientific Session 7 Verspaget, H. OP22 Weiss, B. OP18, DOP36 Zeissig, S. 7th SciCom Workshop, Verstockt, B. OP10, OP11, DOP26, Whitley, L. N03 DOP12 DOP33, DOP37, DOP38, Wijmenga, C. OP01 Zeissig, Y. DOP12 DOP70 Wild, G. DOP75 Zhang, H. OP37, DOP47, Verstockt, S. 5th Y-ECCO Basic Wileman, T. OP07, DOP08 DOP54, DOP71 Science Workshop, Wilkens, R. 1st ECCO-ESGAR Basic Zhang, J. OP09 DOP38, DOP70 Imaging Workshop, Zhang, L. DOP17 Vester-Andersen, M. K. DOP82 6th ECCO-ESGAR Ultrasound Zhernakova, A. OP01 Veyrard, P. OP24 Workshop Advanced Zhou, Q. DOP50 Vicente, R. DOP44 Wilson, D. 4th D-ECCO Workshop, Zhou, W. OP14 Vich Vila, A. OP01 6th P-ECCO Educational Zhu, L. DOP17 Vicuña, M. DOP44 Course, DOP84, DOP87 Ziv Baran, T. OP05 Viennot, S. OP24, DOP74, DOP78 Wine, E. OP05, DOP42, DOP58 Zmora, O. 8th S-ECCO IBD Vilanova, M. OP04 Wisniewska-Jarosinska, M. OP21 Masterclass Villarroel Aguilera, C. OP12 Witte, A. OP27 Zoufir, A. OP10 Vind, I. DOP82 Wollants, W.-J. DOP70 Zundler, S. DOP67 Visschedijk, M. OP01 Wolthuis, A. OP30 Zvyaglova, M. DOP77 von Känel, R. OP06 Wong, K. DOP09 Vossenkamper, A. DOP18 Woodworth, D. A. DOP41, DOP43 Vuitton, L. DOP74, DOP78 Worley, G. DOP61 Vutcovici, M. DOP75 Wright, E. K. DOP81 Wright, J. P. OP35 Wrzesinkski, T. DOP08 Wuhrer, M. DOP10 Wadman, E. OP13 Wagner, B. DOP21 Wagner, C. DOP24 Waldner, M. 7th SciCom Workshop Xavier, R. J. OP01, OP19 Wall, C. 4th D-ECCO Workshop, Xie, W. OP14 10th N-ECCO School Xu, Y. DOP17 Walsh, S. 4th H-ECCO IBD Masterclass Walters, T. D. OP19 Wang, F. DOP17 Yablecovitch, D. DOP36 Wang, H. DOP68 Yanai, H. 17th IBD Intensive Wang, J. DOP79 Advanced Course Wang, J. DOP12 Yang, D. H. DOP65 Wang, L. M. DOP11 Yang, F. OP13, DOP71 Wang, M. DOP17 Yang, S.-K. DOP65, DOP83 Wang, P. DOP35 Yang, Z. DOP17
130 14th Congress of ECCO - European Crohn‘s and Colitis Organisation Imprint
Imprint Publisher ECCO – European Crohn’s and Colitis Organisation OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH
Ungargasse 6/13 1030 Vienna, Austria Phone: +43-(0)1-710 22 42 Fax: +43-(0)1-710 22 42-001 E-Mail: [email protected] Web: www.ecco-ibd.eu
To visit the ECCO website, please scan this code or look at www.ecco-ibd.eu
Dieses Produkt entspricht dem Österreichischen Umweltzeichen für schadstoffarme Druckprodukte (UZ 24). This product conforms to the standards of the Austrian Environmental Seal of Approval for environmentally friendly printing products (UZ 24). Grasl Druck & Neue Medien, Bad Vöslau, UW-Nr. 715, www.fairprint.at
March 6-9, 2019 • Copenhagen, Denmark 131 132 14th Congress of ECCO - European Crohn‘s and Colitis Organisation © Copyright 2018 Arena Pharmaceuticals, Inc. Arena Pharmaceuticals Arena INVESTIGATOR OPPORTUNITY ® are registered service marksArena of Pharmaceuticals, Inc. All RightsReserved Learn more aboutaphase3clinical in inflammatory boweldisease. trial program foranoral, selective S1Pmodulator Paid advertisement by Arena Pharmaceuticals booth 40 ® and
paid advertisementpaid by advertisement Arena Pharmaceuticals by Pfizer Meet the Pfizer Team at booth3
Working together to advance science and patient care
PP-XEL-EUR-2142 – Date of preparation: December 2018
418PFXL0580_ECCO_A5-Pocket-program_v4.indd 2 21/12/18 15:34